

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/00	A2	(11) International Publication Number: WO 00/24768 (43) International Publication Date: 4 May 2000 (04.05.00)
(21) International Application Number: PCT/US99/24826 (22) International Filing Date: 22 October 1999 (22.10.99) (30) Priority Data: 60/105,507 23 October 1998 (23.10.98) US 60/108,685 16 November 1998 (16.11.98) US (71) Applicant (for all designated States except US): MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02138 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KAWASAKI, Hiroaki [JP/JP]; 3-20-2, Aoba, Higashi-ku, Fukuoka 813-0025 (JP). GRAYBIEL, Ann [US/US]; Boyce Farm Road, Lincoln, MA 01773 (US). HOUSMAN, David [US/US]; 64 Homer Street, Newton, MA 02158 (US). (74) Agent: CAMACHO, Jennifer, A.; Testa, Hurwitz & Thibault, LLP, High Street Tower, 125 High Street, Boston, MA 02110 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: GENES INTEGRATING SIGNAL TRANSDUCTION PATHWAYS (57) Abstract The present invention describes the identification, isolation, sequencing and characterization of two human CalDAG-GEF, and two human cAMP-GEF genes, which are associated with the Ras pathway. Also identified are CalDAG-GEF gene homologues in mice and cAMP-GEF gene homologues in rats. Nucleic acids and proteins comprising or derived from the CalDAG-GEFs and/or cAMP-GEFs are useful in screening and diagnosing certain Ras-associated cancers, in identifying and developing therapeutics for treatment of certain Ras-associated cancers, and in producing cell lines and transgenic animals useful as models of Ras-associated cancers.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENES INTEGRATING SIGNAL TRANSDUCTION PATHWAYS

Related Applications

This application claims the benefit of U.S. Application Nos. 60/105,507, filed on October 23, 1998, and 60/108,685, filed on November 16, 1998.

Field of the Invention

The present invention relates generally to novel polynucleotides and proteins encoded by
5 such polynucleotides, along with therapeutic, diagnostic, and research utilities for these polynucleotides and proteins.

Background of the Invention

Ras proteins are key regulators of growth, differentiation and malignant transformation. In addition, these proteins are implicated in synaptic function and region-specific learning and
10 memory functions in the brain.

As shown schematically in Figure 1, Ras proteins cycle between inactive GDP-complexed and active GTP-complexed states. GTPase-activating proteins (GAPs) inactivate Ras proteins by stimulating hydrolysis of the bound GTP to GDP, whereas guanine nucleotide exchange factors (GEFs) activate Ras proteins by stimulating release of GDP and the uptake of
15 GTP. So essential are GEFs to Ras action, that genetic loss of GEF function has similar effects to those induced by loss of the Ras proteins themselves. Loss of GEF function can be circumvented by mutations that constitutively activate the Ras proteins, such as an oncogene mutation, or, in some cases, through loss of GAP activity. Activated Ras proteins, which are localized at the plasma membrane, transmit signals from tyrosine kinases to a cascade of
20 serine/threonine kinases, which delivers the signals to the cell nucleus.

Activation of Ras can result in the activation of the mitogen-activated protein (MAP) kinase (also known as extracellular-signal regulated kinase, or ERK) pathway. For example, a receptor tyrosine kinase is activated by a peptide mitogen such as epidermal growth factor (EGF). The EGF-stimulated receptor undergoes autophosphorylation of specific tyrosine residues in its
25 cytoplasmic domain which creates phosphotyrosyl binding sites for the Src homology 2 (SH2) and/or phosphotyrosyl binding (PTB) domains of certain adapter proteins. The adapter protein becomes autophosphorylated on association with activated receptor tyrosine kinases. The GEF is stably associated with the adapter protein which, upon autophosphorylation, mediates translocation of the GEF to the plasma membrane. The GEF then activates the Ras protein.
30 Activated Ras relays its signal downstream through a cascade of cytoplasmic proteins, including

- 2 -

Raf-1 serine/threonine kinase. The Ras:Raf association promotes translocation of the normally cytoplasmic Raf protein to the plasma membrane, where subsequent events lead to the activation of its kinase function. Upon activation, Raf phosphorylates and activates two MAP kinases (also known as MEKs). MEKs directly associate with the catalytic domain of Raf-1 and are
5 phosphorylated by Raf. Activated MEKs function as dual-specificity kinases and phosphorylate tandem threonine and tyrosine residues in the MAP kinases to activate them. Once activated, the MAP kinases translocate to the nucleus where they phosphorylate and activate a variety of substrates.

Rap proteins, members of the Ras small GTPase superfamily, can inhibit Ras signaling of
10 the Ras/Raf-1(a serine/threonine kinase)/MAP kinase pathway or, through B-Raf, can activate MAP kinase. Rap1 consists of two isoforms, Rap1A and Rap1B, which differ mainly at the C-terminus. Characteristic features of Rap1 are its geranylgeranyl modification at the C-terminus, which is responsible for membrane attachments, and a threonine residue at position 61. In most other GTPases, the corresponding residue is a glutamine. Rap proteins, like Ras proteins, cycle
15 between inactive GDP-complexed and active GTP-complexed states. GEFs are required to activate Rap proteins by stimulating the release of GDP and the uptake of GTP.

Constitutive activation of the Ras pathway contributes to malignant transformation. In fact, the Ras gene has been implicated in many human cancers, including lung cancer, breast cancer, colorectal cancer, exocrine pancreatic cancer, and myeloid leukemia. Biological and
20 biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein since Ras must be localized in the plasma membrane and must bind with GTP in order to transform cells. Gibbs et al., 53 MICROBIOL. REV. 171-286 (1989).

Targeting components of the Ras signaling pathways has been proposed as one approach for the development of anti-Ras drugs for cancer treatment. One potential approach for targeting
25 Ras for cancer treatment involves the use of farnesyltransferase inhibitors (FTIs). Inhibition of farnesyl-protein transferase, and thereby of farnesylation of the Ras protein, blocks the ability of Ras to transform normal cells to cancer cells. Certain inhibitors of Ras farnesylation cause an increase in soluble Ras which can act as a dominant negative inhibitor of Ras function. While soluble Ras in cancer cells can become a dominant negative inhibitor, soluble Ras in normal cells
30 would not be an inhibitor. A cytosol-localized and activated form of Ras acts as a dominant negative Ras inhibitor of membrane-bound Ras function. Gibbs et al., 86 PROC. NAT'L ACAD.

- 3 -

Sci. USA 6630-34 (1989). FTIs block Ras function by preventing its post-translational modification by the farnesyl isoprenoid.

Intervention of Ras signaling at multiple or various points can significantly impact the ability of Ras to cause cellular transformation. Since Ras protein function is believed to be crucial to so many cellular processes, targeting only a subset of Ras functions by downstream intervention may provide significant advantages. Thus, there remains a need for identifying additional means for disrupting the Ras pathway. Applicants have discovered four new targets, namely GEFs specific for Rap1A, for disrupting the Ras pathway.

Summary of the Invention

Applicants have discovered four mammalian genes which have been designated CalDAG-GEFI, CalDAG-GEFII, cAMP-GEFI, and cAMP-GEFII, which encode proteins having a substrate specificity for Rap1A. The proteins encoded by CalDAG-GEFI and CalDAG-GEFII, referred to herein generally as "CalDAG-GEF," have dual binding domains for calcium and diacylglycerol. The proteins cAMP-GEFI and cAMP-GEFII, referred to herein generally as "cAMP-GEF," have a binding domain for cyclic adenosine 3', 5'-monophosphate. The present disclosure provides polypeptide and polynucleotide sequences for *Mus musculus* CalDAG-GEFI, *Homo sapiens* CalDAG-GEFI, *Rattus norvegicus* CalDAG-GEFII, *Homo sapiens* CalDAG-GEFII, *Rattus norvegicus* cAMP-GEFI, *Homo sapiens* cAMP-GEFI, *Homo sapiens* alternatively spliced cAMP-GEFI, *Rattus norvegicus* cAMP-GEFII, and *Homo sapiens* cAMP-GEFII. See Kawasaki et al., 95 Proc. Natl. Acad. Sci. USA 13278-83 (1998), and Kawasaki et al., 282 Sci. 2275-79 (1998), the disclosures of both of which are incorporated by reference herein.

Thus, in one series of embodiments, the present invention provides isolated nucleic acids including nucleotide sequences comprising or derived from CalDAG-GEF or cAMP-GEF, or encoding polypeptides comprising or derived from CalDAG-GEF or cAMP-GEF proteins. The sequences of the invention include the specifically disclosed sequences, splice variants of these sequences, allelic variants of these sequences, synonymous sequences, and homologous or orthologous variants of these sequences. Thus, for example, the invention provides nucleic acid sequences from the *Mus musculus* CalDAG-GEFI, *Homo sapiens* CalDAG-GEFI, *Rattus norvegicus* CalDAG-GEFII, *Homo sapiens* CalDAG-GEFII, *Rattus norvegicus* cAMP-GEFI, *Homo sapiens* cAMP-GEFI, *Homo sapiens* alternatively spliced cAMP-GEFI, *Rattus norvegicus* cAMP-GEFII, and *Homo sapiens* cAMP-GEFII. The present invention also provides allelic variants and homologous or orthologous sequences by providing methods by which such variants

- 4 -

may be routinely obtained. Because the nucleic acids of the invention may be used in a variety of diagnostic, therapeutic and recombinant applications, various subsets of the CalDAG-GEF and cAMP-GEF sequences are also provided. For example, for use in allele specific hybridization screening or PCR amplification techniques, subsets of the CalDAG-GEF and cAMP-GEF sequences, including both sense and antisense sequences, and both normal and mutant sequences, as well as intronic, exonic and untranslated sequences, are provided. Such sequences may comprise a small number of consecutive nucleotides from the sequences which are disclosed or otherwise enabled herein, but preferably include at least 8-10, more preferably 10-15, and most preferably 15-25, consecutive nucleotides from a CalDAG-GEF or cAMP-GEF sequence. In another embodiment, such sequences include at least 25-500 consecutive nucleotides from CalDAG-GEF or cAMP-GEF sequence. Other preferred subsets of a CalDAG-GEF or cAMP-GEF sequence include those encoding one or more of the functional domains or antigenic determinants of the CalDAG-GEF or cAMP-GEF protein and, in particular, may include either normal (wild-type) or mutant sequences. The invention also provides for various nucleic acid constructs in which CalDAG-GEF or cAMP-GEF sequences, either complete or subsets, are operably joined to exogenous sequences to form cloning vectors, expression vectors, fusion vectors, transgenic constructs, and the like. Thus, in accordance with another aspect of the invention, a recombinant vector for transforming a mammalian or invertebrate tissue cell to express a normal or mutant CalDAG-GEF and/or cAMP-GEF sequence in the cells is provided.

In another series of embodiments, the present invention provides for host cells which have been transfected or otherwise transformed with one of the nucleic acids of the invention. The cells may be transformed merely for purposes of propagating the nucleic acid constructs of the invention, or may be transformed so as to express the CalDAG-GEF and/or cAMP-GEF sequences. The transformed cells of the invention may be used in assays to identify proteins and/or other compounds which affect normal or mutant CalDAG-GEF and/or cAMP-GEF expression, which interact with the normal or mutant CalDAG-GEF and/or cAMP-GEF proteins, and/or which modulate the function or effects of the normal or mutant proteins, or to produce the CalDAG-GEF and/or cAMP-GEF proteins, fusion proteins, functional domains, antigenic determinants, and/or antibodies of the invention. Transformed cells may also be implanted into hosts, including humans, for therapeutic or other reasons. Preferred host cells include mammalian cells, including pure or mixed cell cultures, as well as bacterial, yeast, nematode,

- 5 -

insect and other invertebrate cells. For uses as described below, preferred cells also include embryonic stem cells, zygotes, gametes, and germ line cells.

In another series of embodiments, the present invention provides transgenic animal models of diseases or disorders associated with mutations in the CalDAG-GEF and/or cAMP-GEF genes. The animal may be essentially any non-human mammal, including rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates. In addition, invertebrate models, including nematodes and insects, may be used for certain applications. The animal models are produced by standard transgenic methods including microinjection, electroporation, transfection, or other forms of transformation of embryonic stem cells, zygotes, gametes, and germ line cells with vectors including genomic or cDNA fragments, minigenes, homologous recombination vectors, viral insertion vectors and the like. Suitable vectors include vaccinia virus, adenovirus, adeno-associated virus, retrovirus, liposome transport, neurotropic viruses, and Herpes simplex virus. The animal models may include transgenic sequences comprising or derived from the CalDAG-GEF and/or cAMP-GEF genes, including normal and mutant sequences, intronic, exonic and untranslated sequences, and sequences encoding subsets of the CalDAG-GEF and/or cAMP-GEF proteins, such as functional domains. The major types of animal models provided include: (1) Animals in which a normal human CalDAG-GEF and/or cAMP-GEF gene has been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a recombinant gene or a large genomic fragment; in which a normal human CalDAG-GEF and/or cAMP-GEF gene has been recombinantly substituted for one or both copies of the animal's homologous CalDAG-GEF and/or cAMP-GEF gene by homologous recombination or gene targeting; and/or in which one or both copies of one of the animal's homologous CalDAG-GEF and/or cAMP-GEF genes have been recombinantly "humanized" by the partial substitution of sequences encoding the human homologue by homologous recombination or gene targeting; (2) Animals in which a mutant human CalDAG-GEF and/or cAMP-GEF gene has been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a recombinant gene or a large genomic fragment; in which a mutant human CalDAG-GEF and/or cAMP-GEF gene has been recombinantly substituted for one or both copies of the animal's homologous CalDAG-GEF and/or cAMP-GEF gene by homologous recombination or gene targeting; and/or in which one or both copies of one of the animal's

- 6 -

homologous CalDAG-GEF and/or cAMP-GEF gene have been recombinantly "humanized" by the partial substitution of sequences encoding a mutant human homologue by homologous recombination or gene targeting; (3) Animals in which a mutant version of one of that animal's CalDAG-GEF or cAMP-GEF gene has been recombinantly introduced into the genome of the animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a recombinant gene or a large genomic fragment; and/or in which a mutant version of one of that animal's CalDAG-GEF or cAMP-GEF gene has been recombinantly substituted for one or both copies of the animal's homologous CalDAG-GEF or cAMP-GEF gene by homologous recombination or gene targeting; and (4) "Knock-out" animals in which one or both copies of one of the animal's CalDAG-GEF or cAMP-GEF genes have been partially or completely deleted by homologous recombination or gene targeting, or have been inactivated by the insertion or substitution by homologous recombination or gene targeting of exogenous sequences.

In another series of embodiments, the present invention provides for substantially pure protein preparations including polypeptides comprising or derived from the CalDAG-GEF and/or cAMP-GEF proteins. The CalDAG-GEF and cAMP-GEF protein sequences of the invention include the specifically disclosed sequences, variants of these sequences resulting from alternative mRNA splicing, allelic variants of these sequences, and homologous or orthologous variants of these sequences. Thus, for example, the invention provides amino acid sequences from the *Mus musculus* CalDAG-GEFI protein, *Homo sapiens* CalDAG-GEFI protein, *Rattus norvegicus* CalDAG-GEFII protein, *Homo sapiens* CalDAG-GEFII protein, *Rattus norvegicus* cAMP-GEFI protein, *Homo sapiens* cAMP-GEFI protein, *Homo sapiens* alternatively spliced cAMP-GEFI protein, *Rattus norvegicus* cAMP-GEFII protein, and *Homo sapiens* cAMP-GEFII protein. The present invention also provides allelic variants and homologous or orthologous proteins by providing methods by which such variants may be routinely obtained. The present invention also specifically provides for mutant or disease-causing variants of CalDAG-GEF and cAMP-GEF by providing methods by which such variants may be routinely obtained. Because the proteins of the invention may be used in a variety of diagnostic, therapeutic and recombinant applications, various subsets of the CalDAG-GEF and cAMP-GEF protein sequences and combinations of the CalDAG-GEF and cAMP-GEF protein sequences with heterologous sequences are also provided. For example, for use as immunogens or in binding assays, subsets of the CalDAG-GEF and cAMP-GEF protein sequences, including both normal and mutant

- 7 -

sequences, are provided. Such protein sequences may comprise a small number of consecutive amino acid residues from the sequences which are disclosed or otherwise enabled herein, but preferably include at least 4-8, and preferably at least 9-15 consecutive amino acid residues from a CalDAG-GEF or cAMP-GEF sequence. In another embodiment, such sequences comprise at least 15-200 consecutive amino acid residues from a CalDAG-GEF or cAMP-GEF sequence. Other preferred subsets of the CalDAG-GEF and cAMP-GEF protein sequences include those corresponding to one or more of the functional domains or antigenic determinants of the CalDAG-GEF and cAMP-GEF proteins and, in particular, may include either normal (wild-type) or mutant sequences. The invention also provides for various protein constructs in which a CalDAG-GEF and/or cAMP-GEF sequences, either complete or subsets thereof, are joined to exogenous sequences to form fusion proteins and the like. In accordance with these embodiments, the present invention also provides for methods of producing all of the above described proteins which comprise, or are derived from, CalDAG-GEF and/or cAMP-GEF.

In another series of embodiments, the present invention provides for the production and use of polyclonal and monoclonal antibodies, including antibody fragments, including Fab fragments, F(ab')₂, and single chain antibody fragments, which selectively bind to CalDAG-GEF or cAMP-GEF, or to specific antigenic determinants of CalDAG-GEF or cAMP-GEF. The antibodies may be raised in mouse, rabbit, goat or other suitable animals, or may be produced recombinantly in cultured cells such as hybridoma cell lines. Preferably, the antibodies selectively bind to a sequence comprising at least 4-8, and preferably at least 9-15, consecutive amino acid residues from a CalDAG-GEF or cAMP-GEF sequence. The antibodies of the invention may be used in the various diagnostic, therapeutic and technical applications described herein.

In another series of embodiments, the present invention provides methods of screening or identifying proteins, small molecules or other compounds which are capable of inducing or inhibiting the expression and/or function of the CalDAG-GEF and/or cAMP-GEF genes or proteins. The assays may be performed *in vitro* using non-transformed cells, immortalized cell lines, or recombinant cell lines, or *in vivo* using the transgenic animal models enabled herein. In particular, the assays may detect the presence of increased or decreased expression of CalDAG-GEF and/or cAMP-GEF-related genes or proteins on the basis of increased or decreased mRNA expression, increased or decreased levels of CalDAG-GEF and/or cAMP-GEF-related protein products, or increased or decreased levels of expression of a marker gene (*e.g.*, β -galactosidase,

- 8 -

green fluorescent protein, alkaline phosphatase or luciferase) operably joined to a 5' regulatory region in a recombinant construct. Cells known to express CalDAG-GEF or cAMP-GEF, or transformed to express CalDAG-GEF or cAMP-GEF, are incubated and one or more test compounds are added to the medium. After allowing a sufficient period of time (*e.g.*, 0-72 hours) for the compound to induce or inhibit the expression of the CalDAG-GEF or cAMP-GEF, any change in levels of expression from an established baseline may be detected using any of the techniques described above. In particularly preferred embodiments, the cells are from an immortalized cell line such as a human neuroblastoma, glioblastoma or a hybridoma cell line, or are transformed cells of the invention.

In another series of embodiments, the present invention provides methods for identifying proteins and other compounds which bind to, or otherwise directly interact with, CalDAG-GEF and/or cAMP-GEF. The proteins and compounds will include endogenous cellular components which interact with the CalDAG-GEF and/or cAMP-GEF *in vivo* and which, therefore, provide new targets for pharmaceutical and therapeutic interventions, as well as recombinant, synthetic, and otherwise exogenous compounds which may have CalDAG-GEF and/or cAMP-GEF binding capacity and, therefore, may be candidates for pharmaceutical agents. Thus, in one series of embodiments, cell lysates or tissue homogenates (*e.g.*, human brain homogenates, lymphocyte lysates) may be screened for proteins or other compounds which bind to one of the normal or mutant CalDAG-GEF or cAMP-GEF proteins. Alternatively, any of a variety of exogenous compounds, both naturally occurring and/or synthetic (*e.g.*, libraries of small molecules or peptides), may be screened for CalDAG-GEF or cAMP-GEF binding capacity. In each of these embodiments, an assay is conducted to detect binding between a "CalDAG-GEF component" or a "cAMP-GEF component" and some other moiety. In one embodiment, a CalDAG-GEF component comprises a CalDAG-GEF SRC1, SRC2, SRC3, EF hand or a DAG-binding domain. In another embodiment, a cAMP-GEF component comprises a cAMP-GEF SRC1, SRC2, SRC3, or a cAMP-binding domain. The "CalDAG-GEF component" or the "cAMP-GEF component" in these assays may be any polypeptide comprising or derived from a normal or mutant CalDAG-GEF or cAMP-GEF protein, including functional domains or antigenic determinants of CalDAG-GEF or cAMP-GEF, or CalDAG-GEF or cAMP-GEF fusion proteins. Binding may be detected by non-specific measures (*e.g.*, changes in intracellular Ca^{2+} , GTP/GDP ratio) or by specific measures (*e.g.*, changes in the expression of downstream genes which can be monitored by differential display, 2D gel electrophoresis, differential hybridization, or SAGE methods). The

- 9 -

preferred methods involve variations on the following techniques: (1) direct extraction by affinity chromatography; (2) co-isolation of CalDAG-GEF or cAMP-GEF components and bound proteins or other compounds by immunoprecipitation; (3) the Biomolecular Interaction Assay (BIAcore); and (4) the yeast two-hybrid systems.

5 In another series of embodiments, the present invention provides for methods of identifying proteins, small molecules and other compounds capable of modulating the activity of normal or mutant CalDAG-GEF or cAMP-GEF. Using normal cells or animals, the transformed cells and transgenic animal models of the present invention, or cells obtained from subjects bearing normal or mutant CalDAG-GEF or cAMP-GEF genes, the present invention provides
10 methods of identifying such compounds on the basis of their ability to affect the expression of CalDAG-GEF and/or cAMP-GEF, the intracellular localization of the CalDAG-GEF and/or cAMP-GEF, or other biochemical, histological, or physiological markers which distinguish cells bearing normal and mutant CalDAG-GEF and/or cAMP-GEF sequences. Using the transgenic animals of the invention, methods of identifying such compounds are also provided on the basis
15 of the ability of the compounds to affect behavioral, physiological or histological phenotypes associated with mutations in CalDAG-GEF and/or cAMP-GEF.

In another series of embodiments, the present invention provides methods and reagents for the screening and diagnosis of diseases or disorders associated with mutations in the CalDAG-GEF and/or cAMP-GEF genes. Screening and/or diagnosis can be accomplished by
20 methods based upon the nucleic acids (including genomic and mRNA/cDNA sequences), proteins, and/or antibodies disclosed and enabled herein, including functional assays designed to detect failure or augmentation of the normal CalDAG-GEF and/or cAMP-GEF activity and/or the presence of specific new activities conferred by the mutant CalDAG-GEF and/or cAMP-GEF. Thus, for example, screens and diagnostics based upon CalDAG-GEF and/or cAMP-GEF
25 proteins are provided which detect differences between mutant and normal CalDAG-GEF or cAMP-GEF in electrophoretic mobility, in proteolytic cleavage patterns, in molar ratios of the various amino acid residues, or in ability to bind specific antibodies. In addition, screens and diagnostics based upon nucleic acids (gDNA, cDNA or mRNA) are provided which detect differences in nucleotide sequences by direct nucleotide sequencing, hybridization using allele
30 specific oligonucleotides, restriction enzyme digest and mapping (*e.g.*, RFLP, REF-SSCP), electrophoretic mobility (*e.g.*, SSCP, DGGE), PCR mapping, RNase protection, chemical mismatch cleavage, ligase-mediated detection, and various other methods. Other methods are

- 10 -

also provided which detect abnormal processing of CalDAG-GEF and/or cAMP-GEF or proteins reacting with CalDAG-GEF and/or cAMP-GEF, alterations in CalDAG-GEF and/or cAMP-GEF transcription, translation, and post-translational modification; alterations in the intracellular and extracellular trafficking of CalDAG-GEF and/or cAMP-GEF gene products; or abnormal
5 intracellular localization of CalDAG-GEF and/or cAMP-GEF. Such methods and reagents are also useful in the analysis of neoplasias and mammalian immune system function, as well as functional *in vivo* imaging of mammalian organ systems. In accordance with these embodiments, diagnostic kits are also provided which will include the reagents necessary for the above-described diagnostic screens.

10 In another series of embodiments, the present invention provides methods and therapeutic agents for use in the treatment of conditions such as neurological and neuropsychiatric disorders such as Huntington's disease, Parkinson's disease, Alzheimer's disease, dystonia, Tourette's syndrome, obsessive-compulsive disorder, attention deficit/hyperactive disorder, depression, schizophrenia, and stroke; neoplasias such as solid tumors including colon, breast, lung, prostate,
15 and hematopoietic tumors such as leukemia, Hodgkins, and non-Hodgkins lymphomas; and autoimmune diseases, allergies, and asthma; as well as for the enhancement of the immune response in normal and immunocompromised individuals. These methods and therapeutic agents may be based upon (1) administration of normal CalDAG-GEF and/or cAMP-GEF proteins; (2) gene therapy with normal CalDAG-GEF and/or cAMP-GEF genes to compensate for or replace
20 the mutant genes; (3) gene therapy based upon antisense sequences to mutant CalDAG-GEF and/or cAMP-GEF genes or upon sequences which "knock-out" the mutant genes; (4) gene therapy based upon sequences which encode a protein which blocks or corrects the deleterious effects of CalDAG-GEF and/or cAMP-GEF mutants; (5) immunotherapy based upon antibodies to normal and/or mutant CalDAG-GEF and/or cAMP-GEF proteins; or (6) small molecules
25 (drugs) which alter CalDAG-GEF and/or cAMP-GEF expression, block interactions between (normal or mutant) forms of CalDAG-GEF and/or cAMP-GEF and other proteins or ligands, or which otherwise block the function of (normal or mutant) CalDAG-GEF and/or cAMP-GEF proteins by altering the structure of the proteins, by enhancing their metabolic clearance, or by inhibiting their function.

30 In accordance with another aspect of the invention, the proteins of the invention can be used as starting points for rational drug design to provide ligands, therapeutic drugs or other types of small chemical molecules. Alternatively, small molecules or other compounds

- 11 -

identified by the above-described screening assays may serve as "lead compounds" in rational drug design.

Brief Description of the Drawings

Figure 1 is a partial schematic diagram of a Ras pathway.

5 Figure 2A shows human (h) and mouse (m) CalDAG-GEFI, human (h) and rat (r) CalDAG-GEFII, and *C. elegans* (cel) (F25B3.3, GenBank accession number: 1262950) CalDAG-GEF. Figure 2B shows a computer-generated phylogenetic tree analysis of the GEF domains of CalDAG-GEFI and CalDAG-GEFII in relation to other Ras-superfamily GEFs. Figure 2C shows multiple alignment of GEF structurally conserved regions (SCRs) of CalDAG-
10 GEFs and several other GEFs of the Ras superfamily. Figure 2D shows the full-length amino acid sequences of human (h) and mouse (m) CalDAG-GEFI (box indicates amino acid differences). Figure 2E shows the sequence similarity (black indicates identity) of EF-hand domains in CalDAG-GEFs and other calcium binding proteins. Figure 2F shows the sequence similarity of DAG-binding domains of CalDAG-GEFs and PKC (protein kinase C) family
15 proteins.

 Figure 3A is a schematic representation of cAMP-GEF family proteins, including human (h) and rat (r) cAMP-GEFI, human (h) cAMP-GEFII and *C. elegans* (cel) (T2OG5.5, GenBank accession number: 458480) cAMP-GEF. Figure 3B is a phylogenetic tree analysis of cAMP binding domains of cAMP-GEFI and II and other cyclic nucleotide binding proteins. Figure 3C
20 is a phylogenetic tree analysis of GEF domains of cAMP-GEFI and II and other Ras superfamily GEFs. Figure 3D shows the amino acid sequences of the structurally conserved regions (SCRs) of cAMP-GEFs and other Ras superfamily GEFs (black indicates identity). Figure 3E shows the amino acid sequences of the cAMP binding pockets of cAMP-GEFI and II and other cyclic nucleotide-binding proteins. The positions of invariant amino acid residues are shown by black
25 diamonds. The open diamond indicates the amino acid that determines the binding specificity for cAMP or cGMP. The arrow indicates the position of amino acid substitutions specific to cAMP-GEFs. Figure 3F is the full-length amino acid sequences of human cAMP-GEFI and II (boxes indicate amino acid identity).

Detailed Description of the Invention

30 The present invention is based, in part, upon the discovery of a family of mammalian genes which are associated with the Ras pathway. The discovery of these genes, designated

- 12 -

CalDAG-GEFI, CalDAG-GEFII, cAMP-GEFI, and cAMP-GEFII, as well as the characterization of these genes, their protein products, mutants, and possible functional roles, are described below.

I. Definitions

5 In order to facilitate review of the various embodiments of the invention, and an understanding of the various elements and constituents used in making and using the invention, the following definitions are provided for particular terms used in the description and the claims which follow:

CalDAG-GEF. As used without further modification herein, the terms "CalDAG-GEF" or
10 or "CalDAG-GEFs" refer to the CalDAG-GEFI and/or the CalDAG-GEFII genes/proteins. In particular, the unmodified terms "CalDAG-GEF" or "CalDAG-GEFs" refer to the mammalian genes/proteins and, preferably, the human genes/proteins.

cAMP-GEF. As used without further modification herein, the terms "cAMP-GEF" or
15 "cAMP-GEFs" refer to the cAMP-GEFI and/or the cAMP-GEFII genes/proteins. In particular, the unmodified terms "cAMP-GEF" or "cAMP-GEFs" refer to the mammalian genes/proteins and, preferably, the human genes/proteins.

CalDAG-GEF gene. As used herein, the term "CalDAG-GEF gene" means the
mammalian genes represented by SEQ ID NOS: 1, 3, 5, and 7, as well as any allelic variants and
heterospecific mammalian homologues. A murine CalDAG-GEFI cDNA sequence is disclosed
20 herein as SEQ ID NO: 1, and a human CalDAG-GEFI cDNA sequence is disclosed herein as
SEQ ID NO: 3. A rat CalDAG-GEFII cDNA sequence is disclosed herein as SEQ ID NO: 5, and
a human CalDAG-GEFII cDNA sequence is disclosed herein as SEQ ID NO: 7. The term
"CalDAG-GEF gene" primarily relates to a coding sequence, but can also include some or all of
the flanking regulatory regions and/or introns. The term "CalDAG-GEF gene" specifically
25 includes artificial or recombinant genes created from cDNA or genomic DNA, including
recombinant genes based upon splice variants.

CalDAG-GEF protein. As used herein, the term "CalDAG-GEF protein" means a protein
encoded by a CalDAG-GEF gene, including allelic variants and heterospecific mammalian
homologues. A murine CalDAG-GEFI protein sequence is disclosed herein as SEQ ID NO: 2,
30 and a human CalDAG-GEFI protein sequence is disclosed herein as SEQ ID NO: 4. A rat
CalDAG-GEFII protein sequence is disclosed herein as SEQ ID NO: 6, and a human CalDAG-
GEFII protein sequence is disclosed herein as SEQ ID NO: 8. Splice variants are also embraced

- 13 -

by the term CalDAG-GEF protein as used herein. The protein may be produced by recombinant cells or organisms, may be substantially purified from natural tissues or cell lines, or may be synthesized chemically or enzymatically. Therefore, the term "CalDAG-GEF protein" is intended to include the protein in glycosylated, partially glycosylated, or unglycosylated forms, as well as in phosphorylated, partially phosphorylated, unphosphorylated, sulphated, partially sulphated, or unsulphated forms. The term also includes allelic variants and other functional equivalents of the CalDAG-GEF amino acid sequences, including biologically active proteolytic or other fragments.

hCalDAG-GEF gene and/or protein. As used herein, the abbreviation "hCalDAG-GEF" refers to the human homologue and human allelic variants of the CalDAG-GEF genes and/or proteins. Two cDNA sequences of the human CalDAG-GEF genes are disclosed herein as SEQ ID NOS: 3 and 7. The corresponding hCalDAG-GEF protein sequences are disclosed herein as SEQ ID NOS: 4 and 8. Allelic variants, including deleterious mutants, are enabled in the description which follows.

mCalDAG-GEF gene and/or protein. As used herein, the abbreviation "mCalDAG-GEF" refers to the murine homologues and murine allelic variants of the CalDAG-GEF gene and/or protein. A cDNA sequence of one murine CalDAG-GEF gene is disclosed herein as SEQ ID NO: 16. The corresponding mCalDAG-GEF protein sequence is disclosed herein as SEQ ID NO: 17. Allelic variants, including deleterious mutants, are enabled in the description which follows.

rCalDAG-GEF gene and/or protein. As used herein, the abbreviation "rCalDAG-GEF" refers to the rat homologue and rat allelic variants of the CalDAG-GEF genes and/or proteins. A cDNA sequence of one rat CalDAG-GEF gene is disclosed herein as SEQ ID NO: 5. The corresponding rCalDAG-GEF protein sequence is disclosed herein as SEQ ID NO: 6. Allelic variants, including deleterious mutants, are enabled in the description which follows.

cAMP-GEF gene. As used herein, the term "cAMP-GEF gene" means the mammalian genes represented by SEQ ID NOS: 9, 11, 13, 15, and 17, as well as any allelic variants and heterospecific mammalian homologues. A rat cAMP-GEFI cDNA sequence is disclosed herein as SEQ ID NO: 9, and a human cAMP-GEFI cDNA sequence is disclosed as SEQ ID NO: 11. Another human cAMP-GEFI cDNA sequence, resulting from alternative splicing of the mRNA transcript, is disclosed as SEQ ID NO: 13. A rat cAMP-GEFII cDNA sequence is disclosed as SEQ ID NO: 15, and a human cAMP-GEFII cDNA sequence is disclosed as SEQ ID NO: 17.

- 14 -

The term "cAMP-GEF gene" primarily relates to a coding sequence, but can also include some or all of the flanking regulatory regions and/or introns. The term cAMP-GEF gene specifically includes artificial or recombinant genes created from cDNA or genomic DNA, including recombinant genes based upon splice variants.

5 cAMP-GEF protein. As used herein, the term "cAMP-GEF protein" means a protein encoded by a cAMP-GEF gene, including allelic variants and heterospecific mammalian homologues. A rat cAMP-GEFI protein sequence is disclosed herein as SEQ ID NO: 10, and a human cAMP-GEFI protein sequence is disclosed as SEQ ID NO: 12. Another human cAMP-GEFI protein sequence, resulting from alternative splicing of the mRNA transcript, is disclosed
10 as SEQ ID NO: 14. A rat cAMP-GEFII protein sequence is disclosed as SEQ ID NO: 16, and a human cAMP-GEFII protein sequence is disclosed as SEQ ID NO: 18. Splice variants are also embraced by the term cAMP-GEF protein as used herein. The protein may be produced by recombinant cells or organisms, may be substantially purified from natural tissues or cell lines, or may be synthesized chemically or enzymatically. Therefore, the term "cAMP-GEF protein" is
15 intended to include the protein in glycosylated, partially glycosylated, or unglycosylated forms, as well as in phosphorylated, partially phosphorylated, unphosphorylated, sulphated, partially sulphated, or unsulphated forms. The term also includes allelic variants and other functional equivalents of the cAMP-GEF amino acid sequences, including biologically active proteolytic or other fragments.

20 hcAMP-GEF gene and/or protein. As used herein, the abbreviation "hcAMP-GEF" refers to the human homologue and human allelic variants of the cAMP-GEF gene and/or protein. One cDNA sequences of the human cAMP-GEF gene is disclosed herein as SEQ ID NO: 18. The corresponding hcAMP-GEF protein sequence is disclosed herein as SEQ ID NO: 19. Numerous allelic variants, including deleterious mutants, are disclosed and enabled throughout the
25 description which follows.

rcAMP-GEF gene and/or protein. As used herein, the abbreviation "rcAMP-GEF" refers to the rat homologue and rat allelic variants of the cAMP-GEF gene and/or protein. Two cDNA sequences of rat cAMP-GEF genes are disclosed herein as SEQ ID NOS: 9 and 15. The corresponding rcAMP-GEF protein sequences are disclosed herein as SEQ ID NOS: 10 and 16..
30 Numerous allelic variants, including deleterious mutants, are disclosed and enabled throughout the description which follows.

- 15 -

Normal. As used herein with respect to genes, the term "normal" refers to a gene which encodes and expresses a normal protein. As used herein with respect to proteins, the term "normal" means a protein which performs its usual or normal physiological role and which is not associated with, or causative of, a pathogenic condition or state. Therefore, as used herein, the term "normal" is essentially synonymous with the usual meaning of the phrase "wild type." For any given gene, or corresponding protein, a multiplicity of normal allelic variants may exist, none of which is associated with the development of a pathogenic condition or state. Such normal allelic variants include, but are not limited to, variants in which one or more nucleotide substitutions do not result in a change in the encoded amino acid sequence.

Mutant. As used herein with respect to genes, the term "mutant" refers to a gene which encodes a mutant protein and/or fails to express a normal protein. As used herein with respect to proteins, the term "mutant" means a protein which does not perform its usual or normal physiological role and which is associated with, or causative of, a pathogenic condition or state. Therefore, as used herein, the term "mutant" is essentially synonymous with the terms "dysfunctional," "pathogenic," "disease-causing," and "deleterious." With respect to the CalDAG-GEF and cAMP-GEF genes and proteins of the present invention, the term "mutant" refers to CalDAG-GEF and cAMP-GEF genes/proteins bearing one or more nucleotide/amino acid substitutions, insertions and/or deletions which cause the genes/proteins to be dysfunctional, pathogenic, disease-causing or otherwise deleterious. This definition is understood to include the various mutations that naturally exist, including but not limited to those disclosed herein, as well as synthetic or recombinant mutations produced by human intervention. The term "mutant," as applied to the CalDAG-GEF and cAMP-GEF genes, is not intended to embrace sequence variants which, due to the degeneracy of the genetic code, encode proteins identical to the normal sequences disclosed or otherwise enabled herein; nor is it intended to embrace sequence variants which, although they encode different proteins, encode proteins which are functionally equivalent to normal CalDAG-GEF and/or cAMP-GEF proteins.

Functional equivalent. As used herein in describing gene sequences and amino acid sequences, the term "functional equivalent" means that a recited sequence need not be identical to a particularly disclosed sequence of the SEQ ID NOs but need only provide a sequence which functions biologically and/or chemically as the equivalent of the disclosed sequence.

Substantially pure. As used herein with respect to protein preparations, the term "substantially pure" means a preparation which contains at least 60% (by dry weight) the protein

- 16 -

of interest, exclusive of the weight of other intentionally included compounds. Preferably the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by dry weight the protein of interest, exclusive of the weight of other intentionally included compounds. Purity can be measured by any appropriate method, e.g., column chromatography, gel electrophoresis, or HPLC analysis. If a preparation intentionally includes two or more different proteins of the invention, a "substantially pure" preparation means a preparation in which the total dry weight of the proteins of the invention is at least 60% of the total dry weight, exclusive of the weight of other intentionally included compounds. Preferably, for such preparations containing two or more proteins of the invention, the total weight of the proteins of the invention be at least 75%, more preferably at least 90%, and most preferably at least 99%, of the total dry weight of the preparation, exclusive of the weight of other intentionally included compounds. Thus, if the proteins of the invention are mixed with one or more other proteins (e.g., serum albumin, 6-OST) or compounds (e.g., diluents, detergents, excipients, salts, polysaccharides, sugars, lipids) for purposes of administration, stability, storage, and the like, the weight of such other proteins or compounds is ignored in the calculation of the purity of the preparation.

Isolated nucleic acid. As used herein, an "isolated nucleic acid" is a ribonucleic acid, deoxyribonucleic acid, or nucleic acid analog comprising a polynucleotide sequence that has been isolated or separated from sequences that are immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant nucleic acid which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequences and/or including exogenous regulatory elements.

Transformed cell. As used herein, a "transformed cell" is a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid molecule of interest. The nucleic acid of interest will typically encode a peptide or protein. The transformed cell may express the sequence of interest or may be used only to propagate the sequence. The term "transformed" may be used herein to embrace any method of introducing

- 17 -

exogenous nucleic acids including, but not limited to, transformation, transfection, electroporation, microinjection, viral-mediated transfection, and the like.

Operably joined. As used herein, a coding sequence and a regulatory region are said to be "operably joined" when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory region. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of promoter function results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the regulatory region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a regulatory region would be operably joined to a coding sequence if the regulatory region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

Stringent hybridization conditions. Stringent hybridization conditions is a term of art understood by those of ordinary skill in the art. For any given nucleic acid sequence, stringent hybridization conditions are those conditions of temperature, chaotropic acids, buffer, and ionic strength which will permit hybridization of that nucleic acid sequence to its complementary sequence and not to substantially different sequences. The exact conditions which constitute "stringent" conditions, depend upon the nature of the nucleic acid sequence, the length of the sequence, and the frequency of occurrence of subsets of that sequence within other non-identical sequences. By varying hybridization conditions from a level of stringency at which non-specific hybridization occurs to a level at which only specific hybridization is observed, one of ordinary skill in the art can, without undue experimentation, determine conditions which will allow a given sequence to hybridize only with complementary sequences. Suitable ranges of such stringency conditions are described in KRAUSE ET AL., METHODS IN ENZYMOLOGY, 200: 546-56 (1991). Stringent hybridization conditions, depending upon the length and commonality of a sequence, may include temperatures of 20°C-65°C and ionic strengths from 5x to 0.1x SSC. Highly stringent hybridization conditions may include temperatures as low as 40-42°C (when denaturants such as formamide are included) or up to 60-65°C in ionic strengths as low as 0.1x SSC. These ranges, however, are only illustrative and, depending upon the nature of the target sequence, and possible future technological developments, may be more stringent than necessary.

Less than stringent conditions are employed to isolate nucleic acid sequences which are substantially similar, allelic or homologous to any given sequence.

Selectively bind. As used herein with respect to antibodies, an antibody is said to "selectively bind" to a target if the antibody recognizes and binds the target of interest but does not substantially recognize and bind other molecules in a sample, *e.g.*, a biological sample, which includes the target of interest.

CalDAG-GEF- or cAMP-GEF-associated disorder, condition, or disease. As used herein, the term "CalDAG-GEF or cAMP-GEF associated disorder, condition, or disease" means any disorder, condition, or disease to which a normal or mutant CalDAG-GEF and/or cAMP-GEF is related in any manner, such as in the causation, prevention, exacerbation, alleviation of the disorder. Thus, as used herein, a CalDAG-GEF- or cAMP-GEF-associated disorder, condition, or disease includes disorders related to the Ras-pathway, such as Ras-related cancers.

Adapter protein. As used herein, the term "adapter protein" means any protein that binds or is bound to a CalDAG-GEF or a cAMP-GEF protein, and facilitates localization of the bound CalDAG-GEF or cAMP-GEF at the plasma membrane, thereby facilitating Ras activation.

Variant. As used herein a "variant" sequence has, or will result in having, a sufficient amino acid similarity to have a reasonable expectation of success in the methods of the present invention. In order to produce variants of the disclosed sequences that may also functionally serve as a CalDAG-GEF or cAMP-GEF protein, any one or more of the naturally-occurring CalDAG-GEF or cAMP-GEF sequences disclosed herein may be used as a reference sequence to determine whether a candidate sequence possesses sufficient amino acid similarity to have a reasonable expectation of success in the methods of the present invention. Preferably, variant sequences are at least 70% similar or 60% identical, more preferably at least 75% similar or 65% identical, and most preferably 80% similar or 70% identical to one of the disclosed, naturally-occurring sequences.

To determine whether a candidate peptide region has the requisite percentage similarity or identity to a reference polypeptide or peptide oligomer, the candidate amino acid sequence and the reference amino acid sequence are first aligned using the dynamic programming algorithm described in Smith and Waterman (1981), *J. Mol. Biol.* 147:195-197, in combination with the BLOSUM62 substitution matrix described in Figure 2 of Henikoff and Henikoff (1992), "Amino acid substitution matrices from protein blocks", *PNAS* (1992 Nov), 89:10915-10919. For the present invention, an appropriate value for the gap insertion penalty is -12, and an appropriate

- 19 -

value for the gap extension penalty is -4. Computer programs performing alignments using the algorithm of Smith-Waterman and the BLOSUM62 matrix, such as the GCG program suite (Oxford Molecular Group, Oxford, England), are commercially available and widely used by those skilled in the art.

5 Once the alignment between the candidate and reference sequence is made, a percent similarity score may be calculated. The individual amino acids of each sequence are compared sequentially according to their similarity to each other. If the value in the BLOSUM62 matrix corresponding to the two aligned amino acids is zero or a negative number, the pairwise similarity score is zero; otherwise the pairwise similarity score is 1.0. The raw similarity score is
10 the sum of the pairwise similarity scores of the aligned amino acids. The raw score is then normalized by dividing it by the number of amino acids in the smaller of the candidate or reference sequences. The normalized raw score is the percent similarity. Alternatively, to calculate a percent identity, the aligned amino acids of each sequence are again compared sequentially. If the amino acids are non-identical, the pairwise identity score is zero; otherwise
15 the pairwise identity score is 1.0. The raw identity score is the sum of the identical aligned amino acids. The raw score is then normalized by dividing it by the number of amino acids in the smaller of the candidate or reference sequences. The normalized raw score is the percent identity. Insertions and deletions are ignored for the purposes of calculating percent similarity and identity. Accordingly, gap penalties are not used in this calculation, although they are used
20 in the initial alignment.

In all instances, variants of the naturally-occurring CalDAG-GEF or cAMP-GEF proteins, as described above, must be tested for biological activity as described below. Specifically, the proteins must exhibit guanine nucleotide exchange factor activity, and, preferably, they have the ability to inhibit Ras signaling of the Ras/Raf-1/MAP kinase pathway.

25 II. The CalDAG-GEFs

CalDAG-GEFI has a substrate specificity for Rap1A, dual binding domains for calcium (Ca^{2+}) and diacylglycerol (DAG), and enriched expression in brain basal ganglia pathways and their axon-terminal regions. Expression of CalDAG-GEFI activates Rap1A and inhibits Ras-dependent activation of the Erk/MAP kinase cascade in 293T cells. Ca^{2+} ionophore and phorbol ester strongly and additively enhance this Rap1A activation. By contrast, CalDAG-GEFII
30 exhibits a different brain expression pattern and fails to activate Rap1A, but activates H-Ras, R-Ras and the Erk/MAP kinase cascade under Ca^{2+} and DAG modulation. The CalDAG-GEF

proteins have a critical neuronal function in determining the relative activation of Ras and Rap1 signaling induced by Ca^{2+} and DAG mobilization. The expression of CalDAG-GEFI and CalDAG-GEFII in hematopoietic organs indicates that such control has broad significance in Ras/Rap regulation of normal and malignant states.

5 The basal ganglia are centrally implicated in movement control and in forms of procedural learning related to habit formation. It is not yet known whether particular neurochemical specializations of the basal ganglia contribute to these behavioral functions. The basal ganglia do, however, have a unique double-inhibitory pathway design combined with abundant expression of neuromodulators in striatal neurons. A number of genes with
10 differentially high expression in the striatum have also been identified. These include genes coding for proteins with signaling functions, such as adenylate cyclase V (Glatt et al., 361 NATURE (LONDON), 536-38 (1993)) and DARPP-32 (Hemmings et al., 310 NATURE (LONDON) 502-05 (1984)). To identify other cellular signaling molecules that could contribute to basal ganglia functions, a search for striatum-enriched transcripts was performed by a differential
15 display method, as discussed in Example 1. Among the transcripts identified in this search were a family of genes characterized by the presence of a Ras superfamily (GEF) domain.

Specific domains identified include structurally conserved GEF regions SCR1, SCR2, and SCR3, as shown in Figures 2C and 3D, and as shown in the following table.

- 21 -

TABLE 1

Gene	SCR1	SCR2	SCR3
hCalDAG-GEFI	SEQ ID NO.3: 605-677 SEQ ID NO.4: 149-173	SEQ ID NO.3: 817-946 SEQ ID NO.4: 219-262	SEQ ID NO.3: 1053-1185 SEQ ID NO.4: 298-320
hCalDAG-GEFII	SEQ ID NO.7: 728-800 SEQ ID NO.8: 205-229	SEQ ID NO.7: 913-1042 SEQ ID NO.8: 270-313	SEQ ID NO.7: 1084-1216 SEQ ID NO.8: 348-371
hcAMP-GEFI	SEQ ID NO.11: 2058-2130 SEQ ID NO.12: 205-229	SEQ ID NO.11: 2276-2405 SEQ ID NO.12: 688-731	SEQ ID NO.11: 2516-2582 SEQ ID NO.12: 767-789
rcAMP-GEFI	SEQ ID NO.9: 2050-2122 SEQ ID NO.10: 618-642	SEQ ID NO.9: 2267-2396 SEQ ID NO.10: 691-734	SEQ ID NO.9: 2502-2568 SEQ ID NO.10: 770-792
hcAMP-GEFII	SEQ ID NO.17: 2707-2779 SEQ ID NO.18: 767-791		
rcAMP-GEFII	SEQ ID NO.15: 576-648 SEQ ID NO.16: 192-216		

In addition, the EF hand and DAG-binding domains were identified as shown in Figures 2E and 2F, and as shown in the following table:

- 22 -

Table 2

Gene	EF Hand Domain	DAG-Binding Domain
hCalDaG-GEFI	SEQ ID NO.3: 1456-1516 SEQ ID NO.4: 432-452	SEQ ID NO.3: 1652-1804 SEQ ID NO.4: 498-548
hCalDAG-GEFII	SEQ ID NO.7: 1384-1444 SEQ ID NO.8: 427-447	SEQ ID NO.7: 1579-1729 SEQ ID NO.8: 492-542

Finally, the cAMP-binding domains were identified as shown in Figure 3E, and as shown in the following table:

5

Table 3

Gene	cAMP-Binding Domain
hcAMP-GEFI	SEQ ID NO.11: 2012-2255 SEQ ID NO.12: 219-300
rcAMP-GEFI	SEQ ID NO.9: 853-1096 SEQ ID NO.10: 219-300
rcAMP-GEFII	SEQ ID NO.17: 1522-1765 SEQ ID NO.18: 372-453

III. The cAMP-GEFs

Cyclic adenosine 3', 5'-monophosphate (cAMP) is a universal second messenger that induces a variety of physiological responses in eukaryotic cells ranging from growth, differentiation, and gene expression to secretion and neurotransmission. The cAMP second messenger system has also been centrally implicated in modulating synaptic function, neuroplasticity and learning and memory. Most of these effects have been attributed to the binding of cAMP to cAMP-dependent protein kinase (PKA), leading in turn to the activation of

- 23 -

intracellular phosphorylation cascades. Reported herein is the identification of a new family of cAMP binding proteins that are differentially distributed in the brain and body organs and that are characterized by the presence of both a cAMP binding domain and a guanine nucleotide exchange factor (GEF) domain. These proteins, cAMP-GEFs, bind cAMP and selectively
5 activate the Ras superfamily small G protein, Rap1A, in a cAMP-dependent but PKA-independent manner.

The general concept of cAMP signaling involves the sequential activation (or inhibition) of cAMP production by G proteins, the binding of cAMP to PKA, and the triggering of a series of downstream serine-threonine phosphorylation cascades. Viewed as the nearly exclusive
10 target of cAMP binding in eukaryotic cells, PKA has been considered the essential effector molecule mediating a wide range of physiological effects of G protein/cAMP-triggered phosphorylation cascades. As the main cAMP effector, PKA has also been shown to function in the indirect coupling of the cAMP signal transduction system to other intracellular signaling cascades. The cAMP signaling system has also been strongly implicated in neuronal functions
15 ranging from neurotransmitter-initiated signaling to neuroplasticity underlying development and memory, but PKA has not been clearly linked to all of these neuronal functions, and region-specific neuronal effects have been observed as well. The cAMP-GEF gene has a Ras superfamily GEF motif. Thus, the gene codes for a novel cAMP binding protein that directly couples the cAMP signal transduction system to Ras superfamily cascades.

20 IV. Preferred Embodiments

Based, in part, upon the discoveries disclosed and described herein, the following preferred embodiments of the present invention are provided.

1. Isolated Nucleic Acids

In one series of embodiments, the present invention provides isolated nucleic acids
25 corresponding to, or relating to, the CalDAG-GEF or cAMP-GEF nucleic acid sequences disclosed herein. As described more fully below, these sequences include normal CalDAG-GEF and cAMP-GEF sequences from humans and other mammalian species, mutant CalDAG-GEF and cAMP-GEF sequences from humans and other mammalian species, homologous sequences from non-mammalian species such as *Drosophila* and *C. elegans*, subsets of these sequences
30 useful as probes and PCR primers, subsets of these sequences encoding fragments of the CalDAG-GEF or cAMP-GEF proteins or corresponding to particular domains or polymorphic

- 24 -

regions, complementary or antisense sequences corresponding to fragments of the CalDAG-GEF or cAMP-GEF genes, sequences in which the CalDAG-GEF and/or cAMP-GEF coding regions have been operably joined to exogenous regulatory regions, and sequences encoding fusion proteins of the portions of the CalDAG-GEF or cAMP-GEF proteins fused to other proteins useful as markers of expression, as "tags" for purification, or in screens and assays for proteins interacting with the CalDAG-GEFs and/or cAMP-GEFs.

Thus, in a first series of embodiments, isolated nucleic acid sequences are provided which encode normal versions of the CalDAG-GEF and cAMP-GEF proteins. Examples of such nucleic acid sequences are disclosed herein. These nucleic acids may be genomic sequences or may be cDNA sequences (*e.g.*, SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, and 17). Thus, for example, the invention provides nucleic acid sequences in which the alternative splice variants described herein are incorporated at the DNA level, thereby, enabling cells including these sequences to express only one of the alternative splice variants at each splice position. For example, a recombinant gene may be produced in which one of the splice variants of cAMP-GEF is incorporated into DNA such that cells having this recombinant gene can express only one of these variants. For purposes of reducing the size of a recombinant CalDAG-GEF or cAMP-GEF gene, a cDNA gene may be employed or various combinations of the introns and untranslated exons may be removed from a DNA construct. Such constructs may be particularly useful, as described below, in identifying compounds which can induce or repress the expression of the CalDAG-GEF or cAMP-GEF genes.

In addition to the disclosed CalDAG-GEF and/or cAMP-GEF sequences, one of ordinary skill in the art is now enabled to identify and isolate nucleic acids corresponding to CalDAG-GEF or cAMP-GEF genes or cDNAs which are allelic to the disclosed sequences or which are heterospecific homologues. Thus, the present invention provides isolated nucleic acids corresponding to these alleles and homologues, as well as various recombinant constructs derived from these sequences, by means which are well known in the art. Briefly, one of ordinary skill in the art may now screen preparations of genomic or cDNA, including samples prepared from individual organisms (*e.g.*, human cancer patients or their family members) as well as bacterial, viral, yeast or other libraries of genomic or cDNA, using probes or PCR primers to identify allelic or homologous sequences. Because it is desirable to identify additional CalDAG-GEF and/or cAMP-GEF gene mutations which may contribute to the development of Ras-related cancers, because it is desirable to identify additional CalDAG-GEF and/or cAMP-

- 25 -

GEF polymorphisms which are not mutant or have antitumorigenic effects, and because it is also desired to create a variety of animal models which may be used to study Ras-related cancers and screen for potential therapeutics, it is particularly contemplated that additional CalDAG-GEF and/or cAMP-GEF sequences will be isolated from other preparations or libraries of human
5 nucleic acids and from preparations or libraries from animals including rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates. Furthermore, CalDAG-GEF and/or cAMP-GEF homologues from yeast or invertebrate species, including *C. elegans* and other nematodes, as well as *Drosophila* and other insects, may have particular utility for drug screening. For example, invertebrates bearing mutant CalDAG-GEF and/or cAMP-GEF
10 homologues (or mammalian CalDAG-GEF and/or cAMP-GEF transgenes) which cause a rapidly occurring and easily scored phenotype (*e.g.*, abnormal eye development after several days) can be used as screens for drugs which block the effect of the mutant gene. Such invertebrates may prove far more rapid and efficient for mass screenings than larger vertebrate animals. Once lead compounds are found through such screens, they may be tested in higher animals.

15 Depending upon the intended use, the present invention provides nucleic acid subsequences of the CalDAG-GEF and/or cAMP-GEF genes which may have lengths varying from 8-10 nucleotides (*e.g.*, for use as PCR primers) to nearly the full size of the CalDAG-GEF and/or cAMP-GEF genes. Thus, the present invention provides isolated nucleic acids comprising sequences corresponding to at least 8, preferably at least 10, and more preferably at least 15
20 consecutive nucleotides of the CalDAG-GEF and/or cAMP-GEF genes, as disclosed or otherwise enabled herein, or to their complements.

In another series of embodiments, the present invention provides for isolated nucleic acids encoding all or a portion of the CalDAG-GEF and/or cAMP-GEF proteins in the form of a fusion protein. In these embodiments, a nucleic acid regulatory region (endogenous or
25 exogenous) is operably joined to a first coding region which is covalently joined in-frame to a second coding region. The CalDAG-GEF and/or cAMP-GEF sequences of the fusion protein may represent the first, second, or any additional coding regions. The CalDAG-GEF and/or cAMP-GEF sequences may be conserved or non-conserved domains and can be placed in any coding region for the fusion protein.

30 In another series of embodiments, the present invention provides isolated nucleic acids in the form of recombinant DNA constructs in which a marker or reporter gene (*e.g.*, β -galactosidase, luciferase) is operably joined to the 5' regulatory region of a CalDAG-GEF and/or

- 26 -

cAMP-GEF gene such that expression of the marker gene is under the control of the CalDAG-GEF and/or cAMP-GEF regulatory sequences. Such isolated nucleic acids may be used to produce cells, cell lines or transgenic animals which are useful in the identification of compounds which can, directly or indirectly, differentially affect the expression of the CalDAG-GEFs and/or cAMP-GEFs.

Finally, the isolated nucleic acids of the present invention include any of the above described sequences when included in vectors. Appropriate vectors include cloning vectors and expression vectors of all types, including plasmids, phagemids, cosmids, episomes, and the like, as well as integration vectors. The vectors may also include various marker genes (*e.g.*, antibiotic resistance or susceptibility genes) which are useful in identifying cells successfully transformed therewith. In addition, the vectors may include regulatory sequences to which the nucleic acids of the invention are operably joined, and/or may also include coding regions such that the nucleic acids of the invention, when appropriately ligated into the vector, are expressed as fusion proteins. Such vectors may also include vectors for use in yeast "two hybrid," baculovirus, and phage-display systems.

2. Substantially Pure Proteins

The present invention provides for substantially pure preparations of the CalDAG-GEF and/or cAMP-GEF proteins, fragments of the CalDAG-GEF and/or cAMP-GEF proteins, and fusion proteins including the CalDAG-GEFs and/or cAMP-GEFs or fragments thereof. The proteins, fragments and fusions have utility, as described herein, in the generation of antibodies to normal and mutant CalDAG-GEFs and/or cAMP-GEFs, in the identification of CalDAG-GEF and/or cAMP-GEF binding proteins, and in diagnostic and therapeutic methods. Therefore, depending upon the intended use, the present invention provides substantially pure proteins or peptides comprising amino acid sequences which are subsequences of the complete CalDAG-GEF and/or cAMP-GEF proteins and which may have lengths varying from 4-8 amino acids (*e.g.*, for use as immunogens), or 9-15 amino acids (*e.g.*, for use in binding assays), to the complete CalDAG-GEF and/or cAMP-GEF proteins. Thus, the present invention provides substantially pure proteins or peptides comprising sequences corresponding to at least 4, preferably at least 9, more preferably at least 15 consecutive amino acids of the CalDAG-GEF and/or cAMP-GEF proteins, as disclosed or otherwise enabled herein.

Purification can be achieved using standard protein purification procedures including, but not limited to, gel-filtration chromatography, ion-exchange chromatography, high-performance

- 27 -

liquid chromatography (RP-HPLC, ion-exchange HPLC, size-exclusion HPLC, high-performance chromatofocusing chromatography, hydrophobic interaction chromatography, immunoprecipitation, or immunoaffinity purification. Gel electrophoresis (*e.g.*, PAGE, SDS-PAGE) can also be used to isolate a protein or peptide based on its molecular weight, charge
5 properties, and hydrophobicity.

A CalDAG-GEF or cAMP-GEF protein, or a fragment thereof, may also be conveniently purified by creating a fusion protein including the desired CalDAG-GEF or cAMP-GEF sequence fused to another peptide such as an antigenic determinant or poly-His tag (*e.g.*, QIAexpress vectors, (QIAGEN Corp., Chatsworth, CA)), or a larger protein (*e.g.*, GST using the
10 pGEX-27 vector (Amrad, USA) or green fluorescent protein using the Green Lantern vector (GIBCO/BRL, Gaithersburg, MD)).

3. Antibodies to the CalDAG-GEF and/or cAMP-GEFs

The present invention also provides antibodies, and methods of making antibodies, which selectively bind to the CalDAG-GEF and/or cAMP-GEF proteins or fragments thereof. The
15 antibodies of the invention have utility as laboratory reagents for, *inter alia*, immunoaffinity purification of the CalDAG-GEFs and/or cAMP-GEFs, Western blotting to identify cells or tissues expressing the CalDAG-GEFs and/or cAMP-GEFs, and immunocytochemistry or immunofluorescence techniques to establish the subcellular location of the protein.

The antibodies of the invention may be generated in a host using the entire CalDAG-GEF
20 and/or cAMP-GEF proteins of the invention or using any CalDAG-GEF and/or cAMP-GEF epitope which is characteristic of that protein and which substantially distinguishes it from host proteins. Such epitopes may be identified by comparing sequences of, for example, 4-8 amino acid residues from a CalDAG-GEF and/or cAMP-GEF sequence to computer databases of protein sequences from the relevant host. Antibodies against highly conserved domains are
25 expected to have the greatest utility for purification or identification of CalDAG-GEFs and/or cAMP-GEFs.

Amino acid residue positions which are potential antigenic sites in the CalDAG-GEF or cAMP-GEF proteins and which may be useful in generating the antibodies of the invention may be determined by using computer programs such as the IBI Pustell program. Other methods of
30 choosing antigenic determinants are known in the art and may, of course, be employed. In addition, larger fragments (*e.g.*, 9-15 residues) including some of these epitopes may also be employed. Even larger fragments, including, for example, entire functional domains or multiple

- 28 -

functional domains may also be preferred. For an overview of antibody techniques, see Antibody Engineering: A Practical Guide, Borrebaek, ed., W.H. Freeman & Company, NY (1992), or Antibody Engineering, 2nd Ed., Borrebaek, ed., Oxford University Press, Oxford (1995).

5 The antibodies of the invention may be labelled or conjugated with other compounds or materials for diagnostic and/or therapeutic uses. For example, they may be coupled to radionuclides, fluorescent compounds, or enzymes for imaging or therapy, or to liposomes for the targeting of compounds contained in the liposomes to a specific tissue location.

4. Transformed Cell Lines

10 The present invention also provides for cells or cell lines, both prokaryotic and eukaryotic, which have been transformed or transfected with the nucleic acids of the present invention so as to cause clonal propagation of those nucleic acids and/or expression of the proteins or peptides encoded thereby. Such cells or cell lines will have utility not only in the propagation and production of the nucleic acids and proteins of the present invention but also, as further described herein, as model systems for diagnostic and therapeutic assays. As used herein, 15 the term "transformed cell" is intended to embrace any cell, or the descendant of any cell, into which has been introduced any of the nucleic acids of the invention, whether by transformation, transfection, infection, electroporation, microinjection or other means. Methods of producing appropriate vectors, transforming cells with those vectors, and identifying transformants are well known in the art and are only briefly reviewed here (see, for example, Sambrook et al. (1989) 20 Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

Vectors may be introduced into the recipient or "host" cells by various methods well known in the art including, but not limited to, calcium phosphate transfection, strontium phosphate transfection, DEAE dextran transfection, electroporation, lipofection (*e.g.*, Dosper 25 Liposomal transfection reagent, Boehringer Mannheim, Germany), microinjection, ballistic insertion on micro-beads, protoplast fusion or, for viral or phage vectors, by infection with the recombinant virus or phage.

5. Transgenic Animal Models

30 The present invention also provides for the production of transgenic non-human animal models for the study of Ras-related cancers, for the screening of candidate pharmaceutical compounds, for the creation of explanted mammalian cell cultures (*e.g.*, neuronal, glial,

- 29 -

organotypic or mixed cell cultures) in which mutant or wild type CalDAG-GEF and/or cAMP-GEF sequences are expressed or in which the CalDAG-GEF and/or cAMP-GEF genes have been inactivated (*e.g.*, "knock-out" deletions), and for the evaluation of potential therapeutic interventions.

5 Species suitable for use as animal models in the present invention include, but are not limited to, rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates (*e.g.*, Rhesus monkeys, chimpanzees).

Various techniques for generating transgenic animals, as well as techniques for homologous recombination or gene targeting, are now widely accepted and practiced. See, for
10 example, Hogan et al., Manipulating Mouse Embryo (1986). To create a transgene, the target sequence of interest (*e.g.*, mutant or wild-type CalDAG-GEF or cAMP-GEF sequences) is typically ligated into a cloning site located downstream of a promoter element which will regulate the expression of RNA from the CalDAG-GEF or cAMP-GEF sequence. An alternate approach to creating a transgene is to use endogenous CalDAG-GEF or cAMP-GEF regulatory
15 sequences to drive expression of the CalDAG-GEF or cAMP-GEF transgene.

6. Assays for Drugs Which Affect CalDAG-GEF and/or cAMP-GEF Expression

In another series of embodiments, the present invention provides assays for identifying small molecules or other compounds which are capable of inducing or inhibiting the expression of the CalDAG-GEF or cAMP-GEF genes and proteins. The assays may be performed *in vitro*
20 using non-transformed cells, immortalized cell lines, or recombinant cell lines, or *in vivo* using the transgenic animal models enabled herein.

In particular, the assays may detect the presence of increased or decreased expression of CalDAG-GEF, cAMP-GEF, or other CalDAG-GEF or cAMP-GEF-related genes or proteins, on the basis of increased or decreased mRNA expression (using, *e.g.*, the nucleic acid probes
25 disclosed and enabled herein), increased or decreased levels of CalDAG-GEF, cAMP-GEF or other CalDAG-GEF or cAMP-GEF-related protein products (using, *e.g.*, the anti-CalDAG-GEF or anti-cAMP-GEF antibodies disclosed and enabled herein), or increased or decreased levels of expression of a marker gene (*e.g.*, β -galactosidase or luciferase) operably joined to a CalDAG-GEF or cAMP-GEF 5' regulatory region in a recombinant construct.

30 Thus, for example, one may culture cells known to express a particular CalDAG-GEF or cAMP-GEF and add to the culture medium one or more test compounds. After allowing a sufficient period of time (*e.g.*, 0-72 hours) for the compound to induce or inhibit the expression

- 30 -

of the CalDAG-GEF or cAMP-GEF, any change in levels of expression from an established baseline may be detected using any of the techniques described above and well known in the art. In particularly preferred embodiments, the cells are from an immortalized cell line such as a human neuroblastoma, glioblastoma or a hybridoma cell line. Using the nucleic acid probes and/or antibodies disclosed and enabled herein, detection of changes in the expression of a CalDAG-GEF or cAMP-GEF and thus, identification of the compound as an inducer or repressor of CalDAG-GEF and/or cAMP-GEF expression, requires only routine experimentation.

In particularly preferred embodiments, a recombinant assay is employed in which a reporter gene such as a β -galactosidase, green fluorescent protein, alkaline phosphatase, or luciferase is operably joined to a 5' regulatory region of a CalDAG-GEF or cAMP-GEF gene. The reporter gene and regulatory regions are joined in-frame (or in each of the three possible reading frames) so that transcription and translation of the reporter gene may proceed under the control of the CalDAG-GEF or cAMP-GEF regulatory elements. The recombinant construct may then be introduced into any appropriate cell type, although mammalian cells are preferred, and human cells are most preferred. The transformed cells may be grown in culture and, after establishing the baseline level of expression of the reporter gene, test compounds may be added to the medium. The ease of detection of the expression of the reporter gene provides for a rapid, high through-put assay for the identification of inducers and repressors of the CalDAG-GEF or cAMP-GEF gene.

Compounds identified by this method will have potential utility in modifying the expression of the CalDAG-GEF, cAMP-GEF or other CalDAG-GEF or cAMP-GEF-related genes *in vivo*. These compounds may be further tested in the animal models disclosed and enabled herein to identify those compounds having the most potent *in vivo* effects. In addition, as described herein with respect to small molecules having CalDAG-GEF or cAMP-GEF-binding activity, these molecules may serve as "lead compounds" for the further development of pharmaceuticals by, for example, subjecting the compounds to sequential modifications, molecular modeling, and other routine procedures employed in rational drug design.

7. Identification of Compounds with CalDAG-GEF and/or cAMP-GEF Binding Capacity

In light of the present disclosure, one of ordinary skill in the art is enabled to practice new screening methodologies which will be useful in the identification of proteins and other compounds which bind to, or otherwise directly interact with, the CalDAG-GEFs or cAMP-GEFs. The proteins and compounds will include endogenous cellular components which interact

- 31 -

with the CalDAG-GEFs or cAMP-GEFs *in vivo* and which, therefore, provide new targets for pharmaceutical and therapeutic interventions, as well as recombinant, synthetic and otherwise exogenous compounds which may have CalDAG-GEF or cAMP-GEF binding capacity and, therefore, may be candidates for pharmaceutical agents. Thus, in one series of embodiments, cell
5 lysates or tissue homogenates (*e.g.*, human brain homogenates, leukocyte lysates) may be screened for proteins or other compounds which bind to one of the normal or mutant CalDAG-GEFs and/or cAMP-GEFs. Alternatively, any of a variety of exogenous compounds, both naturally occurring and/or synthetic (*e.g.*, libraries of small molecules or peptides), may be screened for CalDAG-GEF or cAMP-GEF binding capacity. Small molecules are particularly
10 preferred in this context because they are more readily absorbed after oral administration, have fewer potential antigenic determinants, and/or are more likely to cross the blood brain barrier than larger molecules such as nucleic acids or proteins. The methods of the present invention are particularly useful in that they may be used to identify molecules which selectively or preferentially bind to a mutant form of a CalDAG-GEF or cAMP-GEF protein (rather than a
15 normal form) and, therefore, may have particular utility in treating the heterozygous victims of a CalDAG-GEF or cAMP-GEF associated disorder.

Compounds which bind to normal, mutant or both forms of the CalDAG-GEFs or cAMP-GEFs may have utility in treatments and diagnostics. Compounds which bind only to a normal CalDAG-GEF or cAMP-GEF may, for example, act as enhancers of its normal activity and
20 thereby at least partially compensate for the lost or abnormal activity of mutant forms of the CalDAG-GEF or cAMP-GEF in victims suffering from CalDAG-GEF- or cAMP-GEF-associated disorders. Compounds which bind to both normal and mutant forms of a CalDAG-GEF or cAMP-GEF may have utility if they differentially affect the activities of the two forms so as to alleviate the overall departure from normal function. Alternatively, blocking the activity of
25 both normal and mutant forms of either CalDAG-GEF or cAMP-GEF may have less severe physiological and clinical consequences than the normal progress of the disorder and, therefore, compounds which bind to and inhibit the activity of both normal and mutant forms of a CalDAG-GEF or cAMP-GEF may be therapeutically useful. Preferably, however, compounds are identified which have a higher affinity of binding to mutant CalDAG-GEF or cAMP-GEF
30 than to normal CalDAG-GEF or cAMP-GEF, and which selectively or preferentially inhibit the activity of the mutant form. Such compounds may be identified by using any of the techniques

- 32 -

described herein, and then comparing the binding affinities of the candidate compound(s) for the normal and mutant forms of CalDAG-GEF or cAMP-GEF.

The effect of agents which bind to the CalDAG-GEFs or cAMP-GEFs (normal or mutant forms of either) can be monitored either by direct monitoring of this binding (*e.g.*, using the BIAcore assay, LKB Pharmacia, Sweden) or by indirect monitoring of binding by detecting, for example, a change in fluorescence, molecular weight, or concentration of either the binding agent or CalDAG-GEF or cAMP-GEF component, either in a soluble phase or in a substrate-bound phase.

Once identified by the methods described above, the candidate compounds may then be produced in quantities sufficient for pharmaceutical administration or testing (*e.g.*, μg or mg or greater quantities), and formulated in a pharmaceutically acceptable carrier (see, *e.g.*, REMINGTON'S PHARMACEUTICAL SCIENCES, Gennaro, A., ed., Mack Pub., (1990)). These candidate compounds may then be administered to the transformed cells of the invention, to the transgenic animal models of the invention, to cell lines derived from the animal models or from human patients, or to patients with CalDAG-GEF- or cAMP-GEF-associated disorders. The animal models described and enabled herein are of particular utility in further testing candidate compounds which bind to normal or mutant CalDAG-GEF or cAMP-GEF for their therapeutic efficacy.

In addition, once identified by the methods described above, the candidate compounds may also serve as "lead compounds" in the design and development of new pharmaceuticals. For example, as is well known in the art, sequential modification of small molecules (*e.g.*, amino acid residue replacement for peptides; functional group replacement for peptide or non-peptide compounds) is a standard approach in the pharmaceutical industry for the development of new pharmaceuticals. Such development generally proceeds from a "lead compound" which is shown to have at least some of the activity (*e.g.*, CalDAG-GEF or cAMP-GEF binding or blocking ability) of the desired pharmaceutical. In particular, when one or more compounds having at least some activity of interest (*e.g.*, modulation of CalDAG-GEF or cAMP-GEF activity) are identified, structural comparison of the molecules can greatly inform the skilled practitioner by suggesting portions of the lead compounds which should be conserved and portions which may be varied in the design of new candidate compounds. Thus, the present invention also provides a means of identifying lead compounds which may be sequentially modified to produce new candidate compounds for use in the treatment of CalDAG-GEF- or cAMP-GEF-associated

- 33 -

disorders. These new compounds then may be tested both for CalDAG-GEF or cAMP-GEF-binding or blocking (*e.g.*, in the binding assays described above) and for therapeutic efficacy (*e.g.*, in the animal models described herein). This procedure may be iterated until compounds having the desired therapeutic activity and/or efficacy are identified.

5 In each of the present series of embodiments, an assay is conducted to detect binding between a "CalDAG-GEF component" or a "cAMP-GEF component" and some other moiety. Of particular utility will be sequential assays in which compounds are tested for the ability to bind to only the normal or only the mutant forms of the CalDAG-GEF or cAMP-GEF functional domains using mutant and normal CalDAG-GEF or cAMP-GEF components in the binding
10 assays. Such compounds are expected to have the greatest therapeutic utilities, as described more fully below. The "CalDAG-GEF component" or the "cAMP-GEF component" in these assays may be a complete normal or mutant form of a CalDAG-GEF or cAMP-GEF protein (*e.g.*, an hCalDAG-GEF or hcAMP-GEF variant) but need not be. Rather, particular functional domains of the CalDAG-GEFs or cAMP-GEFs, as described above, may be employed either as
15 separate molecules or as part of a fusion protein. For example, to isolate proteins or compounds that interact with these functional domains, screening may be carried out using fusion constructs and/or synthetic peptides corresponding to these regions. Obviously, various combinations of fusion proteins and functional domains from CalDAG-GEF or cAMP-GEF are possible. In addition, the functional domains may be altered so as to aid in the assay by, for example,
20 introducing into the functional domain a reactive group or amino acid residue (*e.g.*, cysteine) which will facilitate immobilization of the domain on a substrate (*e.g.*, using sulfhydryl reactions).

Methods for screening cellular lysates, tissue homogenates, or small molecule libraries for candidate CalDAG-GEF or cAMP-GEF-binding molecules are well known in the art and, in
25 light of the present disclosure, may now be employed to identify compounds which bind to normal or mutant CalDAG-GEF or cAMP-GEF components or which modulate CalDAG-GEF or cAMP-GEF activity as defined by non-specific measures (*e.g.*, changes in intracellular Ca^{2+} , GTP/GDP ratio) or by specific measures (*e.g.*, changes in the expression of other downstream genes which can be monitored by differential display, 2D gel electrophoresis, differential
30 hybridization, or SAGE methods). The preferred methods involve variations on the following techniques: (1) direct extraction by affinity chromatography; (2) co-isolation of CalDAG-GEF or cAMP-GEF components and bound proteins or other compounds by immunoprecipitation; (3)

- 34 -

the Biomolecular Interaction Assay (BIAcore); and (4) the yeast two-hybrid systems. These and others are discussed separately below.

A. Affinity Chromatography

In light of the present disclosure, a variety of affinity binding techniques well known in the art may be employed to isolate proteins or other compounds which bind to the CalDAG-GEFs or cAMP-GEFs disclosed or otherwise enabled herein. In general, a CalDAG-GEF or cAMP-GEF component may be immobilized on a substrate (*e.g.*, a column or filter) and a solution including the test compound(s) is contacted with the CalDAG-GEF or cAMP-GEF protein, fusion or fragment under conditions which are permissive for binding. The substrate is then washed with a solution to remove unbound or weakly bound molecules. A second wash may then elute those compounds which strongly bound to the immobilized normal or mutant CalDAG-GEF or cAMP-GEF component. Alternatively, the test compounds may be immobilized and a solution containing one or more CalDAG-GEF or cAMP-GEF components may be contacted with the column, filter, or other substrate. The ability of the CalDAG-GEF or cAMP-GEF component to bind to the test compounds may be determined as above or a labeled form of the CalDAG-GEF or cAMP-GEF component (*e.g.*, a radio-labeled or chemiluminescent functional domain) may be used to more rapidly assess binding to the substrate-immobilized compound(s).

B. Co-Immunoprecipitation

Another well characterized technique for the isolation of the CalDAG-GEF or cAMP-GEF components and their associated proteins or other compounds is direct immunoprecipitation with antibodies. This procedure has been successfully used, for example, to isolate many of the synaptic vesicle associated proteins (Phizicky et al., 59 J. BIOL. CHEM. 94-123 (1994)). Thus, either normal or mutant CalDAG-GEF or cAMP-GEF components may be mixed in a solution with the candidate compound(s) under conditions which are permissive for binding, and the CalDAG-GEF or cAMP-GEF component may be immunoprecipitated. Proteins or other compounds which co-immunoprecipitate with the CalDAG-GEF or cAMP-GEF component may then be identified by standard techniques as described above. General techniques for immunoprecipitation may be found in, for example, Harlow et al., ANTIBODIES: A LABORATORY MANUAL (1988).

- 35 -

The antibodies employed in this assay, as described and enabled herein, may be polyclonal or monoclonal, and include the various antibody fragments as well as single chain antibodies, and the like.

C. The Biomolecular Interaction Assay

5 Another useful method for the detection and isolation of binding proteins is the Biomolecular Interaction Assay or "BIAcore" system developed by Pharmacia Biosensor and described in the manufacturer's protocol (LKB Pharmacia, Sweden). In light of the present disclosure, one of ordinary skill in the art is now enabled to employ this system, or a substantial equivalent, to identify proteins or other compounds having CalDAG-GEF or cAMP-GEF binding capacity. The BIAcore system uses an affinity purified anti-GST antibody to immobilize GST-
10 fusion proteins onto a sensor chip. Obviously, other fusion proteins and corresponding antibodies may be substituted. The sensor utilizes surface plasmon resonance which is an optical phenomenon that detects changes in refractive indices. A homogenate of a tissue of interest is passed over the immobilized fusion protein and protein-protein interactions are registered as
15 changes in the refractive index. This system can be used to determine the kinetics of binding and to assess whether any observed binding is of physiological relevance.

D. The Yeast Two-Hybrid System

The yeast "two-hybrid" system takes advantage of transcriptional factors that are composed of two physically separable, functional domains. One commonly used system employs
20 the yeast GAL4 transcriptional activator, consisting of a DNA binding domain and a transcriptional activation domain. Two different cloning vectors are used to generate separate fusions of the GAL4 domains to genes encoding potential binding proteins. The fusion proteins are co-expressed, targeted to the nucleus and, if interactions occur, activation of a reporter gene (*e.g.*, lacZ) produces a detectable phenotype.

25 E. Other Methods

The nucleotide sequences and protein products, including both mutant and normal forms of these nucleic acids and their corresponding proteins, can be used with the above techniques to isolate other interacting proteins, and to identify other genes whose expression is altered by the over-expression of normal CalDAG-GEF or cAMP-GEF sequences, by the under-expression of
30 normal CalDAG-GEFs or cAMP-GEFs sequences, or by the expression of mutant CalDAG-GEF and/or cAMP-GEF sequences. Identification of these interacting proteins, as well as the identification of other genes whose expression levels are altered in the face of mutant CalDAG-

- 36 -

GEF or cAMP-GEF sequences (for instance) will identify other gene targets which have direct relevance to the pathogenesis of this disease in its clinical or pathological forms. Specifically, these techniques rely on PCR-based and/or hybridization-based methods to identify genes which are differentially expressed between two conditions (a cell line expressing normal CalDAG-GEFs or cAMP-GEFs compared to the same cell type expressing a mutant CalDAG-GEF or cAMP-GEF sequence). These techniques include differential display, serial analysis of gene expression (SAGE), mass-spectrometry of protein, 2D-gels and subtractive hybridization (See, e.g., Nowak, 270 Sci. 368-371 (1995); Kahn, 270 Sci. 369-370 (1995)).

8. Methods of Identifying Compounds Modulating CalDAG-GEF and/or cAMP-GEF Activity

In another series of embodiments, the present invention provides for methods of identifying compounds with the ability to modulate the activity of normal and mutant CalDAG-GEFs and/or cAMP-GEFs. As used with respect to this series of embodiments, the term "activity" broadly includes gene and protein expression, CalDAG-GEF and/or cAMP-GEF protein post-translation processing, trafficking and localization, and any functional activity (e.g., enzymatic, receptor-effector, binding, channel), as well as downstream affects of any of these. Using the transformed cells and transgenic animal models of the present invention, cells obtained from subjects bearing a mutant CalDAG-GEF and/or cAMP-GEF gene, or animals or human subjects bearing naturally occurring CalDAG-GEF and/or cAMP-GEF mutations, it is now possible to screen candidate pharmaceuticals and treatments for their therapeutic effects by detecting changes in one or more of the functional characteristics or phenotypic manifestations of normal or mutant CalDAG-GEF and/or cAMP-GEF expression.

Thus, the present invention provides methods for screening or assaying for proteins, small molecules or other compounds which modulate CalDAG-GEF and/or cAMP-GEF activity by contacting a cell *in vivo* or *in vitro* with a candidate compound and assaying for a change in a marker associated with normal or mutant CalDAG-GEF and/or cAMP-GEF activity. The marker associated with CalDAG-GEF and/or cAMP-GEF activity may be any measurable biochemical, physiological, histological and/or behavioral characteristic associated with CalDAG-GEF and/or cAMP-GEF expression. In particular, useful markers will include any measurable biochemical, physiological, histological and/or behavioral characteristic which distinguishes cells, tissues, animals or individuals bearing at least one mutant CalDAG-GEF and/or cAMP-GEF gene from their normal counterparts. In addition, the marker may be any specific or non-specific measure of CalDAG-GEF and/or cAMP-GEF activity, such as the GDP/GTP bound to Rap1/Ras.

- 37 -

CalDAG-GEF and/or cAMP-GEF specific measures include measures of CalDAG-GEF and/or cAMP-GEF expression (*e.g.*, CalDAG-GEF and/or cAMP-GEF mRNA or protein levels) which may employ the nucleic acid probes or antibodies of the present invention. Non-specific measures include changes in cell physiology such as pH, intracellular calcium, cAMP levels, overall GTP/GDP ratios, phosphatidylinositol activity, protein phosphorylation, etc., which can be monitored by known methods. The activation or inhibition of CalDAG-GEF or cAMP-GEF activity in its mutant or normal form can also be monitored by examining changes in the expression of other genes which are specific to the CalDAG-GEF and/or cAMP-GEF pathway. These can be assayed by such techniques as differential display, differential hybridization, and SAGE, as well as by 2-D gel electrophoresis of cellular lysates. In each case, the differentially-expressed genes can be ascertained by inspection of identical studies before and after application of the candidate compound. Furthermore, as noted elsewhere, the particular genes whose expression is modulated by the administration of the candidate compound can be ascertained by cloning, nucleotide sequencing, amino acid sequencing, or mass spectrometry.

In general, a cell may be contacted with a candidate compound and, after an appropriate period (*e.g.*, 0-72 hours for most biochemical measures of cultured cells), the marker of CalDAG-GEF or cAMP-GEF activity may be assayed and compared to a baseline measurement. The baseline measurement may be made prior to contacting the cell with the candidate compound or may be an external baseline established by other experiments or known in the art. The cell may be a transformed cell of the present invention or an explant from an animal or individual. In particular, the cell may be an explant from a carrier of a CalDAG-GEF or cAMP-GEF mutation or an animal model of the invention (*e.g.*, a transgenic nematode or mouse bearing a mutant CalDAG-GEF or cAMP-GEF gene). Preferred cells include those from neurological tissues such as neuronal, glial or mixed cell cultures; and cultured fibroblasts, liver, kidney, spleen, or bone marrow. The cells may be contacted with the candidate compounds in a culture *in vitro* or may be administered *in vivo* to a live animal or human subject. For live animals or human subjects, the test compound may be administered orally or by any parenteral route suitable to the compound. For clinical trials of human subjects, measurements may be conducted periodically (*e.g.*, daily, weekly or monthly) for several months or years.

In light of the identification, characterization, and disclosure herein of the CalDAG-GEF or cAMP-GEF genes and proteins, the CalDAG-GEF or cAMP-GEF nucleic acid probes and antibodies, and the CalDAG-GEF or cAMP-GEF transformed cells and transgenic animals of the

invention, one of ordinary skill in the art is now enabled by perform a great variety of assays which will detect the modulation of CalDAG-GEF or cAMP-GEF activity by candidate compounds. Particularly preferred and contemplated embodiments are discussed in some detail below.

5 A. CalDAG-GEF and/or cAMP-GEF Expression

In one series of embodiments, specific measures of CalDAG-GEF or cAMP-GEF expression are employed to screen candidate compounds for their ability to affect CalDAG-GEF or cAMP-GEF activity. Thus, using the CalDAG-GEF or cAMP-GEF nucleic acids and antibodies disclosed and otherwise enabled herein, one may use mRNA levels or protein levels
10 as a marker for the ability of a candidate compound to modulate CalDAG-GEF or cAMP-GEF activity. The use of such probes and antibodies to measure gene and protein expression is well known in the art and discussed elsewhere herein.

 B. Intracellular Localization

In another series of embodiments, compounds may be screened for their ability to
15 modulate the activity of the CalDAG-GEFs or cAMP-GEFs based upon their effects on the trafficking and intracellular localization of the CalDAG-GEFs or cAMP-GEFs. Differences in localization of mutant and normal CalDAG-GEFs and/or cAMP-GEFs may contribute to the etiology of CalDAG-GEF and/or cAMP-GEF-associated diseases. Compounds which can affect the localization of the CalDAG-GEFs and/or cAMP-GEFs may, therefore, be identified as
20 potential therapeutics. Standard techniques known in the art may be employed to detect the localization of the CalDAG-GEFs and/or cAMP-GEFs. Generally, these techniques will employ the antibodies of the present invention, and in particular antibodies which selectively bind to one or more mutant CalDAG-GEFs or cAMP-GEFs but not to normal CalDAG-GEFs or cAMP-GEFs. As is well known in the art, such antibodies may be labeled by any of a variety of
25 techniques (e.g., fluorescent or radioactive tags, labeled secondary antibodies, avidin-biotin, etc.) to aid in visualizing the intracellular location of the CalDAG-GEFs or cAMP-GEFs. The CalDAG-GEFs or cAMP-GEFs may be co-localized to particular structures, as is known in the art, using antibodies to markers of those structures (e.g., TGN38 for the Golgi, transferrin receptor for post-Golgi transport vesicles, LAMP2 for lysosomes). Western blots of purified
30 fractions from cell lysates enriched for different intracellular membrane bound organelles (e.g., lysosomes, synaptosomes, Golgi) may also be employed. In addition, the relative orientation of

- 39 -

different domains of the CalDAG-GEFs and/or cAMP-GEFs across cellular domains may be assayed using, for example, electron microscopy and antibodies raised to those domains.

9. Screening and Diagnostics for CalDAG-GEF- or cAMP-GEF-associated disorders

A. General Diagnostic Methods

5 The CalDAG-GEF or cAMP-GEF genes and gene products, as well as the CalDAG-GEF or cAMP-GEF-derived probes, primers and antibodies, disclosed or otherwise enabled herein, are useful in the screening for carriers of alleles associated with CalDAG-GEF- or cAMP-GEF-associated disorders. Individuals at risk for such a disorder or individuals not previously known to be at risk, may be routinely screened using probes to detect the presence of a mutant CalDAG-GEF or cAMP-GEF gene or protein by a variety of techniques. Diagnosis of inherited cases of these diseases can be accomplished by methods based upon the nucleic acids (including genomic and mRNA/cDNA sequences), proteins, and/or antibodies disclosed and enabled herein, including functional assays designed to detect increases or decreases of the normal CalDAG-GEF or cAMP-GEF activity and/or the presence of specific new activities conferred by the mutant CalDAG-GEFs or cAMP-GEFs. Preferably, the methods and products are based upon the human CalDAG-GEF or cAMP-GEF nucleic acids, proteins or antibodies, as disclosed or otherwise enabled herein. For brevity of exposition, but without limiting the scope of the invention, the following description will focus upon uses of the human homologues of CalDAG-GEF and cAMP-GEF. It will be understood, however, that homologous sequences from other species, including those disclosed herein, will be equivalent for many purposes.

B. Protein Based Screens and Diagnostics

When a diagnostic assay is to be based upon CalDAG-GEF or cAMP-GEF proteins, a variety of approaches are possible. For example, diagnosis can be achieved by monitoring differences in the electrophoretic mobility of normal and mutant proteins. Such an approach will be particularly useful in identifying mutants in which insertions, deletions or substitutions have resulted in a significant change in the electrophoretic migration of the resultant protein. Alternatively, diagnosis may be based upon differences in the proteolytic cleavage patterns of normal and mutant proteins, differences in molar ratios of the various amino acid residues, or by functional assays demonstrating altered function of the gene products.

30 C. Nucleic Acid Based Screens and Diagnostics

When the diagnostic assay is to be based upon nucleic acids from a sample, the assay may be based upon mRNA, cDNA or genomic DNA. Whether mRNA, cDNA, or genomic DNA is

- 40 -

assayed, standard methods well known in the art may be used to detect the presence of a particular sequence either *in situ* or *in vitro* (See, e.g., Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed. (1989)).

(1) Appropriate Probes and Primers

5 Whether for hybridization, RNase protection, ligase-mediated detection, PCR amplification or any other standards methods described herein and well known in the art, a variety of subsequences of the CalDAG-GEF and/or cAMP-GEF sequences disclosed or otherwise enabled herein will be useful as probes and/or primers. These sequences or
10 subsequences will include both normal CalDAG-GEF or cAMP-GEF sequences and deleterious mutant sequences. In general, useful sequences will include at least 8-10, more preferably 10-15, and most preferably 15-25 consecutive nucleotides from the CalDAG-GEF or cAMP-GEF
introns, exons or intron/exon boundaries. In another embodiment, useful sequences include at least 25-500 consecutive nucleotides. Depending upon the target sequence, the specificity
15 required, and future technological developments, shorter sequences may also have utility. Therefore, any CalDAG-GEF or cAMP-GEF derived sequence which is employed to isolate, clone, amplify, identify or otherwise manipulate a CalDAG-GEF or cAMP-GEF sequence may be regarded as an appropriate probe or primer.

(2) Hybridization Screening

For *in situ* detection of a normal or mutant CalDAG-GEF, cAMP-GEF or other CalDAG-
20 GEF and/or cAMP-GEF-associated nucleic acid sequence, a sample of tissue may be prepared by standard techniques and then contacted with one or more of the above-described probes, preferably one which is labeled to facilitate detection, and an assay for nucleic acid hybridization is conducted under stringent conditions which permit hybridization only between the probe and
highly or perfectly complementary sequences.

25 (3) Restriction Mapping

Sequence alterations may also create or destroy fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by electrophoresis and visualization. DNA fragments carrying the site (normal or mutant) are detected by their
30 increase or reduction in size, or by the increase or decrease of corresponding restriction fragment numbers. Such restriction fragment length polymorphism analysis (RFLP), or restriction mapping, may be employed with genomic DNA, mRNA or cDNA. The CalDAG-GEF or cAMP-GEF sequences may be amplified by PCR using the above-described primers prior to

- 41 -

restriction, in which case the lengths of the PCR products may indicate the presence or absence of particular restriction sites, and/or may be subjected to restriction after amplification. The CalDAG-GEF or cAMP-GEF fragments may be visualized by any convenient means (*e.g.*, under UV light in the presence of ethidium bromide).

5 (4) PCR Mapping

In another series of embodiments, a single base substitution mutation may be detected based on differential PCR product length or production in PCR. Thus, primers which span mutant sites or which, preferably, have 3' termini at mutation sites, may be employed to amplify a sample of genomic DNA, mRNA or cDNA from a subject. A mismatch at a mutational site may
10 be expected to alter the ability of the normal or mutant primers to promote the polymerase reaction and, thereby, result in product profiles which differ between normal subjects and heterozygous and/or homozygous CalDAG-GEF or cAMP-GEF mutants.

(5) Electrophoretic Mobility

Genetic testing based on DNA sequence differences also may be achieved by detection of
15 alterations in electrophoretic mobility of DNA, mRNA or cDNA fragments in gels. Small sequence deletions and insertions, for example, can be visualized by high resolution gel electrophoresis of single or double stranded DNA, or as changes in the migration pattern of DNA heteroduplexes in non-denaturing gel electrophoresis.

(6) Chemical Cleavage of Mismatches

20 Mutations in the CalDAG-GEFs or cAMP-GEFs may also be detected by employing the chemical cleavage of mismatch (CCM) method (*See, e.g.*, Saleeba et al., METHODS IN ENZYMOLOGY, 217: 286-295 (1993)). In this technique, probes (up to ~ 1 kb) may be mixed with a sample of genomic DNA, cDNA or mRNA obtained from a subject. The sample and probes are mixed and subjected to conditions which allow for heteroduplex formation (if any).
25 Preferably, both the probe and sample nucleic acids are double-stranded, or the probe and sample may be PCR amplified together, to ensure creation of all possible mismatch heteroduplexes. Mismatched T residues are reactive to osmium tetroxide and mismatched C residues are reactive to hydroxylamine. Because each mismatched A will be accompanied by a mismatched T, and each mismatched G will be accompanied by a mismatched C, any nucleotide differences between
30 the probe and sample (including small insertions or deletions) will lead to the formation of at least one reactive heteroduplex. After treatment with osmium tetroxide and/or hydroxylamine to modify any mismatch sites, the mixture is subjected to chemical cleavage at any modified

- 42 -

mismatch sites by, for example, reaction with piperidine. The mixture may then be analyzed by standard techniques such as gel electrophoresis to detect cleavage products which would indicate mismatches between the probe and sample.

(7) Other Methods

5 Various other methods of detecting CalDAG-GEF or cAMP-GEF mutations, based upon the CalDAG-GEF or cAMP-GEF sequences disclosed and otherwise enabled herein, will be apparent to those of ordinary skill in the art. Any of these may be employed in accordance with the present invention. These include, but are not limited to, nuclease protection assays (S1 or
10 ligase-mediated), ligated PCR, denaturing gradient gel electrophoresis (DGGE; *see, e.g.*, Fischer et al., 80 PROC. NAT'L ACAD. SCI (USA), 1578-83 (1983)), restriction endonuclease fingerprinting combined with SSCP (REF-SSCP; *see, e.g.*, Liu et al., 18 BIOTECHNIQUES 470-79 (1995)), and the like.

D. Other Screens and Diagnostics

15 Diagnosis also can be made by observation of alterations in CalDAG-GEF or cAMP-GEF transcription, translation, and post-translational modification and processing as well as alterations in the intracellular and extracellular trafficking of CalDAG-GEF or cAMP-GEF gene products in the brain and peripheral cells. Such changes will include alterations in the amount of CalDAG-GEF or cAMP-GEF messenger RNA and/or protein, alteration in phosphorylation state, abnormal intracellular location/distribution, abnormal extracellular distribution, etc. Such assays
20 will include: Northern Blots (with CalDAG-GEF or cAMP-GEF-specific and non-specific nucleotide probes), Western blots and enzyme-linked immunosorbent assays (ELISA) (with antibodies raised specifically to a CalDAG-GEF or a cAMP-GEF functional domain, including various post-translational modification states).

E. Screening and Diagnostic Kits

25 In accordance with the present invention, diagnostic kits are also provided which will include the reagents necessary for the above-described diagnostic screens. For example, kits may be provided which include antibodies or sets of antibodies which are specific to one or more mutant epitopes. These antibodies may, in particular, be labeled by any of the standard means which facilitate visualization of binding. Alternatively, kits may be provided in which
30 oligonucleotide probes or PCR primers, as described above, are present for the detection and/or amplification of mutant CalDAG-GEF, cAMP-GEF or other CalDAG-GEF and/or cAMP-GEF-associated nucleotide sequences. Again, such probes may be labeled for easier detection of

- 43 -

specific hybridization. As appropriate to the various diagnostic embodiments described above, the oligonucleotide probes or antibodies in such kits may be immobilized to substrates and appropriate controls may be provided.

10. Methods of Treatment

5 The present invention now provides a basis for therapeutic intervention in diseases which are associated to the CalDAG-GEFs or cAMP-GEFs in that they are caused, prevented, exacerbated, or alleviated, or which may be caused, prevented, exacerbated, or alleviated, by the either normal or mutant CalDAG-GEFs or cAMP-GEFs. In considering the various therapies described below, it is understood that such therapies may be targeted at tissue other than the brain
10 where CalDAG-GEF or cAMP-GEF are also expressed.

Therapies to treat CalDAG-GEF and/or cAMP-GEF-associated diseases may be based upon (1) administration of normal CalDAG-GEF or cAMP-GEF proteins, (2) gene therapy with normal CalDAG-GEF or cAMP-GEF genes to compensate for or replace the mutant genes, (3) gene therapy based upon antisense sequences to mutant CalDAG-GEF or cAMP-GEF genes or
15 which "knock-out" the mutant genes, (4) gene therapy based upon sequences which encode a protein which blocks or corrects the deleterious effects of CalDAG-GEF or cAMP-GEF mutants, (5) immunotherapy based upon antibodies to normal and/or mutant CalDAG-GEF or cAMP-GEF proteins, or (6) small molecules (drugs) which alter CalDAG-GEF or cAMP-GEF expression, block abnormal interactions between mutant forms of CalDAG-GEF or cAMP-GEF and other
20 proteins or ligands, or which otherwise block the aberrant function of mutant CalDAG-GEF or cAMP-GEF proteins by altering the structure of the mutant proteins, by enhancing their metabolic clearance, or by inhibiting their function.

A. Protein Therapy

Treatment of CalDAG-GEF and/or cAMP-GEF-associated disorders, or disorders
25 resulting from CalDAG-GEF and/or cAMP-GEF mutations, may be performed by providing an excess of inactive mutant protein to decrease the effect of the normal function of the protein, or by providing an excess of normal protein to reduce the effect of any aberrant function of the mutant protein, by replacing a mutant protein with normal protein, or by modulating the function of the mutant protein.

30 B. Gene Therapy

In one series of embodiments, gene therapy may be employed in which normal or mutant copies of the CalDAG-GEF gene or the cAMP-GEF gene are introduced into patients to code

- 44 -

successfully for normal or mutant protein in one or more different affected cell types. The gene must be delivered to those cells in a form in which it can be taken up and code for sufficient protein to provide effective function. Thus, it is preferred that the recombinant gene be operably joined to a strong promoter so as to provide a high level of expression which will compensate for, or out-compete, the naturally-occurring proteins. As noted above, the recombinant construct may contain endogenous or exogenous regulatory elements, inducible or repressible regulatory elements, or tissue-specific regulatory elements.

In another series of embodiments, gene therapy may be employed to replace the naturally-occurring gene by homologous recombination with a recombinant construct. The recombinant construct may contain a normal or a mutant copy of the targeted CalDAG-GEF and/or cAMP-GEF gene, in which case the defect is corrected *in situ*, or may contain a "knock-out" construct which introduces a stop codon, missense mutation, or deletion which abolished function of the mutant gene. It should be noted in this respect that such a construct may knock-out both the normal and mutant copies of the targeted CalDAG-GEF and/or cAMP-GEF gene in a heterozygous individual, but the total loss of CalDAG-GEF and/or cAMP-GEF gene function may be less deleterious to the individual than continued progression of the disease state.

In another series of embodiments, antisense gene therapy may be employed. The antisense therapy is based on the fact that sequence-specific suppression of gene expression can be achieved by intracellular hybridization between mRNA or DNA and a complementary antisense species. The formation of a hybrid duplex may then interfere with the transcription of the gene and/or the processing, transport, translation and/or stability of the target CalDAG-GEF and/or cAMP-GEF mRNA. Antisense strategies may use a variety of approaches including the administration of antisense oligonucleotides or antisense oligonucleotide analogs (*e.g.*, analogs with phosphorothioate backbones) or transfection with antisense RNA expression vectors. Again, such vectors may include exogenous or endogenous regulatory regions, inducible or repressible regulatory elements, or tissue-specific regulatory elements.

In another series of embodiments, gene therapy may be used to introduce a recombinant construct encoding a protein or peptide which blocks or otherwise corrects the aberrant function caused by a naturally-occurring CalDAG-GEF and/or cAMP-GEF gene. In one embodiment, the recombinant gene may encode a peptide which corresponds to a mutant domain of a CalDAG-GEF and/or cAMP-GEF which has been found to abnormally interact with another cell protein or other cell ligand. Alternatively, the portion of a protein which interacts with a mutant, but not a

- 45 -

normal, CalDAG-GEF and/or cAMP-GEF may be encoded and expressed by a recombinant construct in order to compete with, and thereby inhibit or block, the aberrant interaction.

Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression. The targeted cells however must be able to divide and the expression of the levels of normal protein should be high. The full length CalDAG-GEF or cAMP-GEF genes, subsequences encoding functional domains of the CalDAG-GEFs or cAMP-GEFs, or any of the other therapeutic peptides described above, can be cloned into a retroviral vector and driven from its endogenous promoter, from the retroviral long terminal repeat, or from a promoter specific for the target cell type of interest. Other viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpes virus such as Epstein-Barr virus.

C. Immunotherapy

Antibodies may be raised to a mutant CalDAG-GEF or cAMP-GEF protein (or a portion thereof) and be administered to a patient to bind or block the mutant protein and prevent its deleterious effects. Alternatively, antibodies may be raised to specific complexes between mutant or wild-type CalDAG-GEF or cAMP-GEF and their interaction partners.

A further approach is to stimulate endogenous antibody production to the desired antigen. An immunogenic composition may be prepared as injectables, as liquid solutions or emulsions. The CalDAG-GEF or cAMP-GEF protein or other antigen may be mixed with pharmaceutically acceptable excipients compatible with the protein. Such excipients may include water, saline, dextrose, glycerol, ethanol and combinations thereof. The immunogenic composition and vaccine may further contain auxiliary substances such as emulsifying agents or adjuvants to enhance effectiveness. Immunogenic compositions and vaccines may be administered parenterally by injection subcutaneously or intramuscularly.

The immunogenic preparations and vaccines are administered in such amount as will be therapeutically effective, protective and immunogenic. Dosage depends on the route of administration and will vary according to the size of the host.

D. Small Molecule Therapeutics

As described and enabled herein, the present invention provides for a number of methods of identifying small molecules or other compounds which may be useful in the treatment of CalDAG-GEF- or cAMP-GEF-associated disorders. Thus, for example, the present invention provides for methods of identifying CalDAG-GEF or cAMP-GEF binding proteins and, in

- 46 -

particular, methods for identifying proteins or other cell components which bind to or otherwise interact with mutant CalDAG-GEFs or cAMP-GEFs but not with the normal CalDAG-GEFs or cAMP-GEFs. The invention also provides for methods of identifying small molecules which can be used to disrupt undesired interactions between CalDAG-GEFs or cAMP-GEFs and other proteins or other cell components.

By identifying these proteins and analyzing these interactions, it is possible to screen for or design compounds which counteract or prevent the interaction, thereby, providing treatment for abnormal interactions. Therapies can be designed to modulate these interactions and thereby, to modulate CalDAG-GEF- or cAMP-GEF-associated disorders. The potential efficacy of these therapies can be tested by analyzing the affinity and function of these interactions after exposure to the therapeutic agent by standard pharmacokinetic measurements of affinity (*e.g.*, K_d, V_{max}) using synthetic peptides or recombinant proteins corresponding to functional domains of the CalDAG-GEF gene, the cAMP-GEF gene or other CalDAG-GEF and/or cAMP-GEF homologues. Another method for assaying the effect of any interactions involving functional domains is to monitor changes in the intracellular trafficking and post-translational modification of the relevant genes by *in situ* hybridization, immunohistochemistry, Western blotting and metabolic pulse-chase labeling studies in the presence of, and in the absence of, the therapeutic agents. A further method is to monitor the effects of "downstream" events including changes in second messenger events, *e.g.*, cAMP, intracellular Ca²⁺, protein kinase activities, etc.

The effect of potential therapeutic agents in cell lines and whole animals can be monitored by monitoring transcription, translation, and post-translational modification of the CalDAG-GEF and/or cAMP-GEF proteins. Methods for these studies include Western and Northern blots, immunoprecipitation after metabolic labelling (pulse-chase) with radio-labelled methionine and ATP, and immunohistochemistry. The effect of these agents can also be monitored using studies which examine the relative binding affinities and relative amounts of CalDAG-GEF or cAMP-GEF proteins involved in interactions with Rap1A, using either standard binding affinity assays or co-precipitation and Western blots using antibodies to Rap1A, CalDAG-GEF, cAMP-GEF, or other CalDAG-GEF and/or cAMP-GEF homologues.

Therapy using antisense oligonucleotides to block the expression of the mutant CalDAG-GEF gene or the mutant cAMP-GEF gene, co-ordinated with gene replacement with normal CalDAG-GEF or cAMP-GEF gene can also be applied using standard techniques of either gene therapy or protein replacement therapy.

V. Examples

Example 1: Isolation and characterization of CalDAG-GEF.

Human full-length CalDAG-GEFI cDNAs were isolated from a human frontal cortex λ ZAPII cDNA library (Stratagene) and a U937 λ ZAPII cDNA library. Mouse full-length
5 CalDAG-GEFI was identified in the mouse EST database (GenBank accession number: W71787). Rat full-length CalDAG-GEFII cDNA was isolated from a rat whole brain λ ZAPII cDNA library by using human CalDAG-GEFII as a probe. Mouse ESTs identified through BLAST searches were purchased from Genome Systems Inc. (St. Louis, MO).

CalDAG-GEFI encodes an approximately 69-kD protein (Fig. 2D) that displays in its
10 amino terminal region a GEF domain that is highly homologous to Ras-superfamily GEFs (Fig. 2A-2D). Multiple alignment analysis shows that genes of the CalDAG-GEF family form a cluster within the Ras-GEF superfamily distinct from Ras GEFs such as Sos1 and rRas-GEF (Fig. 2B). The region downstream of the GEF domain contains two tandem repeats of EF-hand Ca^{2+} binding motifs (Figs. 2A, 2E). The carboxy-terminal region displays a typical
15 diacylglycerol/phorbol ester-binding domain, which is present in most PKC family proteins (Fig. 2A, 2F). Multiple sequence alignments and phylogenetic tree analysis were carried out with the LASERGENE Software Package (DNASTAR Inc.). Abbreviations and GenBank accession numbers of the protein sequences used in Figure 2 are as follows: C3G: 474982, mCdc25: 882120, rRas-GRF: 57665, hSos1 (human son-of-sevenless 1): 476780, BUD5: 171141,
20 hCalmodulin: 115512, hCalbindin D28k: 227666, hCalcineurin B: 105504, hParvalbumin a: 131100, hTroponin C: 136043, hPKCa: 125549, hPKCb1: 125538, hPKCg: 462455.

To determine the small G protein target of CalDAG-GEFI, guanine nucleotide exchange activity *in vivo* was analyzed using intact 293T cells cotransfected with a eukaryotic expression construct of mouse CalDAG-GEFI and GST-tagged Ras family proteins. Full-length mouse
25 CalDAG-GEFI cDNA inserted into a pCMV-SPORT expression vector with a carboxy-terminal FLAG epitope was used for transfection. A PCR-amplified fragment of rat CalDAG-GEFII was subcloned into a pCAGGS expression vector with the addition of His₆-tag at its amino-terminus, resulting in pCAGGS-His-CalDAGII. pEBG-Krev1 that expresses Rap1A was used as a fusion protein to glutathione S-transferase (GST) in mammalian cells, as described in Gotoh et al., 15
30 Mol. Cell Biol. 6746-53 (1995), pEBG-R-Ras, other vectors for Ras-family proteins obtained by inserting PCR-amplified cDNAs into pEBG expression vector, pCAGGS-C3G and pCAGGS-MSos1, and pCEV-H-RasV12. CalDAG-GEFI transfection produced a dramatic increase in

- 48 -

GTP-bound Rap1A compared to the control but showed no or minimal activation of H-Ras, R-Ras, or Ral A. The increase in GTP-bound Rap1A was augmented in the presence of either the Ca^{2+} ionophore, A23187, or the phorbol ester, phorbol-12-myristate-13-acetate (TPA). Further, A23187 and TPA had additive effects when administered together.

5 To determine the effect of CalDAG-GEFI on the Erk/MAP kinase cascade, Elk1 activation was measured in 293T cells transfected with CalDAG-GEFI or constitutively active H-Ras (RasV12), or both. 293T cells were transfected by SuperFect (Qiagen) as described in Gotoh, *supra*, with expression vectors for GST-tagged Ras family proteins and with those for various GEFs. Cells were labeled 24 hours after transfection with $^{32}\text{P}_i$ for 2 hr. In some
10 experiments, cells were stimulated with either 10 μM A23187 or 1 μM phorbol-12-myristate-13-acetate (TPA) for 3 min. GST-tagged Ras family proteins were collected from cell lysates with glutathione Sepharose. Guanine nucleotides bound to Ras family proteins were separated by thin layer chromatography (TLC). Activation of Elk1 was examined by the PathDetect Elk1 transreporting system (Stratagene). 293T cells were transfected with pFR-Luc and pFA-Elk1
15 with various expression vectors, and light output was detected and analyzed by the use of LAS1000 film. CalDAG-GEFI reduced RasV12 activation of Elk1 by approximately 4-fold and did not itself activate Elk1. Thus, CalDAG-GEFI strongly inhibits Ras-dependent stimulation of the Erk/MAP kinase cascade.

Northern analysis showed that human CalDAG-GEFI is expressed strongly in the brain
20 and that CalDAG-GEFI mRNA is strikingly enriched in the striatum. Probes used included human CalDAG-GEFI: 729-bp EcoRI fragment, human CalDAG-GEFII: 584-bp SacI and HindIII fragment, rat CalDAG-GEFI: 439-bp fragment of EST clone RBC565 (GenBank accession number: C06861, and rat CalDAG-GEFII: 508-bp PCR amplified and subcloned
25 fragment (nucleic acids 2541 to 3048 of SEQ ID NO:5). *In situ* hybridization of sections from the adult rat brain confirmed these restricted distribution patterns. Intense signal was present in the striatum (caudoputamen) and the ventral striatum (nucleus accumbens, olfactory tubercle). There was weaker signal in the olfactory bulb.

A series of monoclonal antibodies against the carboxy-terminal half of mouse CalDAG-GEFI were raised. His₆-tagged mouse CalDAG-GEFI polypeptide (amino acids 349 to 608 of
30 SEQ ID NO:1) was expressed in bacteria, purified over Ni^{2+} -nitrilotriacetic acid-agarose resin, and then used to immunize BALB/c mice. The resultant polyclonal antiserum was monitored by ELISA, Western blot, immunoprecipitation, and immunofluorescence assays on CalDAG-GEFI.

- 49 -

transfected COS-7 cells. Hybridomas were generated by PEG (polyethylene glycol)-mediated fusion of donor splenocytes to the SP2/O cell line. Positive hybridoma cell lines were identified by screening in the assays described above, and purified by limiting dilution and single-cell cloning. Three hybridoma cell lines against mouse CalDAG-GEFI (mAbs 18B11, 2D9, and 18A7), in addition to the polyclonal fusion serum, were identified. Western analysis showed that mAbs 18B11 and 2D9 were specific for CalDAG-GEFI. Lightly post-fixed, cryostat-cut 10 μ m thick sections were immunostained by the ABC (Vectastain kit) method for CalDAG-GEFI with mAbs 18B11 and 2D9 and the polyclonal fusion serum, for tyrosine hydroxylase (TH) with monoclonal antibodies from INCSTAR, and for μ opioid receptor with polyclonal antiserum. Immunohistochemistry with mAb 18B11 showed a striking basal ganglia-enriched distribution pattern in sections of adult rat brain, with significant but weaker activity elsewhere. CalDAG-GEFI immunoreactivity marked the entire pathway from the striatal matrix compartment to the pallidum and substantia nigra pars reticulata, where very intense CalDAG-GEFI staining was present. Thus, CalDAG-GEFI is synthesized in striatal projection neurons and is transported to striatopallidal and striatonigral terminals.

To confirm that CalDAG-GEFI is synthesized in striatal projection neurons and transported to striatopallidal and striatonigral terminals in rats, intrastriatal injections of ibotenic acid (20 μ g/ μ l, 1.5 μ l per site, 5 day survival) were made unilaterally at 2 sites in the mid-lateral caudoputamen, with contralateral vehicle control injections were made. In other rats, unilateral subthalamic knife-cuts were made at an anteroposterior level between the entopeduncular nucleus and substantia nigra to sever the striatonigral efferents (1 and 3 days survivals), with control contralateral thalamic knife-cuts. These procedures all reduced CalDAG-GEFI staining in the substantia nigra. *In situ* hybridization was performed according to Simmons et al, 12 J. Histotechnol. 169-181 (1989). A 439bp rat EST clone RBC565 (98.4% identical to mouse CalDAG-GEFI nucleic acids 1777 to 2216 of SEQ ID NO:1) was isolated by BLAST search and used for making RNA probes with ³²P-labeled UTP (2,000 Ci/mmol, NEN, 1 Ci = 37 GBq) and T3 and T7 RNA polymerase. Brains were processed as above for CalDAG-GEFI and TH immunostaining. Thus, CalDAG-GEFI is a protein transported in striatal axons to their terminals. The terminal localization of CalDAG-GEFI was confirmed in subcellular fractionation experiments on dissected samples from the rat ventral midbrain, in which Western analysis showed the presence of CalDAG-GEFI in cytosol and in membrane fractions, including synaptosomes.

- 50 -

Because of the similarity of the GEF domains of CalDAG-GEFI and CalDAG-GEFII, the substrate specificity of CalDAG-GEFII with the same 293T cell assay system used for CalDAG-GEFI was examined. It was confirmed that CalDAG-GEFII activates Ras, and further shown that it activates H-Ras and R-Ras, but not Ral A or Rap1A. H-Ras activation was enhanced by A23187 and TPA. Moreover, CalDAG-GEFII, unlike CalDAG-GEFI, increased the transcriptional activity of Elk1 downstream to Erk/MAP kinase. Thus, in the 293T system, CalDAG-GEFI and CalDAG-GEFII target different Ras-superfamily small G proteins and have opposite effects on the MAP kinase cascade. Northern analysis further showed contrasting brain expression for CalDAG-GEFII, with highest expression being in the cerebellum, cerebral cortex, and amygdala, and low expression occurring in the striatum. Both genes are also expressed in hematopoietic organs in both human and rat.

Rap signaling is important in regulating basal ganglia output in response to Ca^{2+} and DAG. Corticostriatal inputs can activate the MAP kinase cascade in striatal projection neurons (Sgambat et al., 18 J. Neurosci. 214-26 (1993)) and phosphoinositide (PI) signaling is strongly represented in these pathways (Fotuhi et al., 13 J. Neurosci. 3300-08 (1993)). Moreover, a number of receptor systems in the striatum and its striatonigral/striatopallidal pathways are linked to Ca^{2+} and PI signaling, notably including NMDA and metabotropic glutamate receptors, D_2 -class dopamine receptors, and tachykinin receptors (Fiorillo et al., 394 Nature 78-82 (1998)). A previously unrecognized signaling target for some of these systems is likely to be Rap1, via CalDAG-GEFI. In addition, CalDAG-GEFI has a synaptic function as demonstrated by the heavy accumulation of CalDAG-GEFI in the target nuclei of striatal outputs and the localization of Rap1 in synaptosomes and synaptic vesicles. The particular basal ganglia projection systems are enriched in CalDAG-GEFI and are differentially vulnerable to neurodegeneration in Huntington's disease.

Rap and Ras functions can be regulated coordinately or disjunctively by Ca^{2+} and DAG in the brain and hematopoietic organs, depending on the relative expression of CalDAG-GEFI and CalDAG-GEFII. In neurons, Ras/MAP kinase signaling has been directly implicated in synaptic transmission and the neuroplasticity underlying learning and memory. Different CalDAG-GEFI and CalDAG-GEFII expression patterns in the brain influence region-specific neuroplasticity mediated by Ca^{2+} and DAG signaling pathways. The presence of CalDAG-GEFI and CalDAG-GEFII in the hematopoietic system demonstrates the direct input of Ca^{2+} and DAG to Ras/Rap regulation of normal growth and differentiation as well as malignant transformation.

- 51 -

Example 2: Isolation and characterization of cAMP-GEFs.

cAMP-GEFI and cAMP-GEFII have similar domain structures, with a cAMP binding domain at the amino terminus and a GEF domain at the carboxy terminus separated by a link region (LR) (Fig. 3A). These mammalian proteins show strong structural homology to a predicted open reading frame (T20G5.5) in *C. elegans* cAMP-GEF (cel cAMP-GEF) (Fig. 3A). The cAMP binding domains of the cAMP-GEF family proteins form a distinct group within the cyclic nucleotide-binding protein superfamily and show the closest similarity to the B domains of PKA regulatory subunits (Fig. 3B). A PR(A/T)AT motif in the cAMP binding pocket is also conserved in the cAMP-GEF proteins (Fig. 3E). The first alanine of this motif confers cAMP (alanine) as opposed to cGMP (threonine) binding specificity. All of the cAMP-GEF family members have alanine at this position, and therefore bind cAMP rather than cGMP.

The GEF domains of the cAMP-GEFs show high homology to those of Ras-GEF family proteins, but form an independent cluster distinct from Ras GEFs such as mCdc25, hSos1, and rRas-GRF (Fig. 3, C and D). The three structurally conserved regions specific to Ras-GEF family proteins (SCR1, SCR2, and SCR3) are present in all of the cAMP-GEF proteins (Fig. 3D). Multiple sequence alignments and phylogenetic tree analyses were carried out with LASERGENE (DNASTAR Inc.). Abbreviations and GenBank accession numbers of the protein sequences used in this figure: hPKARI α (human cAMP-dependent protein kinase regulatory subunit type I-alpha): 125193, hPKARI β : 1346362, hPKARII α : 125198, hPKARII β : 400115, hPKGI α (human cGMP-dependent protein kinase type I-alpha): 1255602, hPKGI β : 125379, hPKGII: 1906312, hCalDAG-GEFI: U71870, hCalDAG-GEFII: AF081195, C3G: 474982, hSos1 (human son-of-sevenless 1): 476780, mCdc25: 882120, rRas-GRF: 57665, BUD5: 171141.

In order to identify the small G protein substrate for cAMP-GEFI and II and the mode of cAMP regulation of GEF activity conferred by these proteins, the effects of cAMP-GEFI and cAMP-GEFII expression were analyzed in 293T cells on the ratio of GTP to GDP bound to different Ras family small G proteins in the presence or absence of forskolin and IBMX. Under basal conditions, in the absence of forskolin and IBMX, only Rap1 was activated significantly. In the presence of forskolin and IBMX, both cAMP-GEFI and II strongly and selectively activated Rap1A, but did not activate H-Ras, R-Ras or RalA. The effects of forskolin/IBMX treatment on cAMP-GEFI and II were dose-dependent with EC₅₀ values of 1.8 μ M and 0.3 μ M, respectively. Forskolin/IBMX treatment given alone had no effect.

- 52 -

A time-course analysis of the activation of Rap1A by forskolin/IBMX in cAMP-GEFI transfectants showed that the activation began within 10 sec, reached a maximum at 5 min, and continued for at least 60 min. Thus, cAMP-GEFI has a direct effect on Rap1A rather than secondary effects mediated by other Ras-superfamily GEFs. In addition, Sp-cAMPS, an analogue of cAMP, activated Rap1A at levels similar to those induced by forskolin/IBMX. Thus, cAMP has the capacity to activate the GEF domain of cAMP-GEFI.

Mutational analyses with cAMP-GEFI was performed to examine whether its cAMP-binding domain is required for the activation of Rap1A. In contrast to wild type cAMP-GEFI, a deletion mutant lacking a cAMP binding domain (pcDNA-rcAMP-GEFI:DcAMP(528) and (595)) did not activate Rap1A with or without forskolin/IBMX treatment. Mutants with a single amino acid substitution at the cAMP binding pocket (pcDNA-rcAMP-GEFI:R(279)K) responded minimally to forskolin/IBMX treatment. Thus, the cAMP binding domain of cAMP-GEFI is necessary for its cAMP-dependent activation of Rap1A.

To assess further the cAMP binding capacity of cAMP-GEFI, a cAMP agarose affinity bead binding assay was performed. *In vitro* translated, radiolabeled cAMP-GEFI showed selective binding to the beads that was competed by excess amounts of either cAMP or 8-Br-cAMP. cAMP-GEF protein can bind cAMP and that this binding can activate Rap1A.

cAMP-dependent activation of Rap1 has previously been ascribed to the phosphorylation of Rap1A by PKA, which raises its affinity to smgGDS, a GEF with broad substrate specificity. However, at least in the 293T cell assay system, an increase of GTP-bound Rap1A in response to increasing cAMP levels with forskolin or treatment with the cAMP analogue, Sp-cAMPS was not detected in the absence of cAMP-GEFs. In addition, even in the presence of H-89, a potent and selective inhibitor of PKA, cAMP-GEFI and II could still activate Rap1A. The activation of Rap1A induced by cAMP-GEFI and II is independent of the PKA pathway.

Intracellular cAMP has been shown to interact directly with ion channels, but the vast majority of cAMP-mediated effects in eukaryotes have been considered as sequels to cAMP binding by the regulatory subunits of the PKA tetramer. The diversity of physiological effects produced by cAMP have been attributed to the fact that, as a kinase, PKA has a large range of molecular targets. Reported herein are novel cAMP binding proteins that directly link the cAMP second messenger system to Ras superfamily signaling pathways and that appear selectively to target Rap.

- 53 -

cAMP can exert profound cell-type specific effects on cell growth and differentiation and that cAMP is capable of inhibiting or stimulating the Ras/mitogen-activated protein (MAP) kinase/Erk pathway. The inhibition can occur at the initial translocation step by which Ras activates Raf, whereas activation of Rap1 is thought to occur through phosphorylation by PKA.

5 Activation of Rap1 has been suggested to be part of a switch mechanism determining whether growth or differentiation occurs in response to nerve growth factor (NGF). cAMP-GEFs directly couple cAMP to Rap1, itself discovered as a negative regulator of Ras but suspected of having independent functions as well. Thus, different levels of cAMP-GEF expression confer cell-type specific regulation of Ras superfamily signaling systems.

10 The genes also exhibit developmentally regulated expression in the septum, medial thalamus and habenula, key structures in the limbic system variously linked to brain reward circuits, addiction and schizophrenia. Thus, cAMP-GEFs, in addition to PKA, underlie some of the neuronal functions of cAMP.

Example 3. Northern hybridization demonstrating the expression of CalDAG-GEFI and

15 CalDAG-GEFII protein mRNAs in a variety of tissues.

Total cytoplasmic RNA was isolated from various human tissue samples including amygdala, cerebellum, corpus callosum, caudate nucleus, cortex, frontal lobe, hippocampus, kidney, liver, lung, medulla oblongata, occipital pole, putamen, spinal cord, substantia nigra, subthalamic nucleus, thalamus, and temporal lobe, obtained from surgical pathology using
20 standard procedures such as CsCl purification. The RNA was then electrophoresed on a formaldehyde gel to permit size fractionation. The nitrocellulose membrane was prepared and the RNA was then transferred onto the membrane. ³²P-labeled cDNA probes were prepared and added to the membrane in order for hybridization between the probe the RNA to occur. After washing, the membrane was wrapped in plastic film and placed into imaging cassettes containing
25 X-ray film. The autoradiographs were then allowed to develop for one to several days. Sizing was established by comparison to standard RNA markers. These northern blots demonstrated that the CalDAG-GEF genes are strongly expressed in the brain. Weaker hybridization was detectable elsewhere.

Example 4. Northern hybridization demonstrating the expression of cAMP-GEFI and cAMP-GEFII protein mRNAs in a variety of tissues.

30

- 54 -

Northern hybridization analysis was performed as in Example 3 to detect the expression of the cAMP-GEFI and cAMP-GEFII genes in a variety of human tissues. The tissues analyzed included adrenal gland, amygdala, bone marrow, cerebellum, corpus callosum, caudate nucleus, colon (mucosal lining), caudputamen, cortex, frontal lobe, hippocampus, habenula, heart, kidney, liver, lung, lymph node, medulla obongata, occipital pole, olfactory bulb, ovary, pons, pancreas, putamen, septum, small intestines, skeletal muscle, spinal cord, spleen, stomach, substantia nigra, subthalamic nucleus, testis, thalamus, temporal lobe, thymus, trachea, and thyroid.

A striking contrast in the expression patterns of human cAMP-GEFI and II was observed by Northern analysis. Human cAMP-GEFI is widely expressed, with highest levels appearing in kidney, spleen, thyroid, heart, and pancreas. Human cAMP-GEFII shows a remarkably selective enrichment in the brain and the adrenal glands. Both genes were developmentally regulated. The expression patterns of the two genes in the nervous system also differ, with cAMP-GEFI having a wider expression than cAMP-GEFII. These region-specific neuronal expression patterns were confirmed in *in situ* hybridization experiments. cAMP-GEFI mRNA is expressed broadly at low levels in the adult brain, but it is strongly and selectively expressed in parts of the neonatal brain, including the septum and the thalamus. By contrast, cAMP-GEFII is strongly expressed in the mature as well as the developing brain. Notable are the high levels of cAMP-GEFII mRNA in the cerebral cortex, the hippocampus (especially CA3 and dentate gyrus), the habenula and the cerebellum. Genes of the cAMP-GEF family have widespread influence on cAMP functions in bodily organs and also region-specific functions in the brain.

Example 5. Isolation of CalDAG-GEF or cAMP-GEF binding proteins by yeast two-hybrid system.

To identify proteins interacting with the CalDAG-GEF or cAMP-GEF proteins, a yeast expression plasmid vector (pAS2-1, Clontech) is generated by ligating an in-frame partial cDNA sequence encoding either residues of the CalDAG-GEF protein or residues of the cAMP-GEF protein into the EcoRI and BamHI sites of the vector. The resultant fusion protein contains the GAL4 DNA binding domain coupled in-frame either to residues of the CalDAG-GEF protein or to residues of the cAMP-GEF protein. These expression plasmids are co-transformed, along with purified plasmid DNA from the human brain cDNA:pACT library, into yeast using the protocols of the Clontech Matchmaker yeast-two-hybrid kit (Clontech). Yeast clones bearing human brain cDNAs which interact with the CalDAG-GEF or cAMP-GEF fragments are selected by HIS resistance and β gal+ activation. The clones are further selected by

- 55 -

cyclohexamide sensitivity and the inserts of the human brain cDNAs are isolated by PCR and sequenced.

Although preferred embodiments of the invention have been described herein in detail, it will be understood by those skilled in the art that variations may be made thereto without
5 departing from the spirit of the invention or the scope of the following claims.

- 56 -

CLAIMS

What is claimed is:

- 1 1. An isolated nucleic acid comprising a nucleotide sequence encoding a protein
2 selected from the group consisting of a normal CalDAG-GEFI protein, a mutant CalDAG-GEFI
3 protein, a normal CalDAG-GEFII protein, and a mutant CalDAG-GEFII protein.
- 1 2. An isolated nucleic acid comprising a nucleotide sequence encoding a protein
2 selected from the group consisting of a normal cAMP-GEFI protein, a mutant cAMP-GEFI
3 protein, a normal cAMP-GEFII protein, and a mutant cAMP-GEFII protein.
- 1 3. An isolated nucleic acid as in claim 1 wherein said nucleic acid encodes a normal
2 CalDAG-GEF protein and wherein said nucleotide sequence is selected from the group
3 consisting of
 - 4 (a) a sequence encoding a protein comprising the human CalDAG-GEFI amino acid
5 sequence of SEQ ID NO: 4;
 - 6 (b) a sequence encoding a protein comprising the murine CalDAG-GEFI amino acid
7 sequence of SEQ ID NO: 2;
 - 8 (c) a sequence encoding a protein comprising the human CalDAG-GEFII amino acid
9 sequence of SEQ ID NO: 8; and
 - 10 (d) a sequence encoding a protein comprising the murine CalDAG-GEFII amino acid
11 sequence of SEQ ID NO: 6; and
 - 12 (e) a sequence encoding a normal CalDAG-GEF protein and capable of hybridizing to
13 a sequence complementary to any sequence of (a) - (d) under stringent hybridization conditions.
- 1 4. An isolated nucleic acid as in claim 2 wherein said nucleic acid encodes a normal
2 cAMP-GEF protein and wherein said nucleotide sequence is selected from the group consisting
3 of
 - 4 (a) a sequence encoding a protein comprising the human cAMP-GEFI amino acid
5 sequence of SEQ ID NO: 12;
 - 6 (b) a sequence encoding a protein comprising the alternatively spliced human cAMP-
7 GEFI amino acid sequence of SEQ ID NO: 14;
 - 8 (c) a sequence encoding a protein comprising the rat cAMP-GEFI amino acid
9 sequence of SEQ ID NO: 10;
 - 10 (d) a sequence encoding a protein comprising the human cAMP-GEFII amino acid
11 sequence of SEQ ID NO: 18;

- 57 -

- 12 (e) a sequence encoding a protein comprising the rat cAMP-GEFII amino acid
13 sequence of SEQ ID NO: 16; and
- 14 (f) a sequence encoding a normal cAMP-GEF protein and capable of hybridizing to a
15 sequence complementary to any sequence of (a) - (e) under stringent hybridization conditions.
- 1 5. An isolated nucleic acid comprising a nucleotide sequence of at least 8 consecutive
2 nucleotides selected from the group consisting SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5,
3 SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO.
4 17, and a sequence complementary to any of these sequences.
- 1 6. An isolated nucleic acid comprising a nucleotide sequence of at least 10 consecutive
2 nucleotides selected from the group consisting SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5,
3 SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO.
4 17, and a sequence complementary to any of these sequences.
- 1 7. An isolated nucleic acid comprising a nucleotide sequence of at least 15 consecutive
2 nucleotides selected from the group consisting SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5,
3 SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO.
4 17, and a sequence complementary to any of these sequences.
- 1 8. An isolated nucleic acid comprising a nucleotide sequence encoding at least one
2 functional domain of a CalDAG-GEF protein selected from the group consisting of a normal
3 CalDAG-GEFI protein, a mutant CalDAG-GEFI protein, a normal CalDAG-GEFII protein, and a
4 mutant CalDAG-GEFII protein.
- 1 9. An isolated nucleic acid comprising a nucleotide sequence encoding at least one
2 functional domain of a cAMP-GEF protein selected from the group consisting of a normal
3 cAMP-GEFI protein, a normal cAMP-GEFII protein, a mutant cAMP-GEFI protein, and a
4 mutant cAMP-GEFII protein.
- 1 10. An isolated nucleic acid comprising a nucleotide sequence encoding an antigenic
2 determinant of a CalDAG-GEF protein selected from the group consisting of a normal CalDAG-
3 GEFI protein, a normal CalDAG-GEFII protein, a mutant CalDAG-GEFI protein, and a mutant
4 CalDAG-GEFII protein.
- 1 11. An isolated nucleic acid comprising a nucleotide sequence encoding an antigenic
2 determinant of a cAMP-GEF protein selected from the group consisting of a normal cAMP-GEFI
3 protein, a normal cAMP-GEFII protein, a mutant cAMP-GEFI protein, and a mutant cAMP-
4 GEFII protein.

- 58 -

- 1 12. A method for identifying an allelic variant or heterospecific homologue of a human
2 CalDAG-GEF gene comprising:
3 choosing a nucleic acid probe or primer capable of hybridizing to a human CalDAG-
4 GEF gene sequence under stringent hybridization conditions;
5 mixing said probe or primer with a sample of nucleic acids which may contain a
6 nucleic acid corresponding to said variant or homologue; and
7 detecting hybridization of said probe or primer to said nucleic acid corresponding to
8 said variant or homologue.
- 1 13. A method as in claim 12 wherein said human CalDAG-GEF gene sequence is
2 selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 7.
- 1 14. A method as in claim 12 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of human genomic DNA, human mRNA, and human cDNA.
- 1 15. A method as in claim 12 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of mammalian genomic DNA, mammalian mRNA, and
3 mammalian cDNA.
- 1 16. A method as in claim 12 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of invertebrate genomic DNA, invertebrate mRNA, and
3 invertebrate cDNA.
- 1 17. A method as in claim 12 further comprising the step of isolating said nucleic acid
2 corresponding to said variant or homologue.
- 1 18. A method as in claim 12 wherein said nucleic acid is identified by hybridization.
- 1 19. A method as in claim 12 wherein said nucleic acid is identified by PCR amplification.
- 1 20. A method for identifying allelic variants or heterospecific homologues of a human
2 cAMP-GEF gene comprising:
3 choosing a nucleic acid probe or primer capable of hybridizing to a human cAMP-
4 GEF gene sequence under stringent hybridization conditions;
5 mixing said probe or primer with a sample of nucleic acids which may contain a
6 nucleic acid corresponding to said variant or homologue; and
7 detecting hybridization of said probe or primer to said nucleic acid corresponding to
8 said variant or homologue.
- 1 21. A method as in claim 12 wherein said human cAMP-GEF gene sequence is selected
2 from the group consisting of SEQ ID NO: 11, SEQ ID NO: 13, and SEQ ID NO: 17.

- 59 -

- 1 22. A method as in claim 20 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of human genomic DNA, human mRNA, and human cDNA.
- 1 23. A method as in claim 20 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of mammalian genomic DNA, mammalian mRNA, and
3 mammalian cDNA.
- 1 24. A method as in claim 20 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of invertebrate genomic DNA, invertebrate mRNA, and
3 invertebrate cDNA.
- 1 25. A method as in claim 20 further comprising the step of isolating said nucleic acid
2 corresponding to said variant or homologue.
- 1 26. A method as in claim 20 wherein said nucleic acid is identified by hybridization.
- 1 27. A method as in claim 20 wherein said nucleic acid is identified by PCR amplification.
- 1 28. A method for identifying an allelic variant or heterospecific homologue of a human
2 CalDAG-GEF gene comprising:
3 choosing an antibody capable of selectively binding to a human CalDAG-GEF
4 protein;
5 mixing said antibody with a sample of proteins which may contain a protein
6 corresponding to said variant or homologue; and
7 detecting binding of said antibody to said protein corresponding to said variant or
8 homologue.
- 1 29. A method as in claim 28 wherein said sample comprises a sample of proteins selected
2 from the group consisting of human proteins, human fusion proteins, and proteolytic fragments
3 thereof.
- 1 30. A method as in claim 28 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of mammalian proteins, mammalian fusion proteins, and
3 proteolytic fragments thereof.
- 1 31. A method as in claim 28 wherein said sample comprises a sample of nucleic acids
2 selected from the group consisting of invertebrate proteins, invertebrate fusion proteins, and
3 proteolytic fragments thereof.
- 1 32. A method as in claim 28 further comprising the step of substantially purifying said
2 protein corresponding to said variant or homologue.

- 60 -

- 1 33. A method for identifying an allelic variant or heterospecific homologue of a human
2 cAMP-GEF gene comprising:
3 choosing an antibody capable of selectively binding to a human cAMP-GEF protein;
4 mixing said antibody with a sample of proteins which may contain a protein
5 corresponding to said variant or homologue; and
6 detecting binding of said antibody to said protein corresponding to said variant or
7 homologue.
- 1 34. A method as in claim 33 wherein said sample comprises a sample of proteins selected
2 from the group consisting of human proteins, human fusion proteins, and proteolytic fragments
3 thereof.
- 1 35. A method as in claim 33 wherein said sample comprises a sample of proteins selected
2 from the group consisting of mammalian proteins, mammalian fusion proteins, and proteolytic
3 fragments thereof.
- 1 36. A method as in claim 33 wherein said sample comprises a sample of proteins selected
2 from the group consisting of invertebrate proteins, invertebrate fusion proteins, and proteolytic
3 fragments thereof.
- 1 37. A method as in claim 33 further comprising the step of substantially purifying said
2 protein corresponding to said variant or homologue.
- 1 38. An isolated nucleic acid comprising an allelic variant or a heterospecific homologue
2 of a gene selected from the group consisting of a human CalDAG-GEF gene, and a human
3 cAMP-GEF gene.
- 1 39. An isolated nucleic acid encoding an allelic variant or heterospecific homologue of a
2 protein selected from the group consisting of a human CalDAG-GEF protein, and a human
3 cAMP-GEF protein.
- 1 40. An isolated nucleic acid comprising a recombinant vector including a nucleotide
2 sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5,
3 SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO:
4 17, and a sequence complementary to any of these sequences.
- 1 41. An isolated nucleic acid as in claim 40 wherein said vector is an expression vector
2 and said nucleotide sequence is operably joined to a regulatory region.
- 1 42. An isolated nucleic acid as in claim 41 wherein said expression vector may express
2 said nucleotide sequence in mammalian cells.

- 61 -

- 1 43. An isolated nucleic acid as in claim 42 wherein said cells are selected from the group
2 consisting of fibroblast, liver, kidney, spleen, bone marrow, and neurological cells.
- 1 44. An isolated nucleic acid as in claim 42 wherein said vector is selected from the group
2 consisting of vaccinia virus, adenovirus, retrovirus, neurotropic viruses, and Herpes simplex.
- 1 45. An isolated nucleic acid as in claim 41 wherein said expression vector encodes at
2 least a functional domain of a protein selected from the group consisting of normal CalDAG-
3 GEFI, a normal CalDAG-GEFII, a mutant CalDAG-GEFI, a mutant CalDAG-GEFII, a normal
4 cAMP-GEFI, a normal cAMP-GEFII, a mutant cAMP-GEFI, and a mutant cAMP-GEFII.
- 1 46. An isolated nucleic acid as in claim 41 wherein said vector further comprises
2 sequences encoding an exogenous protein operably joined to said nucleotide sequence and
3 whereby said vector encodes a fusion protein.
- 1 47. An isolated nucleic acid as in claim 46 wherein said exogenous protein is selected
2 from the group consisting of lacZ, trpE, maltose-binding protein, poly-His tags, and glutathione-
3 S-transferase.
- 1 48. An isolated nucleic acid comprising a recombinant expression vector including
2 nucleotide sequences corresponding to an endogenous regulatory region of a gene selected from
3 the group consisting of a CalDAG-GEF gene, and a cAMP-GEF gene.
- 1 49. An isolated nucleic acid as in claim 48 wherein said endogenous regulatory region is
2 operably joined to a marker gene.
- 1 50. A host cell transformed with an expression vector of any one of claims 41-49, or a
2 descendant thereof.
- 1 51. A host cell as in claim 50 wherein said host cell is selected from the group consisting
2 of bacterial cells and yeast cells.
- 1 52. A host cell as in claim 50 wherein said host cell is selected from the group consisting
2 of fetal cells, embryonic stem cells, zygotes, gametes, and germ line cells.
- 1 53. A host cell as in claim 50 wherein said cell is selected from the group consisting of
2 fibroblast, liver, kidney, spleen, bone marrow and neurological cells.
- 1 54. A host cell as in claim 50 wherein said cell is an invertebrate cell.
- 1 55. A non-human animal model for cancer, wherein a genome of said animal, or an
2 ancestor thereof, has been modified by at least one recombinant construct, and wherein said
3 recombinant construct has introduced a modification selected from the group consisting of

- 62 -

- 4 (a) insertion of nucleotide sequences encoding at least a functional domain of
5 a heterospecific normal CalDAG-GEF gene;
6 (b) insertion of nucleotide sequences encoding at least a functional domain of
7 a heterospecific mutant CalDAG-GEF gene;
8 (c) insertion of nucleotide sequences encoding at least a functional domain of
9 a conspecific homologue of a heterospecific mutant CalDAG-GEF gene;
10 (d) inactivation of an endogenous CalDAG-GEF gene;
11 (e) insertion of nucleotide sequences encoding at least a functional domain of
12 a heterospecific normal cAMP-GEF gene;
13 (f) insertion of nucleotide sequences encoding at least a functional domain of a
14 heterospecific mutant cAMP-GEF gene;
15 (g) insertion of nucleotide sequences encoding at least a functional domain of
16 a conspecific homologue of a heterospecific mutant cAMP-GEF gene; and
17 (h) inactivation of an endogenous cAMP-GEF gene.

1 56. A non-human animal model as in claim 55 wherein said cancer is related to the Ras-
2 pathway.

1 57. A non human animal model as in claim 56 wherein said cancer is selected from the
2 group consisting of lung cancer, pancreatic cancer, breast cancer, colorectal cancer, and myeloid
3 leukemia.

1 58. An animal model as in claim 55 wherein said modification is an insertion of a
2 nucleotide sequence encoding at least a functional domain of a protein selected from the group
3 consisting of a normal human CalDAG-GEF, and a normal cAMP-GEF gene.

1 59. An animal model as in claim 55 wherein said modification is an insertion of a
2 nucleotide sequence encoding at least a functional domain of a protein selected from the group
3 consisting of a mutant human CalDAG-GEF, and a mutant human cAMP-GEF gene.

1 60. An animal as in claim 55 wherein said animal is selected from the group consisting of
2 rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates.

1 61. An animal as in claim 55 wherein said animal is an invertebrate.

1 62. A method for producing at least a functional domain of a protein selected from the
2 group consisting of a CalDAG-GEF protein, and a cAMP-GEF protein, said method comprising
3 culturing a host cell of any of claims 50-54 under suitable conditions to produce said protein by
4 expressing said nucleic acid.

- 63 -

1 63. A substantially pure preparation of a protein selected from the group consisting of a
2 normal CalDAG-GEF protein, a mutant CalDAG-GEF protein, a normal cAMP-GEF protein,
3 and a mutant cAMP-GEF protein.

1 64. A substantially pure preparation as in claim 63 wherein said protein comprises a
2 normal protein selected from the group consisting of

3 (a) a protein comprising the amino acid sequence of SEQ ID NO: 2;

4 (b) a protein comprising the amino acid sequence of SEQ ID NO: 4;

5 (c) a protein comprising the amino acid sequence of SEQ ID NO: 6;

6 (d) a protein comprising the amino acid sequence of SEQ ID NO: 8;

7 (e) a protein comprising the amino acid sequence of SEQ ID NO: 10;

8 (f) a protein comprising the amino acid sequence of SEQ ID NO: 12;

9 (g) a protein comprising the amino acid sequence of SEQ ID NO: 14;

10 (h) a protein comprising the amino acid sequence of SEQ ID NO: 16; and

11 (i) a protein comprising the amino acid sequence of SEQ ID NO: 18.

1 65. A substantially pure preparation of a polypeptide comprising an amino acid sequence
2 of at least 4 consecutive amino acid residues selected from the group consisting of SEQ ID NO:
3 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID
4 NO: 14, SEQ ID NO: 16, and SEQ ID NO: 18.

1 66. A substantially pure preparation of a polypeptide comprising an amino acid sequence
2 of at least 10 consecutive amino acid residues selected from the group consisting of SEQ ID NO:
3 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID
4 NO: 14, SEQ ID NO: 16, and SEQ ID NO: 18.

1 67. A substantially pure preparation of a polypeptide comprising an amino acid sequence
2 of at least 15 consecutive amino acid residues selected from the group consisting of SEQ ID NO:
3 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID
4 NO: 14, SEQ ID NO: 16, and SEQ ID NO: 18.

1 68. A substantially pure preparation of a polypeptide comprising at least one functional
2 domain of a protein selected from the group consisting of a normal CalDAG-GEF protein, a
3 mutant CalDAG-GEF protein, a normal cAMP-GEF protein, and a mutant cAMP-GEF protein.

1 69. A substantially pure preparation of a polypeptide comprising an antigenic determinant
2 of a protein selected from the group consisting of a normal CalDAG-GEF protein, a mutant
3 CalDAG-GEF protein, a normal cAMP-GEF protein, and a mutant cAMP-GEF protein.

- 64 -

1 70. A method of producing antibodies which selectively bind to a CalDAG-GEF protein
2 comprising the steps of
3 administering an immunogenically effective amount of a CalDAG-GEF immunogen
4 to an animal;
5 allowing said animal to produce antibodies to said immunogen; and
6 obtaining said antibodies from said animal or from a cell culture derived therefrom.

1 71. A method of producing antibodies which selectively bind to a cAMP-GEF protein
2 comprising the steps of
3 administering an immunogenically effective amount of a cAMP-GEF immunogen to
4 an animal;
5 allowing said animal to produce antibodies to said immunogen; and
6 obtaining said antibodies from said animal or from a cell culture derived therefrom.

1 72. A substantially pure preparation of an antibody which selectively binds to an
2 antigenic determinant of a protein selected from the group consisting of a normal CalDAG-GEF
3 protein, a mutant CalDAG-GEF protein, a normal cAMP-GEF protein, and a mutant cAMP-GEF
4 protein.

1 73. A substantially pure preparation of an antibody as in claim 72 wherein said antibody
2 selectively binds to an antigenic determinant of a mutant CalDAG-GEF and fails to bind to a
3 normal CalDAG-GEF protein.

1 74. A substantially pure preparation of an antibody as in claim 72 wherein said antibody
2 selectively binds to an antigenic determinant of a mutant cAMP-GEF and fails to bind to a
3 normal cAMP-GEF protein.

1 75. A cell line producing an antibody of any one of claims 72-74.

1 76. A method for identifying compounds which can modulate the expression of a
2 CalDAG-GEF gene comprising:
3 contacting a cell with a test candidate wherein said cell includes a regulatory region of
4 a CalDAG-GEF gene operably joined to a coding region; and
5 detecting a change in expression of said coding region.

1 77. A method for identifying compounds which can modulate the expression of a cAMP-
2 GEF gene comprising:
3 contacting a cell with a test candidate wherein said cell includes a regulatory region of
4 a cAMP-GEF gene operably joined to a coding region; and

- 65 -

5 detecting a change in expression of said coding region.

1 78. A method as in claim 76 or 77 wherein said change comprises a change in a level of
2 an mRNA transcript encoded by said coding region.

1 79. A method as in claim 78 wherein said change comprises a change in a level of a
2 protein encoded by said coding region.

1 80. A method as in claim 78 wherein said change is a result of an activity of a protein
2 encoded by said coding region.

1 81. A method as in claim 78 wherein said coding region encodes a marker protein
2 selected from the group consisting of β -galactosidase, alkaline phosphatase, green fluorescent
3 protein, and luciferase.

1 82. A method for identifying compounds which can selectively bind to a CalDAG-GEF
2 protein comprising the steps of
3 providing a preparation including at least one CalDAG-GEF component;
4 contacting said preparation with a sample including at least one candidate compound;
5 and
6 detecting binding of said CalDAG-GEF component to said candidate compound.

1 83. A method for identifying compounds which can selectively bind to a cAMP-GEF
2 protein comprising the steps of
3 providing a preparation including at least one cAMP-GEF component;
4 contacting said preparation with a sample including at least one candidate compound;
5 and
6 detecting binding of said cAMP-GEF component to said candidate compound.

1 84. The method in claim 82 wherein said binding to said CalDAG-GEF component is
2 detected by an assay selected from the group consisting of: affinity chromatography, co-
3 immunoprecipitation, a Biomolecular Interaction Assay, and a yeast two-hybrid system.

1 85. The method in claim 83 wherein said binding to said cAMP-GEF component is
2 detected by an assay selected from the group consisting of: affinity chromatography, co-
3 immunoprecipitation, a Biomolecular Interaction Assay, and a yeast two-hybrid system.

1 86. A method of identifying compounds which can modulate activity of a CalDAG-GEF
2 comprising the steps of
3 providing a cell expressing a normal or mutant CalDAG-GEF gene;
4 contacting said cell with at least one candidate compound; and

- 66 -

- 5 detecting a change in a marker of said activity.
- 1 87. A method of identifying compounds which can modulate activity of a cAMP-GEF
2 comprising the steps of
3 providing a cell expressing a normal or mutant cAMP-GEF gene;
4 contacting said cell with at least one candidate compound; and
5 detecting a change in a marker of said activity.
- 1 88. A method as in claim 86 wherein measurement of said marker indicates a difference
2 between cells bearing an expressed mutant CalDAG-GEF gene and otherwise identical cells free
3 of an expressed mutant CalDAG-GEF gene.
- 1 89. A method as in claim 86 wherein said change comprises a change in a non-specific
2 marker of cell physiology selected from the group consisting of pH, intracellular calcium, cyclic
3 AMP levels, GTP/GDP ratios, phosphatidylinositol activity, and protein phosphorylation.
- 1 90. A method as in claim 86 wherein said change comprises a change in expression of
2 said CalDAG-GEF.
- 1 91. A method as in claim 86 wherein said change comprises a change in occurrence or
2 rate of apoptosis or cell death.
- 1 92. A method as in claim 86 wherein said cell is a cell cultured *in vitro*.
- 1 93. A method as in claim 92 wherein said cell is a transformed host cell of any one of
2 claims 50-54.
- 1 94. A method as in claim 92 wherein said cell is explanted from a host bearing at least
2 one mutant CalDAG-GEF gene.
- 1 95. A method as in claim 92 wherein said cell is explanted from a transgenic animal of
2 any one of claims 55-61.
- 1 96. A method as in claim 86 wherein said cell is a cell in a live animal.
- 1 97. A method as in claim 96 wherein said cell is a cell of a transgenic animal of any one
2 of claims 55-61.
- 1 98. A method as in claim 86 wherein said cell is in a human subject in a clinical trial.
- 1 99. A method as in claim 87 wherein measurement of said marker indicates a difference
2 between cells bearing an expressed mutant cAMP-GEF gene and otherwise identical cells free of
3 an expressed mutant cAMP-GEF gene.

- 67 -

- 1 100. A method as in claim 87 wherein said change comprises a change in a non-specific
2 marker of cell physiology selected from the group consisting of pH, intracellular calcium, cyclic
3 AMP levels, GTP/GDP ratios, phosphatidylinositol activity, and protein phosphorylation.
- 1 101. A method as in claim 87 wherein said change comprises a change in expression of
2 said cAMP-GEF.
- 1 102. A method as in claim 87 wherein said change comprises a change in occurrence or
2 rate of apoptosis or cell death.
- 1 103. A method as in claim 87 wherein said cell is a cell cultured *in vitro*.
- 1 104. A method as in claim 103 wherein said cell is a transformed host cell of any one of
2 claims 50-54.
- 1 105. A method as in claim 103 wherein said cell is explanted from a host bearing at least
2 one mutant cAMP-GEF gene.
- 1 106. A method as in claim 103 wherein said cell is explanted from a transgenic animal of
2 any one of claims 55-61.
- 1 107. A method as in claim 87 wherein said cell is a cell in a live animal.
- 1 108. A method as in claim 107 wherein said cell is a cell of a transgenic animal of any one
2 of claims 55-61.
- 1 109. A method as in claim 87 wherein said cell is in a human subject in a clinical trial.
- 1 110. A diagnostic method for determining if a subject bears a mutant CalDAG-GEF gene
2 comprising the steps of
3 providing a biological sample of said subject; and
4 detecting in said sample a mutant CalDAG-GEF nucleic acid, a mutant CalDAG-GEF
5 protein, or a mutant CalDAG-GEF activity.
- 1 111. A method as in claim 111, wherein a mutant CalDAG-GEF nucleic acid is detected
2 by an assay selected from the group consisting of direct nucleotide sequencing, probe specific
3 hybridization, restriction enzyme digest and mapping, PCR mapping, ligase-mediated PCR
4 detection, RNase protection, electrophoretic mobility shift detection, and chemical mismatch
5 cleavage.
- 1 112. A method as in claim 110, wherein a mutant CalDAG-GEF protein is detected by an
2 assay selected from the group consisting of an immunoassay, a protease assay, and an
3 electrophoretic mobility assay.


- 68 -

- 1 113. A diagnostic method for determining if a subject bears a mutant cAMP-GEF gene
2 comprising the steps of
3 providing a biological sample of said subject; and
4 detecting in said sample a mutant cAMP-GEF nucleic acid, a mutant cAMP-GEF
5 protein, or a mutant cAMP-GEF activity.
- 1 114. A method as in claim 113, wherein a mutant cAMP-GEF nucleic acid is detected by
2 an assay selected from the group consisting of direct nucleotide sequencing, probe specific
3 hybridization, restriction enzyme digest and mapping, PCR mapping, ligase-mediated PCR
4 detection, RNase protection, electrophoretic mobility shift detection, and chemical mismatch
5 cleavage.
- 1 115. A method as in claim 113, wherein a mutant cAMP-GEF protein is detected by an
2 assay selected from the group consisting of an immunoassay, a protease assay, and an
3 electrophoretic mobility assay.
- 1 116. A pharmaceutical preparation comprising a substantially pure CalDAG-GEF protein
2 and a pharmaceutically acceptable carrier.
- 1 117. A pharmaceutical preparation comprising a substantially pure cAMP-GEF protein and
2 a pharmaceutically acceptable carrier.
- 1 118. A pharmaceutical preparation comprising an expression vector operably encoding a
2 protein selected from the group consisting of a CalDAG-GEF protein, and a cAMP-GEF protein,
3 wherein said expression vector may express said CalDAG-GEF protein or said cAMP-GEF
4 protein in a human subject, and a pharmaceutically acceptable carrier.
- 1 119. A pharmaceutical preparation comprising an expression vector operably encoding a
2 CalDAG-GEF antisense sequence, wherein said expression vector may express said CalDAG-
3 GEF antisense sequence in a human subject, and a pharmaceutically acceptable carrier.
- 1 120. A pharmaceutical preparation comprising an expression vector operably encoding a
2 cAMP-GEF antisense sequence, wherein said expression vector may express said cAMP-GEF
3 antisense sequence in a human subject, and a pharmaceutically acceptable carrier.
- 1 121. A pharmaceutical preparation comprising a substantially pure antibody, and a
2 pharmaceutically acceptable carrier,
3 wherein said antibody selectively binds to a mutant protein selected from the group
4 consisting of a mutant CalDAG-GEF protein, and a mutant cAMP-GEF protein.

- 69 -

- 1 122. A pharmaceutical preparation as in claim 121 wherein said preparation is essentially
2 free of an antibody which selectively binds a normal CalDAG-GEF protein.
- 1 123. A pharmaceutical preparation as in claim 121 wherein said preparation is essentially
2 free of an antibody which selectively binds a normal cAMP-GEF protein.
- 1 124. A pharmaceutical preparation comprising a substantially pure preparation of an
2 antigenic determinant of a mutant CalDAG-GEF protein or a mutant cAMP-GEF protein.
- 1 125. A pharmaceutical preparation as in claim 124 wherein said preparation is essentially
2 free of an antigenic determinant of a normal CalDAG-GEF protein.
- 1 126. A pharmaceutical preparation as in claim 124 wherein said preparation is essentially
2 free of an antigenic determinant of a normal cAMP-GEF protein.
- 1 127. A method of treatment for a patient bearing a mutant CalDAG-GEF gene comprising
2 the step of administering to said patient a therapeutically effective amount of the pharmaceutical
3 preparation of claim 116.
- 1 128. A method for identifying compounds according to claim 82, wherein the CalDAG-
2 GEF component is a CalDAG-GEF domain selected from the group consisting of SCR1, SCR2,
3 SCR3, DAG-binding and an EF hand domain.
- 1 129. A substantially pure preparation of a polypeptide comprising a domain selected from
2 the group consisting of a CalDAG-GEF SCR1 domain, a CalDAG-GEF SCR2 domain,
3 CalDAG-GEF SCR3 domain, CalDAG-GEF DAG-binding domain, CalDAG-GEF EF hand
4 domain.
- 1 130. A substantially pure preparation of a polypeptide comprising a domain selected from
2 the group consisting of a cAMP-GEF SCR1 domain, a cAMP-GEF SCR2 domain, cAMP-GEF
3 SCR3 domain, cAMP-GEF cAMP-binding domain.

1/12



MAPK-ACTIVATED PROTEIN KINASE 2, ETC.

FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C

Best Available Copy

FIG. 2D-1	FIG. 2D-2
--------------	--------------

FIG. 2D

hCaIDAG-GEFI	MAGTLDLDKGCCTVEELLRGCI EA AFD DSGKVRRDPQLVRMFLLMMHPWYIPSS
mCaIDAG-GEFI	MAS TLDLDKGCCTVEELLRGCI EA AFD DSGKVRRDPQLVRMFLLMMHPWYIPSS
hCaIDAG-GEFI	KE LK A L L D Q E G N R R H S S L I D I D S V P T Y K K R Q V T Q R N P V G Q K K R K M S L L F
mCaIDAG-GEFI	KE LK A L L D Q E G N R R H S S L I D I E S V P T Y K K R Q V T Q R N P V E Q K K R K M S L L F
hCaIDAG-GEFI	N S V S Q W V Q L M I L S K P T A P Q R A L V I T H F V H V A E K L L Q L Q N F N T L M A V V G G L
mCaIDAG-GEFI	N S V S Q W V Q L M I L S K P T A T Q R A L V I T H F V H V A E K L L Q L Q N F N T L M A V V G G L
hCaIDAG-GEFI	F P I L G V H L K D L V A L Q L A L P D W L D P A R T R L N G A K M K Q L F S I L E E L A M V T S L
mCaIDAG-GEFI	F P I L G V H L K D L V A L Q L A L P D W L D P G R T R L N G A K M R Q L F S I L E E L A M V T S L
hCaIDAG-GEFI	P P R P P V L E E W Y S A A K P K L D Q A L V V E H I E K M V E S V F R N F D V D G D G H I S Q E E
mCaIDAG-GEFI	P P R P P V L E E W Y S Y A K P K L D Q A L V A E H I E K M V E S V F R N F D V D G D G H I S Q E E
hCaIDAG-GEFI	F Q E S N S L R P V A C R H C K A L I L G I Y K Q G L K C R A C G V N C H K Q C K D R L S L E C R R
mCaIDAG-GEFI	F Q E S N S L R P V A C R H C K A L I L G I Y K Q G L K C R A C G V N C H K Q C K E R L S L E C R R
hCaIDAG-GEFI	E D G V F D I H L
mCaIDAG-GEFI	E D G V F D I H L

FIG. 2D-1

Q L A A K L L H I Y Q Q S R K D N S N S L Q Y K T C H L V R Y W I S A F P A E F D L N P E L A E Q I	100
Q L A S K L L H E Y Q Q S R K D N S N S L Q Y K T C H L V R Y W V S A F P A E F D L N P E L A E P I	100
D H L E P M E L A E H L T Y L E Y R S F C K I L F Q D Y H S F V T H G C T V D N P V L E R F I S L F	200
D H L E P M E L A E H L T Y L E Y R S F C K I L F Q D Y H S F V T H G C T V D N P V L E R F I S L F	200
S H S S I S R L K E T H S H V S P E T I K L W E G L T E L V T A T G N Y G N Y R R R L A A C V G F R	300
S H S S I S R L K E T H S H V S P D T I K L W E G L T E L V T A T G N Y S N Y R R R L A A C V G F R	300
R P P V Q A N P D L L S L L T V S L D Q Y Q T E D E L Y Q L S L Q R E P R S K S S P T S C T P	400
R P P V Q A K P S L L S L L T V S L D Q Y Q T E D E L Y Q L S L Q R E P R S K S S P T S C T P	400
F Q I I R G N F P Y L S A F G D L O Q N Q D G C I S R E E M V S Y F L R S S S V L G G R M G F V H N	500
F Q I I R G N F P Y L S A F G D L O Q N Q D G C I S R E E M I S Y F L R S S S V L G G R M G F V H N	500
R A Q S V S L E G S A P S P S P M H S H H R A F S F S L P R P G R R G S R P P E I R E E E V Q T V	600
R A Q S V S L E G S A P S P S P T H T H H R A F S F S L P R P G R R G S R P P E I R E E E V Q S V	599
	609
	608

FIG. 2D-2

6/12

F2583.3	A	V	F	K	H	Y	D	H	D	R	D	G	F	I	S	Q	E	E	F	Q	473
hCaIDAG-GEFI	S	V	F	R	N	F	D	V	D	G	D	G	H	I	S	Q	E	E	F	Q	452
hCaIDAG-GEFII	S	V	F	K	N	Y	D	H	D	Q	D	G	Y	I	S	Q	E	E	F	E	447
hCalmodulin	E	A	F	S	L	F	D	K	D	G	D	G	T	I	T	T	K	F	L	G	34
hCalbindin D28K	L	M	L	K	L	F	D	S	N	N	D	G	K	L	E	L	T	E	M	A	168
hCalcineurin B	F	A	F	R	I	Y	D	M	D	K	D	G	Y	I	S	N	G	E	L	F	113
hParvalbumin α	K	V	F	H	M	L	D	K	D	K	S	G	F	I	E	E	D	E	L	G	65
hTroponin C	E	C	F	R	I	F	D	R	K	A	D	G	Y	I	D	P	E	E	L	A	117

FIG. 2E

F2583.3	H	N	F	H	E	T	T	F	L	T	P	T	T	C	N	H	C	N	K	L	L	W	G	I	L	R	Q	G	F	K	C	K	D	C	G	L	A	V	H	S	C	C	K	S	N	A	V	A	E	C	570
hCaIDAG-GEFI	H	N	F	Q	E	S	N	S	L	R	P	V	A	C	R	H	C	K	A	L	I	L	G	I	Y	K	Q	G	L	K	C	R	A	C	G	V	N	C	H	K	Q	C	K	D	R	L	S	V	E	C	548
hCaIDAG-GEFII	H	N	F	Q	E	T	Y	L	K	P	T	F	C	D	N	C	A	G	F	L	W	G	V	I	K	Q	G	Y	R	C	C	D	C	C	M	N	C	H	K	Q	C	K	D	L	V	V	E	C	542		
hPKC α	H	K	F	I	A	R	F	F	K	Q	P	T	F	C	S	H	C	T	D	F	I	W	G	F	G	K	Q	G	F	Q	C	Q	V	C	C	F	V	V	H	K	R	C	H	E	F	V	T	F	S	C	86
hPKC β 1	H	K	F	T	A	R	F	F	K	Q	P	T	F	C	S	H	C	T	D	F	I	W	G	F	G	K	Q	G	F	Q	C	Q	V	C	C	F	V	V	H	K	R	C	H	E	F	V	T	F	S	C	86
hPKC γ	H	K	F	T	A	R	F	F	K	Q	P	T	F	C	S	H	C	T	D	F	I	W	G	I	G	K	Q	G	L	Q	C	Q	V	C	S	F	V	V	H	R	R	C	H	E	F	V	T	F	E	C	85

FIG. 2F

Best Available Copy

7/12




FIG. 3A




FIG. 3C

FIG. 3B

hcAMP-GEFI	SCR 1	10	20	SCR 3	10	20	
rcAMP-GEFI	LDLVSAKDLAAGQLTDRDWSLFNSI	639		PVIPPMPPLLLKDMTFIHEGNKT	789		
hcAMP-GEFII	LDLVSAKDLAAGQLTDRDWSLFNSI	642		PVIPPMPPLLLKDMTFIHEGNKT	792		
rcAMP-GEFII	FELMSSKDLAYQKTIYDWELFNCV	791		PLIPPMPPLLLKDMTFIHEGNKT	940		
rcAMP-GEFII	FELMSSKDLAYQKTIYDWELFNCV	216		PLIPPMPPLLLKDMTFIHEGNKT	365		
celcAMP-GEF	LHLIDSQELAYQLFLFRQLLRST	1010		PYIPFVPLILKDDLNFHQGNKS	1159		
hcCaIDAG-GEFI	FDMLEPEMELAEERLTYLRRYSFCRI	173		FRFPILGVLKDDLVAALQLALPD	320		
hcCaIDAG-GEFII	FDNLEPEMELAEERLTYLRRYSFCRI	224		FKIPIILGVLKDDLISLYEAMPD	371		
C3G	LNDFNSNEIAEQTLTLLDAELFTETI	859		PCIPIYLGVLILQLDLTFVHLGNPV	1001		
CDC25	LLDIDPEYTTATQTLTLLDSELVFKSI	1323		ACVPPFEGVYLLSDDLTFVGNPD	1474		
rRas-GRF	FENN SAM EIAEQTLTLLDSELVFKSI	1028		PCVPPFEGVYLLSDDLTFVGNPD	1177		
hSos1	LTLNPIEIAEQTLTLLDSELVFKSI	799		PCVPPFEGVYLLSDDLTFVGNPD	946		
BUD5	ALNVSPWSLAKTTLTLLSLSLLOI	327		PCVPPFEGVYLLSDDLTFVGNPD	644		

hcAMP-GEFI	SCR 2	10	20	40			
rcAMP-GEFI	RAQLLRLKFKFIKLLAAHLLKKEQKKNVNSFFA	731		VMFFGLSN	734		
hcAMP-GEFII	RAQLLRLKFKFIKLLAAHLLKKEQKKNVNSFFA	882		VMFFGLSN	307		
rcAMP-GEFII	RVQLLRLKFKFIKLLAAHLLKKEQKKNVNSFFA	1101		VMFFGLSN	262		
celcAMP-GEF	RMELI LKFKFIKLLAAHLLKKEQKKNVNSFFA	313		VMFFGLSN	946		
hCaIDEG-GEFI	RAELVITHTHFVHVAEKLLQNLQNMNFNS	1415		VMFFGLSN	1119		
hCaIDAG-GEFII	RAELVITHTHFVHVAEKLLQNLQNMNFNS	890		VMFFGLSN	406		
C3G	RELLTQYEFVTVAQKHLLKKEQKKNVNSFFA			VMFFGLSN			
CDC25	RSKLTQYEFVTVAQKHLLKKEQKKNVNSFFA			VMFFGLSN			
rRas-GRF	RASTKRWVAVAEIILQVACL			VMFFGLSN			
hSos1	RVAVVSRIRIIEIILQVACL			VMFFGLSN			
BUD5	QTNNTISSYWLQVACL			VMFFGLSN			

FIG. 3D

Best Available Copy

9/12





FIG. 3E

FIG. 3F-1	FIG. 3F-2	FIG. 3F-3
-----------	-----------	-----------

FIG. 3F

Best Available Copy

10/12

hcAMP-GEFI	M V L - - - - - - - - - - - - - - -
hcAMP-GEFII	M V A A H A A H S S S S A E W I A C L D K
hcAMP-GEFI	- - - - - - - - - - - - - - - H Q H P
hcAMP-GEFII	Y A V L A G S L D V K V S E T S S H Q D A
hcAMP-GEFI	- - - - - - - - - - - - - - - T P
hcAMP-GEFII	P Y G V M E T G S M M D R I P D K K N T P
hcAMP-GEFI	L V D G I L A L G L G V H S R S Q V V G I
hcAMP-GEFII	L V D W M M Q Q T P C V H S R T Q A V G M
hcAMP-GEFI	S Q R G P D A L L T V A L R K P P G Q R T
hcAMP-GEFII	S Q M G P D A M M R W I L R K P P G Q R T
hcAMP-GEFI	G S N K V V T N G K G L V T T L H K G D D
hcAMP-GEFII	G S N S V V I Y G K G V V C T L H K G D D
hcAMP-GEFI	A S Q G A - G P S R P P T P G R N R Y T V
hcAMP-GEFII	V P A G N R R S N Q G N S Q P Q Q K Y T V
hcAMP-GEFI	G G S E Q E R S T Y V C M E R Q Q I L R L
hcAMP-GEFII	Q G T E Q E K K D Y A L M N K K K V I R L
hcAMP-GEFI	S P Q K K A R M L P V W L P N Q D K P L P
hcAMP-GEFII	A P Q R K H K V L L Q Q F N T G D K R - A
hcAMP-GEFI	G D A I G L Q P D A R G V A T S L G L N E
hcAMP-GEFII	G K K V V L K P N D V S V F T F L T I N G
hcAMP-GEFI	H Y V L G P Q H L R D V T T A K L E R F N
hcAMP-GEFII	Y M T F Q R M N F K K - T T A K L D L F L
hcAMP-GEFI	R L A M T W E R L P H K V R K L Y S A L K
hcAMP-GEFII	R L A L T W E K L P S K F K K F Y A E F K
hcAMP-GEFI	A A R M L H H C R S R N P V P L S F L R S
hcAMP-GEFII	T A R T V R Y Y R S Q - - - P F N F - - -

FIG. 3F-1

RRMHRPRS - - - - -
RFLEKSSDVDIIFTRLKEVKAFEFHPNLLMO

S - - C I Q G - - - - -
V T I C T L G I G T A F G E S I L D N T F R N A T I V T R E S S E

L	T	N	S	E	E	S	L	D	F	S	E	S	L	E	Q	A	S	T	E	R	V	L	R	A	G	R	Q	L	K	Q	N	L
L	I	E	P	H	V	P	L	R	P	A	N	T	I	T	K	V	P	S	E	K	T	L	R	A	G	K	I	L	R	N	A	I

C	Q	V	L	L	D	K	G	A	L	C	H	V	K	K	D	W	A	F	Q	D	K	D	A	Q	F	Y	R	F	P	G	P	E
W	Q	V	L	L	K	D	G	V	L	N	H	V	D	Q	E	H	N	F	Q	D	K	-	Y	L	F	Y	R	F	L	D	D	E

D	E	E	L	D	L	I	F	E	E	L	H	I	K	A	V	A	N	L	S	N	S	V	K	R	E	L	A	A	V	L	L
V	D	D	L	E	I	I	Y	E	E	L	H	I	K	A	L	S	N	L	S	T	T	V	R	R	E	L	A	G	V	L	I

FG	Q	L	A	L	V	N	D	A	P	R	A	A	T	I	I	L	R	E	Y	N	C	H	F	L	R	V	D	K	Q	D	F
FG	K	L	A	L	V	N	D	A	P	R	A	A	S	I	V	L	R	E	D	N	C	H	F	L	R	V	D	K	E	D	F

M	S	G	T	P	D	K	I	L	E	L	L	L	E	A	N	G	L	D	S	E	A	H	D	P	K	E	T	T	L	S	D	F
M	S	G	T	P	E	K	I	L	E	H	F	L	E	T	I	R	L	E	A	T	L	N	E	A	T	D	S	V	L	N	D	F

V	S	Q	W	V	A	L	Y	G	S	M	L	H	T	D	P	V	A	T	S	F	L	M	K	L	S	D	L	V	G	R	D	T
V	L	Q	W	A	A	M	Y	G	D	L	L	Q	E	D	D	V	S	K	A	F	L	E	E	F	Y	V	S	V	S	D	D	A

G S S C A I Q V G D K V P Y D I C R P D H S V L T L Q L P V T A S
 Q K R Q P I R S S D E V L F K V Y C K D H T T T T R V P V A T S

R	L	F	V	V	N	P	Q	E	V	H	E	L	I	P	H	P	D	Q	L	G	P	T	V	G	S	A	E	G	L	D	L	V
R	L	F	A	C	P	R	E	Q	F	D	S	L	T	P	L	P	E	Q	K	G	P	T	V	G	T	V	G	T	F	E	L	M

R	R	F	N	E	I	L	Q	Y	W	V	A	T	E	I	L	C	L	C	P	V	P	G	P	R	A	Q	L	L	K	K	F	I	K	L
R	R	F	N	E	I	I	Q	F	W	V	V	T	E	I	I	C	L	C	S	Q	L	B	K	R	V	Q	L	L	K	K	F	I	K	I

R	L	L	D	P	S	W	N	H	R	V	Y	R	L	A	L	A	K	L	S	P	P	Y	I	P	F	M	P	L	L	L	K	D
S	L	M	D	P	S	R	N	H	R	A	Y	R	L	T	V	A	K	L	E	P	P	L	I	P	F	M	P	L	L	I	K	D

RVSHLKGDSQVARISTCSEQSLSTKSPASTWAY
- - - - - DAAQANKNHODVRSY

SUBSTITUTE SHEET (RULE 26)

12/12

- - - C S Y Q L L L K - - - - -	20
I C L C G Y Y E N L K K G I T L F R Q G D I G T N W	80
- L R - - - - - W - - - - -	32
L L R I E Q K D F K A L W E K Y R Q Y M A G L L A P	160
L A T C P N L I R D R K Y H L R L Y R Q C C S G R E	92
L S R A P H M I R D R K Y H L K T Y R Q C C V G T E	240
F E - - P V G T H E M - - - - E E E L A E A V A L L	166
H E D A P L P T E E E K K E C D E E L Q D T M L L L	319
F E P H S K A G T V L F S Q G D K G T S W Y X X W K	246
F E S H A K G G T V L F N Q G E E G T S W Y X X L K	399
N R I I K D V E A K T M K L E G K G K V V L V L K R	326
N R I L R D V E A N T V K L K G K D Q D V L V L K K	479
L L T H R V F M P S A Q L C A A L L H H F H V E P A	405
I M M H C V F M P N T Q L C P A L V A H Y H A Q P S	559
R L S N L L R E Q W P E R R R C H R L E N G C G M A	485
R M I A A L K E Q L P E L E K I V K Q I S E - D A K	638
V R E V M A A L A Q E D G W T K G Q V L V K V N S A	565
V K E V I S A V A D K L G S G E G L I I V K M S S G	717
S A K D L A G Q L T D H D W S L F N S I H Q V E L I	645
S S K D L A Y Q M T I Y D W E L F N C V H R L E L I	797
A A H L R R Q K N V N S F F A V M F G L G K S P I S	725
A A H C R R Y K N L N S F F A I V X G L G K I A V S	876
M T F I H E G N H T L W E N L I N F G R M R N M A R	805
M T F T H E G N K T F I D N L V N F G R M R N I A N	956
V Q Q L K V I D N Q R E L S R L S R E L E P	881
V R Q L N V I D N Q R T L S Q N S H R L E P R R F	1011

FIG. 3F-3

SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

<110> Kawasaki, Hiroaki
Graybiel, Ann
Housman, David

<120> Genes Integrating Signal Transduction Pathways

<130> MIT-103

<140>

<141>

<150> US 60/105,507

<151> 1998-10-23

<150> US 60/108,685

<151> 1998-11-16

<160> 18

<170> PatentIn Ver. 2.0

<210> 1

<211> 2250

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (166)..(1989)

<223> CalDAG-GEFI

<400> 1

```

cgaaggatca gaggctgagc tgggttcaagt gaacagaagg tctgggaggt gaactgcatt 60
cggggtttgca ttctgaagta aaggacttgg gacaggggta cgaatcgagc actgtgggag 120
gctctgagag tgtaacttgg gtctagccca ctggcaccgg cagcc atg gcg agc act 177
                                     Met Ala Ser Thr
                                     1
ctg gac ctg gac aag ggt tgc acc gtg gag gag ctg ctc cgt ggc tgt 225
Leu Asp Leu Asp Lys Gly Cys Thr Val Glu Glu Leu Leu Arg Gly Cys
5 10 15 20
atc gaa gcc ttt gat gac tct gga aag gtg cga gat cca cag cta gtg 273
Ile Glu Ala Phe Asp Asp Ser Gly Lys Val Arg Asp Pro Gln Leu Val
25 30 35
cgc atg ttt ctc atg atg cac ccc tgg tac ata cct tcc tct cag ctg 321
Arg Met Phe Leu Met Met His Pro Trp Tyr Ile Pro Ser Ser Gln Leu
40 45 50
gct tcg aaa ctg ctc cac ttc tat cag caa tcc cgg aag gac aac tcc 369
Ala Ser Lys Leu Leu His Phe Tyr Gln Gln Ser Arg Lys Asp Asn Ser
55 60 65
aat tcc cta cag gtg aaa acc tgt cac ctg gtc agg tac tgg gtc tca 417
Asn Ser Leu Gln Val Lys Thr Cys His Leu Val Arg Tyr Trp Val Ser
70 75 80
gcc ttc cca gca gag ttc gac ttg aac cca gag ctg gct gaa ccg atc 465
Ala Phe Pro Ala Glu Phe Asp Leu Asn Pro Glu Leu Ala Glu Pro Ile
85 90 95 100
aag gag ctg aag gct ctg tta gac caa gaa gga aac cgc agg cac agc 513
Lys Glu Leu Lys Ala Leu Leu Asp Gln Glu Gly Asn Arg Arg His Ser
105 110 115
agc ctc atc gac atc gag agt gtc ccc acc tac aag tgg aag cgg cag 561
Ser Leu Ile Asp Ile Glu Ser Val Pro Thr Tyr Lys Trp Lys Arg Gln
120 125 130
gtg acc cag cgg aac cct gtg gaa cag aaa aag cgc aag atg tcc ctg 609
Val Thr Gln Arg Asn Pro Val Glu Gln Lys Lys Arg Lys Met Ser Leu
135 140 145

```


- 2 -

ttg ttt gat cac ttg gag cct atg gaa ctg gca gaa cat ctc acc tac	657
Leu Phe Asp His Leu Glu Pro Met Glu Leu Ala Glu His Leu Thr Tyr	
150 155 160	
ttg gag tat cgg tcc ttc tgc aag atc ctg ttc cag gac tat cac agc	705
Leu Glu Tyr Arg Ser Phe Cys Lys Ile Leu Phe Gln Asp Tyr His Ser	
165 170 175 180	
ttt gtg act cat ggc tgc act gta gac aat ccg gtc ctg gag cga ttc	753
Phe Val Thr His Gly Cys Thr Val Asp Asn Pro Val Leu Glu Arg Phe	
185 190 195	
atc tcc ctc ttc aac agt gtc tct cag tgg gtc caa ctc atg atc ctc	801
Ile Ser Leu Phe Asn Ser Val Ser Gln Trp Val Gln Leu Met Ile Leu	
200 205 210	
agc aag ccc aca gcc acg cag cgg gcg ctg gtc atc aca cat ttc gtg	849
Ser Lys Pro Thr Ala Thr Gln Arg Ala Leu Val Ile Thr His Phe Val	
215 220 225	
cat gtg gca gag aag ctg ctg cag ctg cag aac ttc aac acg ttg atg	897
His Val Ala Glu Lys Leu Leu Gln Leu Gln Asn Phe Asn Thr Leu Met	
230 235 240	
gcc gtc gtg gga ggc ctg agc cac agc tcc atc tca cgc ctc aag gag	945
Ala Val Val Gly Gly Leu Ser His Ser Ser Ile Ser Arg Leu Lys Glu	
245 250 255 260	
acc cac agc cat gtc agc cct gac acc atc aag ctc tgg gaa ggt ctg	993
Thr His Ser His Val Ser Pro Asp Thr Ile Lys Leu Trp Glu Gly Leu	
265 270 275	
aca gaa cta gtg aca gct act ggc aac tac agc aac tac cgg cga agg	1041
Thr Glu Leu Val Thr Ala Thr Gly Asn Tyr Ser Asn Tyr Arg Arg Arg	
280 285 290	
ctg gcg gcc tgc gtg ggc ttc cgc ttt cct atc ctg ggt gtg cac ctc	1089
Leu Ala Ala Cys Val Gly Phe Arg Phe Pro Ile Leu Gly Val His Leu	
295 300 305	
aag gat cta gtg gct ctg cag ctg gct ctg cct gac tgg ctg gac cca	1137
Lys Asp Leu Val Ala Leu Gln Leu Ala Leu Pro Asp Trp Leu Asp Pro	
310 315 320	
ggt cgg acc cgg ctc aat gga gcc aag atg agg cag ctt ttc agc att	1185
Gly Arg Thr Arg Leu Asn Gly Ala Lys Met Arg Gln Leu Phe Ser Ile	
325 330 335 340	
ctg gag gag ttg gct atg gtg acc agt ctt cga cca cca gtg caa gcc	1233
Leu Glu Glu Leu Ala Met Val Thr Ser Leu Arg Pro Pro Val Gln Ala	
345 350 355	
aac ccc gac ctg ctg agt ctg ctc acg gtg tcc ctg gac cag tat cag	1281
Asn Pro Asp Leu Leu Ser Leu Leu Thr Val Ser Leu Asp Gln Tyr Gln	
360 365 370	
acg gag gat gag ctg tat cag ctc tct ctg cag cga gag cca cgt tcc	1329
Thr Glu Asp Glu Leu Tyr Gln Leu Ser Leu Gln Arg Glu Pro Arg Ser	
375 380 385	
aag tca tcg ccc acc agc ccc acc agc tgc acc ccg cct ccc cgg ccg	1377
Lys Ser Ser Pro Thr Ser Pro Thr Ser Cys Thr Pro Pro Arg Pro	
390 395 400	
cct gtg ctg gaa gag tgg acc tca gtt gcc aag cct aag ctg gac caa	1425
Pro Val Leu Glu Glu Trp Thr Ser Val Ala Lys Pro Lys Leu Asp Gln	
405 410 415 420	
gcc ttg gtg gcc gag cac att gag aag atg gtg gag tct gtg ttc cgg	1473
Ala Leu Val Ala Glu His Ile Glu Lys Met Val Glu Ser Val Phe Arg	
425 430 435	
aac ttt gac gtt gat ggg gac ggt cac atc tcc cag gag gag ttc cag	1521
Asn Phe Asp Val Asp Gly Asp Gly His Ile Ser Gln Glu Glu Phe Gln	

- 3 -

440 445 450

atc atc cgg ggc aac ttc cct tat ctc agc gcc ttt ggg gac ttg gac 1569
 Ile Ile Arg Gly Asn Phe Pro Tyr Leu Ser Ala Phe Gly Asp Leu Asp
 455 460 465

cag aac cag gat ggc tgc atc agc cgg gag gag atg att tcc tac ttc 1617
 Gln Asn Gln Asp Gly Cys Ile Ser Arg Glu Glu Met Ile Ser Tyr Phe
 470 475 480

ctg cgc tcc agc tcc gtg ctg gga ggc cgc atg ggc ttc gta cac aac 1665
 Leu Arg Ser Ser Ser Val Leu Gly Gly Arg Met Gly Phe Val His Asn
 485 490 495 500

ttc cag gag agt aac tcg cta agg ccg gtc gcc tgc cga cac tgc aaa 1713
 Phe Gln Glu Ser Asn Ser Leu Arg Pro Val Ala Cys Arg His Cys Lys
 505 510 515

gct ctg atc ctg ggc atc tac aag cag ggc ctc aaa tgt aga gct tgt 1761
 Ala Leu Ile Leu Gly Ile Tyr Lys Gln Gly Leu Lys Cys Arg Ala Cys
 520 525 530

ggg gtg aac tgc cac aag cag tgc aaa gac cga ctg tca gtg gaa tgt 1809
 Gly Val Asn Cys His Lys Gln Cys Lys Asp Arg Leu Ser Val Glu Cys
 535 540 545

cgc cgc cgc gcc cag agt gtg agc ctg gag ggc tct gca ccc tct ccc 1857
 Arg Arg Arg Ala Gln Ser Val Ser Leu Glu Gly Ser Ala Pro Ser Pro
 550 555 560

tca ccc aca cat acc cac cat cgg gcc ttc agc ttc tcc ctg cct cgc 1905
 Ser Pro Thr His Thr His His Arg Ala Phe Ser Phe Ser Leu Pro Arg
 565 570 575 580

cca ggc agg cgc agc tct cgg cct cca gag atc cgt gaa gag gag gtg 1953
 Pro Gly Arg Arg Ser Ser Arg Pro Pro Glu Ile Arg Glu Glu Glu Val
 585 590 595

cag act gtg gaa gat ggt gtg ttc gac atc cac tta taagacgctg 1999
 Gln Thr Val Glu Asp Gly Val Phe Asp Ile His Leu
 600 605

tgactatcaa ggactcatc ctgccttgga gaaaagactt ggagcagagc agggagccag 2059

ggattctggg gcaggagggt ggggctgaag gtgggggaag ttgaagggtg catgcactga 2119

aaaaaaggcc agggctggtg tccctaaggt tgtacagact tctgtgaata tttgtatttt 2179

ccagatggaa taaaaaggcc cgaataatta acctcgaaaa aaaaaaaaaa aaaaaaaaaa 2239

aaaaaaaaa a 2250

<210> 2
 <211> 608
 <212> PRT
 <213> Mus musculus

<400> 2
 Met Ala Ser Thr Leu Asp Leu Asp Lys Gly Cys Thr Val Glu Glu Leu
 1 5 10 15
 Leu Arg Gly Cys Ile Glu Ala Phe Asp Asp Ser Gly Lys Val Arg Asp
 20 25 30
 Pro Gln Leu Val Arg Met Phe Leu Met Met His Pro Trp Tyr Ile Pro
 35 40 45
 Ser Ser Gln Leu Ala Ser Lys Leu Leu His Phe Tyr Gln Gln Ser Arg
 50 55 60
 Lys Asp Asn Ser Asn Ser Leu Gln Val Lys Thr Cys His Leu Val Arg
 65 70 75 80
 Tyr Trp Val Ser Ala Phe Pro Ala Glu Phe Asp Leu Asn Pro Glu Leu

- 4 -

85										90					95				
Ala	Glu	Pro	Ile	Lys	Glu	Leu	Lys	Ala	Leu	Leu	Asp	Gln	Glu	Gly	Asn				
			100					105					110						
Arg	Arg	His	Ser	Ser	Leu	Ile	Asp	Ile	Glu	Ser	Val	Pro	Thr	Tyr	Lys				
		115					120					125							
Trp	Lys	Arg	Gln	Val	Thr	Gln	Arg	Asn	Pro	Val	Glu	Gln	Lys	Lys	Arg				
	130					135					140								
Lys	Met	Ser	Leu	Leu	Phe	Asp	His	Leu	Glu	Pro	Met	Glu	Leu	Ala	Glu				
145					150					155					160				
His	Leu	Thr	Tyr	Leu	Glu	Tyr	Arg	Ser	Phe	Cys	Lys	Ile	Leu	Phe	Gln				
				165					170					175					
Asp	Tyr	His	Ser	Phe	Val	Thr	His	Gly	Cys	Thr	Val	Asp	Asn	Pro	Val				
			180					185					190						
Leu	Glu	Arg	Phe	Ile	Ser	Leu	Phe	Asn	Ser	Val	Ser	Gln	Trp	Val	Gln				
		195					200					205							
Leu	Met	Ile	Leu	Ser	Lys	Pro	Thr	Ala	Thr	Gln	Arg	Ala	Leu	Val	Ile				
	210					215					220								
Thr	His	Phe	Val	His	Val	Ala	Glu	Lys	Leu	Leu	Gln	Leu	Gln	Asn	Phe				
225					230					235					240				
Asn	Thr	Leu	Met	Ala	Val	Val	Gly	Gly	Leu	Ser	His	Ser	Ser	Ile	Ser				
				245					250					255					
Arg	Leu	Lys	Glu	Thr	His	Ser	His	Val	Ser	Pro	Asp	Thr	Ile	Lys	Leu				
			260					265					270						
Trp	Glu	Gly	Leu	Thr	Glu	Leu	Val	Thr	Ala	Thr	Gly	Asn	Tyr	Ser	Asn				
		275					280					285							
Tyr	Arg	Arg	Arg	Leu	Ala	Ala	Cys	Val	Gly	Phe	Arg	Phe	Pro	Ile	Leu				
	290					295					300								
Gly	Val	His	Leu	Lys	Asp	Leu	Val	Ala	Leu	Gln	Leu	Ala	Leu	Pro	Asp				
305					310					315					320				
Trp	Leu	Asp	Pro	Gly	Arg	Thr	Arg	Leu	Asn	Gly	Ala	Lys	Met	Arg	Gln				
				325					330					335					
Leu	Phe	Ser	Ile	Leu	Glu	Glu	Leu	Ala	Met	Val	Thr	Ser	Leu	Arg	Pro				
			340					345					350						
Pro	Val	Gln	Ala	Asn	Pro	Asp	Leu	Leu	Ser	Leu	Leu	Thr	Val	Ser	Leu				
		355					360					365							
Asp	Gln	Tyr	Gln	Thr	Glu	Asp	Glu	Leu	Tyr	Gln	Leu	Ser	Leu	Gln	Arg				
	370					375					380								
Glu	Pro	Arg	Ser	Lys	Ser	Ser	Pro	Thr	Ser	Pro	Thr	Ser	Cys	Thr	Pro				
385					390					395					400				
Pro	Pro	Arg	Pro	Pro	Val	Leu	Glu	Glu	Trp	Thr	Ser	Val	Ala	Lys	Pro				
				405					410					415					
Lys	Leu	Asp	Gln	Ala	Leu	Val	Ala	Glu	His	Ile	Glu	Lys	Met	Val	Glu				
			420					425					430						
Ser	Val	Phe	Arg	Asn	Phe	Asp	Val	Asp	Gly	Asp	Gly	His	Ile	Ser	Gln				
			435				440					445							
Glu	Glu	Phe	Gln	Ile	Ile	Arg	Gly	Asn	Phe	Pro	Tyr	Leu	Ser	Ala	Phe				
	450					455					460								
Gly	Asp	Leu	Asp	Gln	Asn	Gln	Asp	Gly	Cys	Ile	Ser	Arg	Glu	Glu	Met				
465					470					475					480				
Ile	Ser	Tyr	Phe	Leu	Arg	Ser	Ser	Ser	Val	Leu	Gly	Gly	Arg	Met	Gly				

SUBSTITUTE SHEET (RULE 26)

- 5 -

485 490 495

Phe Val His Asn Phe Gln Glu Ser Asn Ser Leu Arg Pro Val Ala Cys
500 505 510

Arg His Cys Lys Ala Leu Ile Leu Gly Ile Tyr Lys Gln Gly Leu Lys
515 520 525

Cys Arg Ala Cys Gly Val Asn Cys His Lys Gln Cys Lys Asp Arg Leu
530 535 540

Ser Val Glu Cys Arg Arg Arg Ala Gln Ser Val Ser Leu Glu Gly Ser
545 550 555 560

Ala Pro Ser Pro Ser Pro Thr His Thr His His Arg Ala Phe Ser Phe
565 570 575

Ser Leu Pro Arg Pro Gly Arg Arg Ser Ser Arg Pro Pro Glu Ile Arg
580 585 590

Glu Glu Glu Val Gln Thr Val Glu Asp Gly Val Phe Asp Ile His Leu
595 600 605

<210> 3
<211> 2236
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (161)..(1987)
<223> CalDAG-GEFI

<400> 3
ggggactcaa ggctggcctg gctcaagtga acagcacgtc caggaggcga cctcgctccgc 60
gggtttgcat tctggggtgg acgagctggg gggttcggtcc gagcccgggtg ggaggctccc 120
ggagcgcagc ctgggcccag cccaccccgc gccggcgccc atg gca ggc acc ctg 175
Met Ala Gly Thr Leu
1 5

gac ctg gac aag ggc tgc acg gtg gag gag ctg ctc cgc ggc tgc atc 223
Asp Leu Asp Lys Gly Cys Thr Val Glu Glu Leu Leu Arg Gly Cys Ile
10 15 20

gaa gcc ttc gat gac tcc ggg aag gtg cgg gac ccg cag ctg gtg cgc 271
Glu Ala Phe Asp Asp Ser Gly Lys Val Arg Asp Pro Gln Leu Val Arg
25 30 35

atg ttc ctc atg atg cac ccc tgg tac atc ccc tcc tct cag ctg gcg 319
Met Phe Leu Met Met His Pro Trp Tyr Ile Pro Ser Ser Gln Leu Ala
40 45 50

gcc aag ctg ctc cac atc tac caa caa tcc cgg aag gac aac tcc aat 367
Ala Lys Leu Leu His Ile Tyr Gln Gln Ser Arg Lys Asp Asn Ser Asn
55 60 65

tcc ctg cag gtg aaa acg tgc cac ctg gtc agg tac tgg atc tcc gcc 415
Ser Leu Gln Val Lys Thr Cys His Leu Val Arg Tyr Trp Ile Ser Ala
70 75 80 85

ttc cca gcg gag ttt gac ttg aac ccg gag ttg gct gag cag atc aag 463
Phe Pro Ala Glu Phe Asp Leu Asn Pro Glu Leu Ala Glu Gln Ile Lys
90 95 100

gag ctg aag gct ctg cta gac caa gaa ggg aac cga cgg cac agc agc 511
Glu Leu Lys Ala Leu Leu Asp Gln Glu Gly Asn Arg Arg His Ser Ser
105 110 115

cta atc gac ata gac agc gtc cct acc tac aag tgg aag cgg cag gtg 559
Leu Ile Asp Ile Asp Ser Val Pro Thr Tyr Lys Trp Lys Arg Gln Val
120 125 130

- 6 -

act	cag	cgg	aac	cct	gtg	gga	cag	aaa	aag	cgc	aag	atg	tcc	ctg	ttg	607
Thr	Gln	Arg	Asn	Pro	Val	Gly	Gln	Lys	Lys	Arg	Lys	Met	Ser	Leu	Leu	
	135					140					145					
ttt	gac	cac	ctg	gag	ccc	atg	gag	ctg	gcg	gag	cat	ctc	acc	tac	ttg	655
Phe	Asp	His	Leu	Glu	Pro	Met	Glu	Leu	Ala	Glu	His	Leu	Thr	Tyr	Leu	
	150				155					160					165	
gag	tat	cgc	tcc	ttc	tgc	aag	atc	ctg	ttt	cag	gac	tat	cac	agt	ttc	703
Glu	Tyr	Arg	Ser	Phe	Cys	Lys	Ile	Leu	Phe	Gln	Asp	Tyr	His	Ser	Phe	
				170					175					180		
gtg	act	cat	ggc	tgc	act	gtg	gac	aac	ccc	gtc	ctg	gag	cgg	ttc	atc	751
Val	Thr	His	Gly	Cys	Thr	Val	Asp	Asn	Pro	Val	Leu	Glu	Arg	Phe	Ile	
			185					190					195			
tcc	ctc	ttc	aac	agc	gtc	tca	cag	tgg	gtg	cag	ctc	atg	atc	ctc	agc	799
Ser	Leu	Phe	Asn	Ser	Val	Ser	Gln	Trp	Val	Gln	Leu	Met	Ile	Leu	Ser	
		200					205					210				
aaa	ccc	aca	gcc	ccg	cag	cgg	gcc	ctg	gtc	atc	aca	cac	ttt	gtc	cac	847
Lys	Pro	Thr	Ala	Pro	Gln	Arg	Ala	Leu	Val	Ile	Thr	His	Phe	Val	His	
	215				220						225					
gtg	gcg	gag	aag	ctg	cta	cag	ctg	cag	aac	ttc	aac	acg	ctg	atg	gca	895
Val	Ala	Glu	Lys	Leu	Leu	Gln	Leu	Gln	Asn	Phe	Asn	Thr	Leu	Met	Ala	
	230				235					240					245	
gtg	gtc	ggg	ggc	ctg	agc	cac	agc	tcc	atc	tcc	cgc	ctc	aag	gag	acc	943
Val	Val	Gly	Gly	Leu	Ser	His	Ser	Ser	Ile	Ser	Arg	Leu	Lys	Glu	Thr	
				250					255					260		
cac	agc	cac	gtt	agc	cct	gag	acc	atc	aag	ctc	tgg	gag	ggt	ctc	acg	991
His	Ser	His	Val	Ser	Pro	Glu	Thr	Ile	Lys	Leu	Trp	Glu	Gly	Leu	Thr	
			265					270					275			
gaa	cta	gtg	acg	gcg	aca	ggc	aac	tat	ggc	aac	tac	cgg	cgt	cgg	ctg	1039
Glu	Leu	Val	Thr	Ala	Thr	Gly	Asn	Tyr	Gly	Asn	Tyr	Arg	Arg	Arg	Leu	
		280					285					290				
gca	gcc	tgt	gtg	ggc	ttc	cgc	ttc	ccg	atc	ctg	ggt	gtg	cac	ctc	aag	1087
Ala	Ala	Cys	Val	Gly	Phe	Arg	Phe	Pro	Ile	Leu	Gly	Val	His	Leu	Lys	
	295					300					305					
gac	ctg	gtg	gcc	ctg	cag	ctg	gca	ctg	cct	gac	tgg	ctg	gac	cca	gcc	1135
Asp	Leu	Val	Ala	Leu	Gln	Leu	Ala	Leu	Pro	Asp	Trp	Leu	Asp	Pro	Ala	
	310				315					320					325	
cgg	acc	cgg	ctc	aac	ggg	gcc	aag	atg	aag	cag	ctc	ttt	agc	atc	ctg	1183
Arg	Thr	Arg	Leu	Asn	Gly	Ala	Lys	Met	Lys	Gln	Leu	Phe	Ser	Ile	Leu	
				330					335					340		
gag	gag	ctg	gcc	atg	gtg	acc	agc	ctg	cgg	cca	cca	gta	cag	gcc	aac	1231
Glu	Glu	Leu	Ala	Met	Val	Thr	Ser	Leu	Arg	Pro	Pro	Val	Gln	Ala	Asn	
			345					350					355			
ccc	gac	ctg	ctg	agc	ctg	ctc	acg	gtg	tct	ctg	gat	cag	tat	cag	acg	1279
Pro	Asp	Leu	Leu	Ser	Leu	Leu	Thr	Val	Ser	Leu	Asp	Gln	Tyr	Gln	Thr	
		360					365					370				
gag	gat	gag	ctg	tac	cag	ctg	tcc	ctg	cag	cgg	gag	ccg	cgc	tcc	aag	1327
Glu	Asp	Glu	Leu	Tyr	Gln	Leu	Ser	Leu	Gln	Arg	Glu	Pro	Arg	Ser	Lys	
	375					380					385					
tct	tcg	cca	acc	agc	ccc	acg	agt	tgc	acc	cca	cca	ccc	cgg	ccc	ccg	1375
Ser	Ser	Pro	Thr	Ser	Pro	Thr	Ser	Cys	Thr	Pro	Pro	Pro	Arg	Pro	Pro	
					395					400					405	
gta	ttg	gag	gag	tgg	acc	tcg	gct	gcc	aaa	ccc	aag	ctg	gat	cag	gcc	1423
Val	Leu	Glu	Glu	Trp	Thr	Ser	Ala	Ala	Lys	Pro	Lys	Leu	Asp	Gln	Ala	
				410					415					420		
ctc	gtg	gtg	gag	cac	atc	gag	aag	atg	gtg	gag	tct	gtg	ttc	cgg	aac	1471
Leu	Val	Val	Glu	His	Ile	Glu	Lys	Met	Val	Glu	Ser	Val	Phe	Arg	Asn	
			425					430					435			

- 7 -

ttt gac gtc gat ggg gat ggc cac atc tca cag gaa gaa ttc cag atc 1519
 Phe Asp Val Asp Gly Asp Gly His Ile Ser Gln Glu Glu Phe Gln Ile
 440 445 450
 atc cgt ggg aac ttc cct tac ctc agc gcc ttt ggg gac ctc gac cag 1567
 Ile Arg Gly Asn Phe Pro Tyr Leu Ser Ala Phe Gly Asp Leu Asp Gln
 455 460 465
 aac cag gat ggc tgc atc agc agg gag gag atg gtt tcc tat ttc ctg 1615
 Asn Gln Asp Gly Cys Ile Ser Arg Glu Glu Met Val Ser Tyr Phe Leu
 470 475 480 485
 cgc tcc agc tct gtg ttg ggg ggg cgc atg ggc ttc gta cac aac ttc 1663
 Arg Ser Ser Ser Val Leu Gly Gly Arg Met Gly Phe Val His Asn Phe
 490 500
 cag gag agc aac tcc ttg cgc ccc gtc gcc tgc cgc cac tgc aaa gcc 1711
 Gln Glu Ser Asn Ser Leu Arg Pro Val Ala Cys Arg His Cys Lys Ala
 505 510 515
 ctg atc ctg ggc atc tac aag cag ggc ctc aaa tgc cga gcc tgt gga 1759
 Leu Ile Leu Gly Ile Tyr Lys Gln Gly Leu Lys Cys Arg Ala Cys Gly
 520 525 530
 gtg aac tgc cac aag cag tgc aag gat cgc ctg tca gtt gag tgt cgg 1807
 Val Asn Cys His Lys Gln Cys Lys Asp Arg Leu Ser Val Glu Cys Arg
 535 540 545
 cgc agg gcc cag agt gtg agc ctg gag ggg tct gca ccc tca ccc tca 1855
 Arg Arg Ala Gln Ser Val Ser Leu Glu Gly Ser Ala Pro Ser Pro Ser
 550 555 560 565
 ccc atg cac agc cac cat cac cgc gcc ttc agc ttc tct ctg ccc cgc 1903
 Pro Met His Ser His His His Arg Ala Phe Ser Phe Ser Leu Pro Arg
 570 575 580
 cct ggc agg cga ggc tcc agg cct cca gag atc cgt gag gag gag gta 1951
 Pro Gly Arg Arg Gly Ser Arg Pro Pro Glu Ile Arg Glu Glu Glu Val
 585 590 595
 cag acg gtg gag gat ggg gtg ttt gac atc cac ttg taatagatgc 1997
 Gln Thr Val Glu Asp Gly Val Phe Asp Ile His Leu
 600 605
 tgtgtgttga tcaaggactc attcctgcct tggagaaaat acttcaacca gagcagggag 2057
 cctgggggtg tcggggcagg aggctgggga tgggggtggg atatgagggt ggcatgcagc 2117
 tgagggcagg gccagggctg gtgtccctaa ggttgtagag actcttgtga atatttgtat 2177
 tttccagatg gaataaaaag gcccggtgtaa ttaaccttca aaaaaaaaaa aaaaaaaaaa 2236

 <210> 4
 <211> 609
 <212> PRT
 <213> Homo sapiens

 <400> 4
 Met Ala Gly Thr Leu Asp Leu Asp Lys Gly Cys Thr Val Glu Glu Leu
 1 5 10 15
 Leu Arg Gly Cys Ile Glu Ala Phe Asp Asp Ser Gly Lys Val Arg Asp
 20 25 30
 Pro Gln Leu Val Arg Met Phe Leu Met Met His Pro Trp Tyr Ile Pro
 35 40 45
 Ser Ser Gln Leu Ala Ala Lys Leu Leu His Ile Tyr Gln Gln Ser Arg
 50 55 60
 Lys Asp Asn Ser Asn Ser Leu Gln Val Lys Thr Cys His Leu Val Arg
 65 70 75 80

- 8 -

Tyr Trp Ile Ser Ala Phe Pro Ala Glu Phe Asp Leu Asn Pro Glu Leu
 85 90 95
 Ala Glu Gln Ile Lys Glu Leu Lys Ala Leu Leu Asp Gln Glu Gly Asn
 100 105 110
 Arg Arg His Ser Ser Leu Ile Asp Ile Asp Ser Val Pro Thr Tyr Lys
 115 120 125
 Trp Lys Arg Gln Val Thr Gln Arg Asn Pro Val Gly Gln Lys Lys Arg
 130 135 140
 Lys Met Ser Leu Leu Phe Asp His Leu Glu Pro Met Glu Leu Ala Glu
 145 150 155 160
 His Leu Thr Tyr Leu Glu Tyr Arg Ser Phe Cys Lys Ile Leu Phe Gln
 165 170 175
 Asp Tyr His Ser Phe Val Thr His Gly Cys Thr Val Asp Asn Pro Val
 180 185 190
 Leu Glu Arg Phe Ile Ser Leu Phe Asn Ser Val Ser Gln Trp Val Gln
 195 200 205
 Leu Met Ile Leu Ser Lys Pro Thr Ala Pro Gln Arg Ala Leu Val Ile
 210 215 220
 Thr His Phe Val His Val Ala Glu Lys Leu Leu Gln Leu Gln Asn Phe
 225 230 235 240
 Asn Thr Leu Met Ala Val Val Gly Gly Leu Ser His Ser Ser Ile Ser
 245 250 255
 Arg Leu Lys Glu Thr His Ser His Val Ser Pro Glu Thr Ile Lys Leu
 260 265 270
 Trp Glu Gly Leu Thr Glu Leu Val Thr Ala Thr Gly Asn Tyr Gly Asn
 275 280 285
 Tyr Arg Arg Arg Leu Ala Ala Cys Val Gly Phe Arg Phe Pro Ile Leu
 290 295 300
 Gly Val His Leu Lys Asp Leu Val Ala Leu Gln Leu Ala Leu Pro Asp
 305 310 315 320
 Trp Leu Asp Pro Ala Arg Thr Arg Leu Asn Gly Ala Lys Met Lys Gln
 325 330 335
 Leu Phe Ser Ile Leu Glu Glu Leu Ala Met Val Thr Ser Leu Arg Pro
 340 345 350
 Pro Val Gln Ala Asn Pro Asp Leu Leu Ser Leu Leu Thr Val Ser Leu
 355 360 365
 Asp Gln Tyr Gln Thr Glu Asp Glu Leu Tyr Gln Leu Ser Leu Gln Arg
 370 375 380
 Glu Pro Arg Ser Lys Ser Ser Pro Thr Ser Pro Thr Ser Cys Thr Pro
 385 390 395 400
 Pro Pro Arg Pro Pro Val Leu Glu Glu Trp Thr Ser Ala Ala Lys Pro
 405 410 415
 Lys Leu Asp Gln Ala Leu Val Val Glu His Ile Glu Lys Met Val Glu
 420 425 430
 Ser Val Phe Arg Asn Phe Asp Val Asp Gly Asp Gly His Ile Ser Gln
 435 440 445
 Glu Glu Phe Gln Ile Ile Arg Gly Asn Phe Pro Tyr Leu Ser Ala Phe
 450 455 460
 Gly Asp Leu Asp Gln Asn Gln Asp Gly Cys Ile Ser Arg Glu Glu Met
 465 470 475 480

- 9 -

Val Ser Tyr Phe Leu Arg Ser Ser Ser Val Leu Gly Gly Arg Met Gly
 485 490 495
 Phe Val His Asn Phe Gln Glu Ser Asn Ser Leu Arg Pro Val Ala Cys
 500 505 510
 Arg His Cys Lys Ala Leu Ile Leu Gly Ile Tyr Lys Gln Gly Leu Lys
 515 520 525
 Cys Arg Ala Cys Gly Val Asn Cys His Lys Gln Cys Lys Asp Arg Leu
 530 535 540
 Ser Val Glu Cys Arg Arg Arg Ala Gln Ser Val Ser Leu Glu Gly Ser
 545 550 555 560
 Ala Pro Ser Pro Ser Pro Met His Ser His His His Arg Ala Phe Ser
 565 570 575
 Phe Ser Leu Pro Arg Pro Gly Arg Arg Gly Ser Arg Pro Pro Glu Ile
 580 585 590
 Arg Glu Glu Glu Val Gln Thr Val Glu Asp Gly Val Phe Asp Ile His
 595 600 605
 Leu

<210> 5
 <211> 3624
 <212> DNA
 <213> Rattus norvegicus

<220>
 <221> CDS
 <222> (145)..(2529)
 <223> CalDAG-GEFII

<400> 5
 gcgcctgggt cggctcgccg ggctccgaga gtggccgggt ccgggctgcg agggccggcg 60
 ggggcccagg gatgcgccgc tccggccga gccgatcca ccgctccagg tgagacggct 120
 ccaggggcgc agagagccgc ggcc atg gga acc ctg ggc aag gcg aga gag 171
 Met Gly Thr Leu Gly Lys Ala Arg Glu
 1 5
 gct ccg cgg aaa cct tgc cat ggc tcc aga gct ggc ccc aaa gga aga 219
 Ala Pro Arg Lys Pro Cys His Gly Ser Arg Ala Gly Pro Lys Gly Arg 25
 10 15 20
 cta gag gcc aaa tca acc aac agt cct ctg cct gcc cag ccc agc ttg 267
 Leu Glu Ala Lys Ser Thr Asn Ser Pro Leu Pro Ala Gln Pro Ser Leu 40
 30 35 40
 gcc cag atc acc cag ttc cga atg atg gtg tcc ctg gga cat ctg gcc 315
 Ala Gln Ile Thr Gln Phe Arg Met Met Val Ser Leu Gly His Leu Ala 55
 45 50 55
 aaa gga gcc agc ctg gat gat ctt att gac agc tgc att caa tct ttc 363
 Lys Gly Ala Ser Leu Asp Asp Leu Ile Asp Ser Cys Ile Gln Ser Phe 70
 60 65 70
 gat gca gat gga aac ctg tgt cga agt aac cag ctg tta caa gtc atg 411
 Asp Ala Asp Gly Asn Leu Cys Arg Ser Asn Gln Leu Leu Gln Val Met 85
 75 80 85
 cta acc atg cac cga atc atc atc tcc tcg gcc gag ctg ctg caa aaa 459
 Leu Thr Met His Arg Ile Ile Ile Ser Ser Ala Glu Leu Leu Gln Lys 105
 90 95 100 105
 ctc atg aat cta tat aag gac gcc ctg gaa aag aat tct cca gga att 507
 Leu Met Asn Leu Tyr Lys Asp Ala Leu Glu Lys Asn Ser Pro Gly Ile 120
 110 115 120

- 10 -

tgc ttg aag atc tgc tat ttt gtc agg tat tgg ata aca gaa ttc tgg	555
Cys Leu Lys Ile Cys Tyr Phe Val Arg Tyr Trp Ile Thr Glu Phe Trp	
125 130 135	
atc atg ttc aaa atg gat gcc agc ttg acc agc acc atg gaa gag ttt	603
Ile Met Phe Lys Met Asp Ala Ser Leu Thr Ser Thr Met Glu Glu Phe	
140 145 150	
cag gac ctg gtg aaa gcc aat ggt gag gag tcc cac tgc cac ctc atc	651
Gln Asp Leu Val Lys Ala Asn Gly Glu Glu Ser His Cys His Leu Ile	
155 160 165	
gac acg aca caa att aat tct cga gac tgg tcc agg aaa ctg act cag	699
Asp Thr Thr Gln Ile Asn Ser Arg Asp Trp Ser Arg Lys Leu Thr Gln	
170 175 180 185	
agg ata aaa tca aat acc agc aag aag cgg aaa gtg tcc ctg ctg ttt	747
Arg Ile Lys Ser Asn Thr Ser Lys Lys Arg Lys Val Ser Leu Leu Phe	
190 195 200	
gac cat ctt gaa cct gaa gaa ctg tct gaa cac ctc acc tac ctt gag	795
Asp His Leu Glu Pro Glu Glu Leu Ser Glu His Leu Thr Tyr Leu Glu	
205 210 215	
ttc aag tcc ttc cga cgg ata tct ttc tct gat tat cag aat tac ctt	843
Phe Lys Ser Phe Arg Arg Ile Ser Phe Ser Asp Tyr Gln Asn Tyr Leu	
220 225 230	
gta aac agc tgc gta aag gag aac ccc acc atg gag cgg tcc att gcc	891
Val Asn Ser Cys Val Lys Glu Asn Pro Thr Met Glu Arg Ser Ile Ala	
235 240 245	
ctg tgc aat ggc atc tcc cag tgg gta caa ctg atg gtt ctc agc cgt	939
Leu Cys Asn Gly Ile Ser Gln Trp Val Gln Leu Met Val Leu Ser Arg	
250 255 260 265	
ccc acc cca cag ctc cgg gca gag gtc ttc atc aag ttc atc cat gtg	987
Pro Thr Pro Gln Leu Arg Ala Glu Val Phe Ile Lys Phe Ile His Val	
270 275 280	
gct cag aag ctc cac cag cta cag aac ttc aac acg cta atg gct gtg	1035
Ala Gln Lys Leu His Gln Leu Gln Asn Phe Asn Thr Leu Met Ala Val	
285 290 295	
atc ggg gga ctg tgt cac agc tcc atc tcc agg ctc aag gag aca agt	1083
Ile Gly Gly Leu Cys His Ser Ser Ile Ser Arg Leu Lys Glu Thr Ser	
300 305 310	
tca cat gtc cca cat gag atc aat aag gtt ctg ggt gag atg act gaa	1131
Ser His Val Pro His Glu Ile Asn Lys Val Leu Gly Glu Met Thr Glu	
315 320 325	
ctg ctg tcc tcc tgc aga aac tat gac aac tac agg cga gcc tat ggt	1179
Leu Leu Ser Ser Cys Arg Asn Tyr Asp Asn Tyr Arg Arg Ala Tyr Gly	
330 335 340 345	
gag tgc acc cac ttc aaa atc ccc ata ctg ggt gtg cac ctc aag gac	1227
Glu Cys Thr His Phe Lys Ile Pro Ile Leu Gly Val His Leu Lys Asp	
350 355 360	
ctc ata tcc cta tat gaa gcc atg cct gac tac ctg gaa gac ggg aag	1275
Leu Ile Ser Leu Tyr Glu Ala Met Pro Asp Tyr Leu Glu Asp Gly Lys	
365 370 375	
gtg aat gtc caa aag ctc ctg gcc ctt tac aat cac atc aat gag ttg	1323
Val Asn Val Gln Lys Leu Leu Ala Leu Tyr Asn His Ile Asn Glu Leu	
380 385 390	
gtc cag ctg cag gac gtg gcc cca cca ttg gat gcc aac aag gac ctg	1371
Val Gln Leu Gln Asp Val Ala Pro Pro Leu Asp Ala Asn Lys Asp Leu	
395 400 405	
gtg cac ctg ctg acg tta tcc ctg gat cta tac tac acc gaa gat gaa	1419
Val His Leu Leu Thr Leu Ser Leu Asp Leu Tyr Tyr Thr Glu Asp Glu	
410 415 420 425	

- 11 -

atc	tat	gag	ctt	tcc	tac	gcc	cgt	gaa	cca	agg	aac	cac	agg	gcc	ccg	1467
Ile	Tyr	Glu	Leu	Ser	Tyr	Ala	Arg	Glu	Pro	Arg	Asn	His	Arg	Ala	Pro	
				430					435					440		
cca	ctg	aca	cct	tcg	aag	cca	cca	gtt	gta	gtg	gac	tgg	gcc	tct	gga	1515
Pro	Leu	Thr	Pro	Ser	Lys	Pro	Pro	Val	Val	Val	Asp	Trp	Ala	Ser	Gly	
			445					450					455			
gtg	tct	ccc	aaa	cct	gac	ccg	aag	acc	atc	agc	aaa	cac	gtc	caa	agg	1563
Val	Ser	Pro	Lys	Pro	Asp	Pro	Lys	Thr	Ile	Ser	Lys	His	Val	Gln	Arg	
		460					465					470				
atg	gtg	gat	tct	gtc	ttt	aag	aac	tat	gat	ctc	gac	cag	gat	gga	tat	1611
Met	Val	Asp	Ser	Val	Phe	Lys	Asn	Tyr	Asp	Leu	Asp	Gln	Asp	Gly	Tyr	
	475					480					485					
atc	tct	cag	gag	gag	ttt	gaa	aag	att	gct	gcg	agc	ttt	cca	ttt	tcc	1659
Ile	Ser	Gln	Glu	Glu	Phe	Glu	Lys	Ile	Ala	Ala	Ser	Phe	Pro	Phe	Ser	
490				495					500						505	
ttc	tgt	gtg	atg	gac	aaa	gat	agg	gag	ggc	ctc	atc	agc	aga	gac	gag	1707
Phe	Cys	Val	Met	Asp	Lys	Asp	Arg	Glu	Gly	Leu	Ile	Ser	Arg	Asp	Glu	
				510					515					520		
atc	aca	gcc	tac	ttc	atg	agg	gcc	agc	tcc	atc	tat	tcc	aag	ctg	ggc	1755
Ile	Thr	Ala	Tyr	Phe	Met	Arg	Ala	Ser	Ser	Ile	Tyr	Ser	Lys	Leu	Gly	
			525					530					535			
cta	ggc	ttt	cca	cac	aac	ttt	caa	gag	acc	act	tac	ctg	aag	ccc	acc	1803
Leu	Gly	Phe	Pro	His	Asn	Phe	Gln	Glu	Thr	Thr	Tyr	Leu	Lys	Pro	Thr	
		540					545					550				
ttc	tgt	gac	aac	tgt	gct	ggc	ttt	ctc	tgg	ggc	gtg	atc	aag	caa	ggc	1851
Phe	Cys	Asp	Asn	Cys	Ala	Gly	Phe	Leu	Trp	Gly	Val	Ile	Lys	Gln	Gly	
	555					560					565					
tat	cgc	tgt	aaa	gac	tgt	ggg	atg	aac	tgc	cac	aaa	cag	tgc	aaa	gac	1899
Tyr	Arg	Cys	Lys	Asp	Cys	Gly	Met	Asn	Cys	His	Lys	Gln	Cys	Lys	Asp	
570					575					580					585	
ctg	gta	gtg	ttt	gag	tgc	aag	aaa	cga	tcc	aag	agc	ccg	gcg	gta	tcc	1947
Leu	Val	Val	Phe	Glu	Cys	Lys	Lys	Arg	Ser	Lys	Ser	Pro	Ala	Val	Ser	
				590					595					600		
aca	gaa	aac	atc	agc	tct	gtg	gtg	cca	atg	tcc	act	ctt	tgt	cca	ctg	1995
Thr	Glu	Asn	Ile	Ser	Ser	Val	Val	Pro	Met	Ser	Thr	Leu	Cys	Pro	Leu	
			605					610					615			
gga	acc	aaa	gat	ctg	ctc	cat	gca	ccc	gaa	gaa	gga	tct	ttc	att	ttc	2043
Gly	Thr	Lys	Asp	Leu	Leu	His	Ala	Pro	Glu	Glu	Gly	Ser	Phe	Ile	Phe	
		620					625					630				
cag	aat	gga	gag	gtt	gtg	gac	cac	agt	gag	gag	agc	aag	gat	agg	acc	2091
Gln	Asn	Gly	Glu	Val	Val	Asp	His	Ser	Glu	Glu	Ser	Lys	Asp	Arg	Thr	
	635					640					645					
atc	atg	ctc	ttg	ggc	gta	tcc	tca	cag	aaa	att	tca	gtt	cgg	ctg	aag	2139
Ile	Met	Leu	Leu	Gly	Val	Ser	Ser	Gln	Lys	Ile	Ser	Val	Arg	Leu	Lys	
650				655						660					665	
agg	act	gtt	gcc	cac	aag	acc	acc	cag	aca	gaa	tca	ttt	cct	tgg	gtt	2187
Arg	Thr	Val	Ala	His	Lys	Thr	Thr	Gln	Thr	Glu	Ser	Phe	Pro	Trp	Val	
				670					675					680		
ggc	ggc	gag	atg	ccc	cct	ggt	cac	ttt	gtg	ctg	act	tct	cca	aga	aag	2235
Gly	Gly	Glu	Met	Pro	Pro	Gly	His	Phe	Val	Leu	Thr	Ser	Pro	Arg	Lys	
			685					690					695			
tca	gca	caa	ggg	gct	ctt	tat	gtg	cac	agt	cca	gca	tct	ccg	tgc	ccc	2283
Ser	Ala	Gln	Gly	Ala	Leu	Tyr	Val	His	Ser	Pro	Ala	Ser	Pro	Cys	Pro	
		700					705					710				
agc	cca	gca	ctg	gtc	cgg	aag	cgg	gca	ttc	gtc	aag	tgg	gag	aac	aaa	2331
Ser	Pro	Ala	Leu	Val	Arg	Lys	Arg	Ala	Phe	Val	Lys	Trp	Glu	Asn	Lys	

- 12 -

715 720 725

gag tcc ctt atc^{aaa} cca^{aaa} cca gag ctt cac ctc agg ctc cgg acc 2379
 Glu Ser Leu Ile Lys Pro Lys Pro Glu Leu His Leu Arg Leu Arg Thr
 730 735 740 745

tac caa gaa ctg gaa cag gag gta aat acc ctg agg gca gat aac gat 2427
 Tyr Gln Glu Leu Glu Gln Glu Val Asn Thr Leu Arg Ala Asp Asn Asp
 750 755 760

gct ctg aag atc cag ctg aag tat gca cag aaa caa ata gaa tcc ctg 2475
 Ala Leu Lys Ile Gln Leu Lys Tyr Ala Gln Lys Gln Ile Glu Ser Leu
 765 770 775

cag ctt ggc aaa agc aat cac gtc tta gca cag atg gac cac ggt gat 2523
 Gln Leu Gly Lys Ser Asn His Val Leu Ala Gln Met Asp His Gly Asp
 780 785 790

ggt act taatccagaa attcaaggaa cagaatctgc agacggggtt actgggatct 2579
 Gly Thr
 795

cacttcaaaa ctgattgcag aggttcagca actttagact gattgacttt taaagggcag 2639

agatagccac tgttattggt gtccttggtt tttccctaa ctgtctttaa tgtgagtcgt 2699

gggttttcag tcagttgagt aaaagggag aaaagttcca gcatgtaaaa cactgagcag 2759

tcatattcta accttttctt tcttttactg aaaccaatac caaacatgtg ctaaaataag 2819

agtatagttt cctgacagtg tctcaggcag cctgctttac tgattcgcac ttagataaaag 2879

agcccctggt gaatcaattt gctgccttcc ccagggttcc tgcaaaactgg gagttacttt 2939

gttctacccg aaaacctgct cataatggaa acaataccct aaaagtgggt actttgacat 2999

gcctgcattg tttgtgaagc tgatccctac cttattcact acctcagatc tcaagagcct 3059

ctttccctgt cctttacttg cccctattt cctccctgct ttgtaggcac atcagcatat 3119

ctacctagaa gtgacctcct agagatgtag cctgtgttta aatccagagc ttcttaattg 3179

aacttgacat tgtctgattg caggccaact tatagctcta ggtcttagtc attatgaaat 3239

acaaaataaa actaccata atcatcaatt accatgtcat acacagaact cattatctaa 3299

gtcaaacgac gtaaacacgc ctgtccagat agtctttctt tagtggatag aattaacaat 3359

ctgtgacctt ttaaaagaca tggctctgtga acagtgttta gttcttcacg ttctagtctc 3419

tctctctctc tctctctctc tctctctctc tctctctctc tctctcaagt aaactatcgt 3479

aaggctctct tttgaactga atctgtgctt aaaattgtct tcacttttat tatctacaaa 3539

taagctatgg gaggcgatgg ctttaacagc tgacagcatt tacctatgtg tagaatatgt 3599

gtatatagta tcaggcatgc atgga 3624

<210> 6

<211> 795

<212> PRT

<213> Rattus norvegicus

<400> 6

Met Gly Thr Leu Gly Lys Ala Arg Glu Ala Pro Arg Lys Pro Cys His
 1 5 10 15

Gly Ser Arg Ala Gly Pro Lys Gly Arg Leu Glu Ala Lys Ser Thr Asn
 20 25 30

Ser Pro Leu Pro Ala Gln Pro Ser Leu Ala Gln Ile Thr Gln Phe Arg
 35 40 45

Met Met Val Ser Leu Gly His Leu Ala Lys Gly Ala Ser Leu Asp Asp

- 13 -

50 55 60
 Leu Ile Asp Ser Cys Ile Gln Ser Phe Asp Ala Asp Gly Asn Leu Cys
 65 70 75 80
 Arg Ser Asn Gln Leu Leu Gln Val Met Leu Thr Met His Arg Ile Ile
 85 90 95
 Ile Ser Ser Ala Glu Leu Leu Gln Lys Leu Met Asn Leu Tyr Lys Asp
 100 105 110
 Ala Leu Glu Lys Asn Ser Pro Gly Ile Cys Leu Lys Ile Cys Tyr Phe
 115 120 125
 Val Arg Tyr Trp Ile Thr Glu Phe Trp Ile Met Phe Lys Met Asp Ala
 130 135 140
 Ser Leu Thr Ser Thr Met Glu Glu Phe Gln Asp Leu Val Lys Ala Asn
 145 150 155 160
 Gly Glu Glu Ser His Cys His Leu Ile Asp Thr Thr Gln Ile Asn Ser
 165 170 175
 Arg Asp Trp Ser Arg Lys Leu Thr Gln Arg Ile Lys Ser Asn Thr Ser
 180 185 190
 Lys Lys Arg Lys Val Ser Leu Leu Phe Asp His Leu Glu Pro Glu Glu
 195 200 205
 Leu Ser Glu His Leu Thr Tyr Leu Glu Phe Lys Ser Phe Arg Arg Ile
 210 215 220
 Ser Phe Ser Asp Tyr Gln Asn Tyr Leu Val Asn Ser Cys Val Lys Glu
 225 230 235 240
 Asn Pro Thr Met Glu Arg Ser Ile Ala Leu Cys Asn Gly Ile Ser Gln
 245 250 255
 Trp Val Gln Leu Met Val Leu Ser Arg Pro Thr Pro Gln Leu Arg Ala
 260 265 270
 Glu Val Phe Ile Lys Phe Ile His Val Ala Gln Lys Leu His Gln Leu
 275 280 285
 Gln Asn Phe Asn Thr Leu Met Ala Val Ile Gly Gly Leu Cys His Ser
 290 295 300
 Ser Ile Ser Arg Leu Lys Glu Thr Ser Ser His Val Pro His Glu Ile
 305 310 315 320
 Asn Lys Val Leu Gly Glu Met Thr Glu Leu Leu Ser Ser Cys Arg Asn
 325 330 335
 Tyr Asp Asn Tyr Arg Arg Ala Tyr Gly Glu Cys Thr His Phe Lys Ile
 340 345 350
 Pro Ile Leu Gly Val His Leu Lys Asp Leu Ile Ser Leu Tyr Glu Ala
 355 360 365
 Met Pro Asp Tyr Leu Glu Asp Gly Lys Val Asn Val Gln Lys Leu Leu
 370 375 380
 Ala Leu Tyr Asn His Ile Asn Glu Leu Val Gln Leu Gln Asp Val Ala
 385 390 395 400
 Pro Pro Leu Asp Ala Asn Lys Asp Leu Val His Leu Leu Thr Leu Ser
 405 410 415
 Leu Asp Leu Tyr Tyr Thr Glu Asp Glu Ile Tyr Glu Leu Ser Tyr Ala
 420 425 430
 Arg Glu Pro Arg Asn His Arg Ala Pro Pro Leu Thr Pro Ser Lys Pro
 435 440 445
 Pro Val Val Val Asp Trp Ala Ser Gly Val Ser Pro Lys Pro Asp Pro

- 14 -

450 455 460
 Lys Thr Ile Ser Lys His Val Gln Arg Met Val Asp Ser Val Phe Lys
 465 470 475 480
 Asn Tyr Asp Leu Asp Gln Asp Gly Tyr Ile Ser Gln Glu Glu Phe Glu
 485 490 495
 Lys Ile Ala Ala Ser Phe Pro Phe Ser Phe Cys Val Met Asp Lys Asp
 500 505 510
 Arg Glu Gly Leu Ile Ser Arg Asp Glu Ile Thr Ala Tyr Phe Met Arg
 515 520 525
 Ala Ser Ser Ile Tyr Ser Lys Leu Gly Leu Gly Phe Pro His Asn Phe
 530 535 540
 Gln Glu Thr Thr Tyr Leu Lys Pro Thr Phe Cys Asp Asn Cys Ala Gly
 545 550 555 560
 Phe Leu Trp Gly Val Ile Lys Gln Gly Tyr Arg Cys Lys Asp Cys Gly
 565 570 575
 Met Asn Cys His Lys Gln Cys Lys Asp Leu Val Val Phe Glu Cys Lys
 580 585 590
 Lys Arg Ser Lys Ser Pro Ala Val Ser Thr Glu Asn Ile Ser Ser Val
 595 600 605
 Val Pro Met Ser Thr Leu Cys Pro Leu Gly Thr Lys Asp Leu Leu His
 610 615 620
 Ala Pro Glu Glu Gly Ser Phe Ile Phe Gln Asn Gly Glu Val Val Asp
 625 630 635 640
 His Ser Glu Glu Ser Lys Asp Arg Thr Ile Met Leu Leu Gly Val Ser
 645 650 655
 Ser Gln Lys Ile Ser Val Arg Leu Lys Arg Thr Val Ala His Lys Thr
 660 665 670
 Thr Gln Thr Glu Ser Phe Pro Trp Val Gly Gly Glu Met Pro Pro Gly
 675 680 685
 His Phe Val Leu Thr Ser Pro Arg Lys Ser Ala Gln Gly Ala Leu Tyr
 690 695 700
 Val His Ser Pro Ala Ser Pro Cys Pro Ser Pro Ala Leu Val Arg Lys
 705 710 715 720
 Arg Ala Phe Val Lys Trp Glu Asn Lys Glu Ser Leu Ile Lys Pro Lys
 725 730 735
 Pro Glu Leu His Leu Arg Leu Arg Thr Tyr Gln Glu Leu Glu Gln Glu
 740 745 750
 Val Asn Thr Leu Arg Ala Asp Asn Asp Ala Leu Lys Ile Gln Leu Lys
 755 760 765
 Tyr Ala Gln Lys Gln Ile Glu Ser Leu Gln Leu Gly Lys Ser Asn His
 770 775 780
 Val Leu Ala Gln Met Asp His Gly Asp Gly Thr
 785 790 795

<210> 7
 <211> 5075
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (104)..(2494)
 <223> CalDAG-GEFII

SUBSTITUTE SHEET (RULE 26)

- 16 -

aag	ttc	atc	cag	gtg	gct	cag	aag	ctc	cac	caa	cta	cag	aac	ttc	aat	979
Lys	Phe	Ile	Gln	Val	Ala	Gln	Lys	Leu	His	Gln	Leu	Gln	Asn	Phe	Asn	
			280					285					290			
aca	ctg	atg	gct	gtg	ata	ggg	ggg	ctg	tgt	cac	agc	tca	atc	tcg	agg	1027
Thr	Leu	Met	Ala	Val	Ile	Gly	Gly	Leu	Cys	His	Ser	Ser	Ile	Ser	Arg	
		295					300					305				
ctc	aag	gag	aca	agt	tcg	cat	gtc	cca	cat	gaa	atc	aat	aag	gtt	ctc	1075
Leu	Lys	Glu	Thr	Ser	Ser	His	Val	Pro	His	Glu	Ile	Asn	Lys	Val	Leu	
	310					315					320					
ggt	gag	atg	act	gag	ctg	ctg	tcc	tcc	tcc	aga	aac	tac	gac	aat	tac	1123
Gly	Glu	Met	Thr	Glu	Gln	Leu	Ser	Ser	Ser	Arg	Asn	Tyr	Asp	Asn	Tyr	
	325				330					335					340	
cgg	cga	gcc	tat	gga	gag	tgc	acc	gac	ttc	aag	atc	ccc	att	ctg	ggg	1171
Arg	Arg	Ala	Tyr	Gly	Glu	Cys	Thr	Asp	Phe	Lys	Ile	Pro	Ile	Leu	Gly	
				345					350					355		
gtg	cat	ctc	aag	gac	ctc	atc	tcc	ctg	tat	gaa	gcc	atg	cct	gac	tat	1219
Val	His	Leu	Lys	Asp	Leu	Ile	Ser	Leu	Tyr	Glu	Ala	Met	Pro	Asp	Tyr	
			360					365					370			
ctg	ggg	gac	ggg	aaa	gtg	aac	gtc	cat	aag	cta	ctg	gcc	cta	tac	aat	1267
Leu	Gly	Asp	Gly	Lys	Val	Asn	Val	His	Lys	Leu	Leu	Ala	Leu	Tyr	Asn	
	375						380					385				
cat	atc	agt	gaa	ttg	gtc	cag	ctg	caa	gag	gtg	gcc	cca	ccc	ttg	gag	1315
His	Ile	Ser	Glu	Leu	Val	Gln	Leu	Gln	Glu	Val	Ala	Pro	Pro	Leu	Glu	
	390					395					400					
gct	aac	aag	gac	ttg	gta	cac	ttg	ctg	acg	tta	tcc	ctg	gat	ctt	tac	1363
Ala	Asn	Lys	Asp	Leu	Val	His	Leu	Leu	Thr	Leu	Ser	Leu	Asp	Leu	Tyr	
	405				410				415					420		
tac	act	gag	gat	gaa	atc	tat	gag	ctt	tcc	tat	gcc	cgg	gaa	cca	agg	1411
Tyr	Thr	Glu	Asp	Glu	Ile	Tyr	Glu	Leu	Ser	Tyr	Ala	Arg	Glu	Pro	Arg	
			425					430					435			
aac	cac	aga	gct	cca	cca	cta	aca	cct	tca	aag	cca	cca	gta	gta	gtg	1459
Asn	His	Arg	Ala	Pro	Pro	Leu	Thr	Pro	Ser	Lys	Pro	Pro	Val	Val	Val	
			440					445					450			
gac	tgg	gct	tct	gga	gtg	tct	ccc	aaa	cct	gat	cca	aaa	acc	att	agc	1507
Asp	Trp	Ala	Ser	Gly	Val	Ser	Pro	Lys	Pro	Asp	Pro	Lys	Thr	Ile	Ser	
		455					460					465				
aaa	cac	gtc	cag	agg	atg	gtg	gat	tct	gtc	ttc	aag	aac	tat	gat	cac	1555
Lys	His	Val	Gln	Arg	Met	Val	Asp	Ser	Val	Phe	Lys	Asn	Tyr	Asp	His	
	470					475					480					
gac	cag	gat	gga	tac	att	tct	cag	gaa	gaa	ttt	gaa	aag	att	gct	gcg	1603
Asp	Gln	Asp	Gly	Tyr	Ile	Ser	Gln	Glu	Glu	Phe	Glu	Lys	Ile	Ala	Ala	
	485				490					495				500		
agt	ttt	cca	ttt	tcc	ttc	tgt	gtg	atg	gac	aaa	gac	agg	gaa	ggc	ctc	1651
Ser	Phe	Pro	Phe	Ser	Phe	Cys	Val	Met	Asp	Lys	Asp	Arg	Glu	Gly	Leu	
				505					510				515			
atc	agc	agg	gat	gag	atc	aca	gcc	tac	ttc	atg	aga	gcc	agc	tca	atc	1699
Ile	Ser	Arg	Asp	Glu	Ile	Thr	Ala	Tyr	Phe	Met	Arg	Ala	Ser	Ser	Ile	
			520					525					530			
tat	tcc	aag	ctg	ggc	ctg	ggc	ttt	cct	cac	aac	ttc	caa	gag	acc	acc	1747
Tyr	Ser	Lys	Leu	Gly	Leu	Gly	Phe	Pro	His	Asn	Phe	Gln	Glu	Thr	Thr	
		535					540					545				
tac	ctg	aag	ccc	act	ttt	tgt	gac	aac	tgt	gct	gga	ttt	ctc	tggt	gga	1795
Tyr	Leu	Lys	Pro	Thr	Phe	Cys	Asp	Asn	Cys	Ala	Gly	Phe	Leu	Trp	Gly	
	550					555					560					
gtg	atc	aaa	caa	gga	tat	cga	tgt	aaa	gac	tgc	ggg	atg	aac	tgt	cac	1843
Val	Ile	Lys	Gln	Gly	Tyr	Arg	Cys	Lys	Asp	Cys	Gly	Met	Asn	Cys	His	

- 17 -

565	570	575	580	
aaa Lys	caa Gln	tgc Cys	aaa Lys	gat Asp 585
ctg Leu	gtt Val	gtg Val	ttt Phe	gag Glu 590
tgt Cys	aag Lys	aag Lys	cga Arg	gcc Ala 595
aag Lys	1891			
aac Asn	cca Pro	gta Val	gct Ala 600	ccc Pro
aca Thr	gag Glu	aac Asn	aac Asn 605	act Thr
tct Ser	gtg Val	ggg Gly	cca Pro 610	gtg Val
tcc Ser	1939			
aac Asn	ctt Leu	tgc Cys 615	tca Ser	ttg Leu
gga Gly	cct Pro	ttt Phe	aca Thr	ttc Phe
cct Pro	aaa Lys 620	gat Asp	ctg Leu	ctc Leu
cat His	gca Ala 625	cct Pro	gag Glu	gaa Glu
1987				
gga Gly	cct Pro	ttt Phe 630	aca Thr	ttc Phe
cct Pro	aaa Lys 635	gag Glu	gct Ala	gtg Val
gaa Glu	cat His 640	ggg Gly	gag Glu	gag Glu
2035				
agt Ser	aag Lys	gat Asp	cgg Arg	acc Thr
atc Ile	atg Met	ctg Leu	atg Met	ctg Leu
gga Gly	gtg Val	tcc Ser	tca Ser	cag Gln
aag Lys	att Ile 660	2083		
tct Ser	ctt Leu	cgg Arg	ctg Leu	aag Lys 665
agg Arg	gct Ala	ggt Val	gcc Ala 670	acc Thr
cag Gln	act Thr 675	gaa Glu	ctg Leu	2131
tca Ser	cag Gln	cct Pro	tgg Trp 680	att Ile
ggc Gly	agt Ser	gag Glu	ggc Gly 685	cct Pro
tca Ser	ggt Gly	ccc Pro	ttt Phe 690	gtg Val
ctg Leu	2179			
tct Ser	tcc Ser	cca Pro 695	agg Arg	aag Lys
aca Thr	gcc Ala 700	cag Gln	gat Asp	act Thr
cta Leu	tat Tyr	gtg Val 705	ctt Leu	ccc Pro
agt Ser	2227			
ccc Pro	acc Thr 710	tct Ser	cca Pro	tgt Cys
cct Pro	agc Ser 715	cca Pro	gtc Val	ttg Leu
gtc Val	aaa Lys 730	gac Asp	tcc Ser	ctc Leu
ata Ile	aaa Lys 735	tca Ser	aag Lys	cgg Arg
gct Ala	ttt Phe	2275		
gtc Val	aag Lys	tgg Trp	gag Glu	gag Glu
ctc Leu	2323			
cgt Arg	cac His	ctc Leu	aga Arg	ctg Leu
cct Pro	acc Thr	tac Tyr	caa Gln	gaa Glu
gaa Glu	ctg Leu	gaa Glu	cag Gln	gaa Glu
ata Ile	aat Asn 755	2371		
act Thr	ctg Leu	aaa Lys 760	gca Ala	gat Asp
aat Asn	gat Asp	gcc Ala 765	cta Leu	aag Lys
atc Ile	caa Gln	ctg Leu	gaa Glu	cag Gln
aaa Lys	agc Asn 785	aat His	cat His	gtc Val
tta Leu	2467			
gct Ala	caa Gln	atg Met	gag Glu	cag Gln
ggt Gly	gac Asp 795	tgt Cys	tct Ser	tagccccagaa
actaagtagc	2514			
acaatctgta	gatgagtata	gtgatctcat	ttcctaaact	gtaatgcaca
gacctgagga	2574			
actttacact	gaccagcttt	aaaacagtac	tttaaaagga	aaagcctgtt
actgtttatt	2634			
tacctaanaag	attcctaattg	tcgagcactg	ttttctcttt	cagtttagttg
actcaaagg	2694			
ggaaaactaa	agaatgcaaa	acttttgcta	ttcataccac	tgatgttcat
caaaagtatg	2754			
cgatctaanaa	catgactatc	atttcttgac	aatggggcat	ctcgggtggcc
tgctggctg	2814			
attcttcctt	aaaactaaaa	tctctggaaa	atggatttgc	ttcttaccct
gtgttttctg	2874			
caaactgact	tactttgttc	cagccaaagc	ttgctaataa	tagaaaacta
cccatattcc	2934			
aaaagtagat	ttcctctgta	tcccagcata	ctttgtgaac	ctggctcctt
cttcactacc	2994			
tcagatctaa	tcaattagtc	catgtaccct	ccttcctcac	tacagtcata
acacatgagc	3054			

- 18 -

atatctacct agaagccaat ttctactgat gtagccacaa ctttttagag gcctattaaa 3114
catgacggtta tccaattgca ggtcaactta tagttgtagc cttacaactt acaggcatca 3174
gaaaaataagt aatcaaatta ggtacctgga aacatagcta ttaccatctc atattactgt 3234
ctaattaaaa taaacataac gcaaacatgt ttgtccttat atattctaca gtggatagaa 3294
ttaggaattg atggcttaaa aaaaaaagtc tatgaagagt ctgtttaact cttcatgttc 3354
catctttctc ttctgaagta aactattttg aaagttctct ttttgaaatg aatttgtgct 3414
taactgtctt cactattaat actatttaga aataagctaa ttggatcagt ggcttaata 3474
atagctgact gtgtgtacat atgtatataa tatgtatata caatatcagg catgcatgtg 3534
gcttgaatt ttgtttctc cataaaatgt ggaagtgaat taaacaagtt ttagtcattt 3594
atacaaagtc acaaataaa agttcagttt gtcacaagat taaattgctc acaaggtaaa 3654
attgtattgt ttggcaaaat cacaagtaac aatcctgtga gttttctatt atgaagggtta 3714
ataataaatg ggctcattta gttgctggg cacctattca caaattcatt tgtcagctc 3774
tttttagttc tcttaaaaaa aaaaaaatca tatgatcatt ttcctttttg ggggtactta 3834
gcttccatgc ctataaagtc tgggtaccaga ctgacttgaa attcataaac aagttgtcca 3894
attgccaaga atatgttaac aattaaaagt tccaaactaa agccaatagc accaagtctt 3954
cataagaata caaagtatac atacagtatt gttacctgg aggattcaga tcatttagga 4014
attctctttg atgaaagatc agttcccat tgagttctc cttgactga gttttagtga 4074
tatagaacta gcttgtagt agtgtttcat tacattataa agaatagttt tacacacgta 4134
tttaccgttt tccaaattta aactcagaaa taccocaaagc aggcctgctt aagccacta 4194
cctggcatat aaacttatag taacactttg ttactttctt tttaatagga caagcatgag 4254
ttaggacaaa ctctaaaaat tcatattctt cactattctt gttttcctt gattgatata 4314
gaccaaagat ggtgtactct aatttttta aacagtaatg gaacacaatt ttttcatc 4374
ttctctctt ccattcgaag taaagatccc cagttagttt ttatataaat aatctatagg 4434
gattcaaaag gtgtcacagt ccacttaatt agtcaaatta gcaatggcta aacagtatca 4494
agtactgcag aatttatcac tgaaatggat aagaggaaat agtttagtca caggttttta 4554
cagtccagca agggccaaag aggtatagta tacaagttaa tagtatttgt gttgagcaac 4614
atggggctag tgggatcaca gaaatctgga aaaaaaaaaa aaaaggctt ggcttatcaa 4674
gcctagtgt aatttctgca tctcacacga ctttagtttg gccagggtatt tatctgcaa 4734
aacaaggaca aatcttgttg tattaacagc agggtcactt ctcattttct ttgtgactt 4794
acctttttac tgaccgttgt gaatttctgt ctcaaatgt ataatataga aatgcaagaa 4854
aaaaacaaat gtacagattg taaagttttt tgatacctaa tgtaagtttt ctttgtgtaa 4914
tatttatatg ataaaagaca ttaggatccc taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4974
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaggg atcgacaatt 5034
acgactcccc gggggggccc ggtccaattc ccccaaaagg g 5075

<210> 8
<211> 797
<212> PRT
<213> Homo sapiens

- 19 -

<400> 8
 Met Gly Thr Leu Gly Lys Ala Arg Glu Ala Pro Arg Lys Pro Ser His
 1 5 10 15
 Gly Cys Arg Ala Ala Ser Lys Ala Arg Leu Glu Ala Lys Pro Ala Asn
 20 25 30
 Ser Pro Phe Pro Ser His Pro Ser Leu Ala His Ile Thr Gln Phe Arg
 35 40 45
 Met Met Val Ser Leu Gly His Leu Ala Lys Gly Ala Ser Leu Asp Asp
 50 55 60
 Leu Ile Asp Ser Cys Ile Gln Ser Phe Asp Ala Asp Gly Asn Leu Cys
 65 70 75 80
 Arg Ser Asn Gln Leu Leu Gln Val Met Leu Thr Met His Arg Ile Val
 85 90 95
 Ile Ser Ser Ala Glu Leu Leu Gln Lys Val Ile Thr Leu Tyr Lys Asp
 100 105 110
 Ala Leu Ala Lys Asn Ser Pro Gly Leu Cys Leu Lys Ile Cys Tyr Phe
 115 120 125
 Val Arg Tyr Trp Ile Thr Glu Phe Trp Val Met Phe Lys Met Asp Ala
 130 135 140
 Ser Leu Thr Asp Thr Met Glu Glu Phe Gln Glu Leu Val Lys Ala Lys
 145 150 155 160
 Gly Glu Glu Leu His Cys Arg Leu Ile Asp Thr Thr Gln Ile Asn Ala
 165 170 175
 Arg Asp Trp Ser Arg Lys Leu Thr Gln Arg Ile Lys Ser Asn Thr Ser
 180 185 190
 Lys Lys Arg Lys Val Ser Leu Leu Phe Asp His Leu Glu Pro Glu Glu
 195 200 205
 Leu Ser Glu His Leu Thr Tyr Leu Glu Phe Lys Ser Phe Arg Arg Ile
 210 215 220
 Ser Phe Ser Asp Tyr Gln Asn Tyr Leu Val Asn Ser Cys Val Lys Glu
 225 230 235 240
 Asn Pro Thr Met Glu Arg Ser Ile Ala Leu Cys Asn Gly Ile Ser Gln
 245 250 255
 Trp Val Gln Leu Met Val Leu Ser Arg Pro Thr Pro Gln Leu Arg Ala
 260 265 270
 Glu Val Phe Ile Lys Phe Ile Gln Val Ala Gln Lys Leu His Gln Leu
 275 280 285
 Gln Asn Phe Asn Thr Leu Met Ala Val Ile Gly Gly Leu Cys His Ser
 290 295 300
 Ser Ile Ser Arg Leu Lys Glu Thr Ser Ser His Val Pro His Glu Ile
 305 310 315 320
 Asn Lys Val Leu Gly Glu Met Thr Glu Leu Ser Ser Ser Arg Asn
 325 330 335
 Tyr Asp Asn Tyr Arg Arg Ala Tyr Gly Glu Cys Thr Asp Phe Lys Ile
 340 345 350
 Pro Ile Leu Gly Val His Leu Lys Asp Leu Ile Ser Leu Tyr Glu Ala
 355 360 365
 Met Pro Asp Tyr Leu Gly Asp Gly Lys Val Asn Val His Lys Leu Leu
 370 375 380
 Ala Leu Tyr Asn His Ile Ser Glu Leu Val Gln Leu Gln Glu Val Ala
 385 390 395 400

- 20 -

Pro Pro Leu Glu Ala Asn Lys Asp Leu Val His Leu Leu Thr Leu Ser
 405 410 415
 Leu Asp Leu Tyr Tyr Thr Glu Asp Glu Ile Tyr Glu Leu Ser Tyr Ala
 420 425 430
 Arg Glu Pro Arg Asn His Arg Ala Pro Pro Leu Thr Pro Ser Lys Pro
 435 440 445
 Pro Val Val Val Asp Trp Ala Ser Gly Val Ser Pro Lys Pro Asp Pro
 450 455 460
 Lys Thr Ile Ser Lys His Val Gln Arg Met Val Asp Ser Val Phe Lys
 465 470 475 480
 Asn Tyr Asp His Asp Gln Asp Gly Tyr Ile Ser Gln Glu Glu Phe Glu
 485 490 495
 Lys Ile Ala Ala Ser Phe Pro Phe Ser Phe Cys Val Met Asp Lys Asp
 500 505 510
 Arg Glu Gly Leu Ile Ser Arg Asp Glu Ile Thr Ala Tyr Phe Met Arg
 515 520 525
 Ala Ser Ser Ile Tyr Ser Lys Leu Gly Leu Gly Phe Pro His Asn Phe
 530 535 540
 Gln Glu Thr Thr Tyr Leu Lys Pro Thr Phe Cys Asp Asn Cys Ala Gly
 545 550 555 560
 Phe Leu Trp Gly Val Ile Lys Gln Gly Tyr Arg Cys Lys Asp Cys Gly
 565 570 575
 Met Asn Cys His Lys Gln Cys Lys Asp Leu Val Val Phe Glu Cys Lys
 580 585 590
 Lys Arg Ala Lys Asn Pro Val Ala Pro Thr Glu Asn Asn Thr Ser Val
 595 600 605
 Gly Pro Val Ser Asn Leu Cys Ser Leu Gly Ala Lys Asp Leu Leu His
 610 615 620
 Ala Pro Glu Glu Gly Pro Phe Thr Phe Pro Asn Gly Glu Ala Val Glu
 625 630 635 640
 His Gly Glu Glu Ser Lys Asp Arg Thr Ile Met Leu Met Gly Val Ser
 645 650 655
 Ser Gln Lys Ile Ser Leu Arg Leu Lys Arg Ala Val Ala His Lys Ala
 660 665 670
 Thr Gln Thr Glu Ser Gln Pro Trp Ile Gly Ser Glu Gly Pro Ser Gly
 675 680 685
 Pro Phe Val Leu Ser Ser Pro Arg Lys Thr Ala Gln Asp Thr Leu Tyr
 690 695 700
 Val Leu Pro Ser Pro Thr Ser Pro Cys Pro Ser Pro Val Leu Val Arg
 705 710 715 720
 Lys Arg Ala Phe Val Lys Trp Glu Asn Lys Asp Ser Leu Ile Lys Ser
 725 730 735
 Lys Glu Glu Leu Arg His Leu Arg Leu Pro Thr Tyr Gln Glu Leu Glu
 740 745 750
 Gln Glu Ile Asn Thr Leu Lys Ala Asp Asn Asp Ala Leu Lys Ile Gln
 755 760 765
 Leu Lys Tyr Ala Gln Lys Lys Ile Glu Ser Leu Gln Leu Glu Lys Ser
 770 775 780
 Asn His Val Leu Ala Gln Met Glu Gln Gly Asp Cys Ser
 785 790 795

- 21 -

<210> 9
 <211> 3373
 <212> DNA
 <213> Rattus norvegicus

 <220>
 <221> CDS
 <222> (197) .. (2848)
 <223> cAMP-GEFI

 <400> 9
 cgctaagcct ggggtggtgg taggaaggtc cagctcctcc ggccgatggc tgtccacttt 60
 cctcccccca tcacagggtca gctggccagg tgagaaccac tggcagggtgg gccagctgt 120
 ggtggagagt ccagctgtgg gggcaccgca ggtgcgaggt ctcccgagc tggttcgga 180
 gggcacgctg ctcaat atg gtg ctg aag aga atg cac cgt ccc cgg tgc tgc 232
 Met Val Leu Lys Arg Met His Arg Pro Arg Cys Cys
 1 5 10

 tct tac cag cta gtg ttc gag cac cgg cgc cca agc tgc atc cag gga 280
 Ser Tyr Gln Leu Val Phe Glu His Arg Arg Pro Ser Cys Ile Gln Gly
 15 20 25

 ctt cgc tgg acg cca ctt acc aac agt gag ggc tcc ctg gac ttc aga 328
 Leu Arg Trp Thr Pro Leu Thr Asn Ser Glu Gly Ser Leu Asp Phe Arg
 30 35 40

 gtg agc ctg gag cag gcc acc aca gag cat gtg cac aag gcc ggg aag 376
 Val Ser Leu Glu Gln Ala Thr Thr Glu His Val His Lys Ala Gly Lys
 45 50 55 60

 ctc ctg tac cgt cat ctc ttg gca acg tac cct acc ctc atc cga gac 424
 Leu Leu Tyr Arg His Leu Leu Ala Thr Tyr Pro Thr Leu Ile Arg Asp
 65 70 75

 aga aaa tac cat ctg cga cta cat cgg cag tgc tgc tct ggc cgg gag 472
 Arg Lys Tyr His Leu Arg Leu His Arg Gln Cys Cys Ser Gly Arg Glu
 80 85 90

 cta gtg gat ggg atc ttg gct ctg ggt ctt ggg gtc cac tca cgg agc 520
 Leu Val Asp Gly Ile Leu Ala Leu Gly Leu Gly Val His Ser Arg Ser
 95 100 105

 caa gct gtg ggc atc tgc cag gtg ttg ctg gat gag ggt gcc ctt tgc 568
 Gln Ala Val Gly Ile Cys Gln Val Leu Leu Asp Glu Gly Ala Leu Cys
 110 115 120

 cat gta aaa cat gac tgg acc ttc cag gac cga gac gcc caa ttc tac 616
 His Val Lys His Asp Trp Thr Phe Gln Asp Arg Asp Ala Gln Phe Tyr
 125 130 135 140

 aga ttc cct gga ccg gag ccc cag cct gca gga act cat gac gtg gaa 664
 Arg Phe Pro Gly Pro Glu Pro Gln Pro Ala Gly Thr His Asp Val Glu
 145 150 155

 gag gag ctt gtt gag gca atg gcc cta ctc tcc cag cga ggg cct gat 712
 Glu Glu Leu Val Glu Ala Met Ala Leu Leu Ser Gln Arg Gly Pro Asp
 160 165 170

 gcc cta ctc act gtt gca ctc cgg aag tcc ccg ggt cag cgt aca gat 760
 Ala Leu Leu Thr Val Ala Leu Arg Lys Ser Pro Gly Gln Arg Thr Asp
 175 180 185

 gaa gag ctg gac ctc atc ttc gag gag ctc gta cat atc aag gcg gtg 808
 Glu Glu Leu Asp Leu Ile Phe Glu Glu Leu Val His Ile Lys Ala Val
 190 195 200

 gct cac ctt tct aac tcg gtg aaa cgg gaa cta gct gct gtt ctg ctc 856
 Ala His Leu Ser Asn Ser Val Lys Arg Glu Leu Ala Ala Val Leu Leu
 205 210 215 220

- 22 -

ttt gaa cca cac agc aag gca gga act gtg ttg ttc agc cag ggg gac Phe Glu Pro His Ser 225 Val Leu Phe Ser Gln Gly Asp 235	904
aag ggt acc tca tgg tac att atc tgg aag gga tct gtc aat gtg gtg Lys Gly Thr Ser Trp Tyr Ile Ile Trp 245 Lys Gly Ser Val Asn Val Val 250	952
acc cgt ggc aag ggg ctg gtg acc acg ttg cac gag gga gat gac ttt Thr Arg Gly Lys Gly Leu Val Thr Thr Leu His Glu Gly Asp Asp Phe 255 260 265	1000
gga cag ctg gct ctg gtg aac gac gca cct cga gca gcc acc atc atc Gly Gln Leu Ala Leu Val Asn Asp Ala Pro Arg Ala Ala Thr Ile Ile 270 275 280	1048
ctt cga gaa aat aac tgt cac ttt ctg cgt gtg gac aag cag gac ttc Leu Arg Glu Asn Asn Cys 290 His Phe Leu Arg Val Asp 295 Lys Gln Asp Phe 300	1096
aac cgc atc atc aag gat gtg gaa gca aaa acc atg aga ctg gaa gaa Asn Arg Ile Ile Lys Asp Val Glu Ala Lys Thr Met Arg Leu Glu Glu 305 310 315	1144
cac ggc aaa gtg gtg tta gtt ttg gag aga acc tct cag ggt gct ggc His Gly Lys Val Val Leu Val Leu Glu Arg Thr Ser Gln Gly Ala Gly 320 325 330	1192
cct tcc cgc cct ccg acc cca ggc agg aac cga tat acg gta atg tct Pro Ser Arg Pro Pro Thr Pro Gly Arg Asn Arg Tyr Thr Val Met Ser 335 340 345	1240
ggc acc cca gag aaa atc cta gaa ctc ctg ttg gag gct atg aga ccg Gly Thr Pro Glu Lys Ile Leu Glu Leu Leu Leu Glu Ala Met Arg Pro 350 355 360	1288
gat tcc agt gct cat gac cca aca gag aca ttc ctc agt gac ttc ctg Asp Ser Ser Ala His Asp Pro Thr Glu Thr Phe Leu Ser Asp Phe Leu 365 370 375 380	1336
ctg acg cac agt gtc ttc atg ccc tgc aca cag ctc ttt gcc gcc ctc Leu Thr His Ser Val Phe Met Pro Cys Thr Gln Leu Phe Ala Ala Leu 385 390 395	1384
ctg cac cac ttc cac gtg gag cca tca gag cct gcc ggg ggc agc gag Leu His His Phe His Val Glu Pro Ser Glu Pro Ala Gly Gly Ser Glu 400 405 410	1432
cag gaa cgc agc acc tac atc tgc aac aag agg cag cag att ctg cgt Gln Glu Arg Ser Thr Tyr Ile Cys Asn Lys Arg Gln Gln Ile Leu Arg 415 420 425	1480
ctg gtc agc cgg tgg gtg gcc ctc tac agc ccc atg ctc cgc tca gat Leu Val Ser Arg Trp Val Ala Leu Tyr Ser Pro Met Leu Arg Ser Asp 430 435 440	1528
ccc gtg gcc acc agc ttc ctc cag aaa ctc tca gac ctg gtg agc aga Pro Val Ala Thr Ser Phe Leu Gln Lys Leu Ser Asp Leu Val Ser Arg 445 450 455 460	1576
gat acc cga ctt agc aac ttg ctg agg gaa cag tat ccg gag aga ccg Asp Thr Arg Leu Ser Asn Leu Leu Arg Glu Gln Tyr Pro Glu Arg Arg 465 470 475	1624
cga cac cac agg ttg gag aat ggc tgt ggg aat gta tct cct cag acc Arg His His Arg Leu Glu Asn Gly Cys Gly Asn Val Ser Pro Gln Thr 480 485 490	1672
aag gcc cgg aat gca cct gtt tgg ttt cct aac cat gag gaa ccc ctc Lys Ala Arg Asn Ala Pro Val Trp Phe Pro Asn His Glu Glu Pro Leu 495 500 505	1720
cca agc agc gct ggg gcc atc cga gtc ggg gac aaa gtc ccc tat gat Pro Ser Ser Ala Gly Ala Ile Arg Val Gly Asp Lys Val Pro Tyr Asp 510 515 520	1768

- 23 -

atc Ile 525	tgc Cys	aga Arg	ccc Pro	gac Asp	cac His 530	tcg Ser	gtg Val	ctg Leu	acc Thr	ctg Leu 535	cac His	ctg Leu	ccg Pro	gtg Val	aca Thr 540	1816
gcc Ala	tcc Ser	gtg Val	agg Arg	gaa Glu 545	gtg Val	atg Met	gca Ala	gct Ala	ttg Leu 550	gcc Ala	cat His	gag Glu	gac Asp	cac His 555	tgg Trp	1864
acc Thr	aag Lys	ggg Gly	cag Gln 560	gtg Val	ctg Leu	gta Val	aag Lys	gtc Val 565	aat Asn	tct Ser	gcc Ala	ggt Gly	gat Asp 570	gtc Val	gtt Val	1912
ggc Gly	ttg Leu	cag Gln 575	cca Pro	gat Asp	gcc Ala	cgc Arg	ggt Gly 580	gtg Val	gcc Ala	aca Thr	tcc Ser	ctg Leu 585	ggg Gly	ctc Leu	aat Asn	1960
gag Glu	cgg Arg 590	atc Ile	ttt Phe	gtt Val	gtc Val	gac Asp 595	cca Pro	cag Gln	gaa Glu	gtg Val	cac His 600	gag Glu	ctg Leu	acc Thr	cca Pro	2008
cac His 605	cct Pro	gag Glu	cag Gln	ctg Leu	ggg Gly 610	ccc Pro	act Thr	ctg Leu	ggt Gly	tct Ser 615	tct Ser	gag Glu	atg Met	ctg Leu	gac Asp 620	2056
cta Leu	gtg Val	agt Ser	gcc Ala	aag Lys 625	gac Asp	ctg Leu	gca Ala	ggc Gly	cag Gln 630	ctc Leu	aca Thr	gag Glu	cat His	gac Asp 635	tgg Trp	2104
aac Asn	ctc Leu	ttc Phe	aac Asn 640	agg Arg	atc Ile	cac His	cag Gln	gtg Val 645	gag Glu	ctg Leu	atc Ile	cac His	tat Tyr 650	gta Val	ctg Leu	2152
ggc Gly	ccc Pro	cag Gln 655	cac His	ctg Leu	cgg Arg	gac Asp	gtc Val 660	acc Thr	act Thr	gca Ala	aac Asn	ctg Leu 665	gag Glu	cgc Arg	ttc Phe	2200
atg Met 670	cga Arg	cgc Arg	ttc Phe	aac Asn	gag Glu 675	ctg Leu	cag Gln	tac Tyr	tgg Trp	gtg Val	gcc Ala 680	acc Thr	gaa Glu	ctc Leu	tgt Cys	2248
ctc Leu 685	tgc Cys	ccg Pro	gtt Val	cct Pro	ggc Gly 690	ccc Pro	cgg Arg	gct Ala	cag Gln 695	cta Leu 695	ctc Leu	cgg Arg	aag Lys	ttc Phe 700	atc Ile	2296
aag Lys	ctg Leu	gca Ala	gcc Ala	cac His 705	ctc Leu	aag Lys	gag Glu	cag Gln	aag Lys 710	aat Asn	ctc Leu	aac Asn	tct Ser	ttc Phe 715	ttt Phe	2344
gcg Ala	gtc Val	atg Met	ttt Phe 720	ggc Gly	ctc Leu	agc Ser	aac Asn	tcg Ser 725	gcc Ala	atc Ile	agc Ser	cgc Arg	ctg Leu 730	gcc Ala	cac His	2392
acc Thr	tgg Trp	gag Glu 735	cgt Arg	ctg Leu	ccc Pro	cat His	aaa Lys 740	gta Val	cgg Arg	aag Lys	ctg Leu	tac Tyr 745	tcg Ser	gcc Ala	ctg Leu	2440
gaa Glu 750	agg Arg	ttg Leu	ctg Leu	gac Asp	cct Pro	tcc Ser 755	tgg Trp	aac Asn	cac His	cga Arg	gtg Val 760	tac Tyr	cga Arg	ttg Leu	gct Ala	2488
ctc Leu 765	acc Thr	aag Lys	ctc Leu	tct Ser	cct Pro 770	cct Pro	gtc Val	atc Ile	cct Pro	ttc Phe 775	atg Met	ccc Pro	ctg Leu	cta Leu	ctc Leu 780	2536
aaa Lys	gac Asp	atg Met	acc Thr	ttc Phe 785	att Ile	cat His	gaa Glu	ggg Gly	aac Asn 790	cac His	aca Thr	ctg Leu	gta Val	gaa Glu 795	aac Asn	2584
ctc Leu	atc Ile	aac Asn	ttt Phe 800	gag Glu	aag Lys	atg Met	cga Arg	atg Met 805	atg Met	gcc Ala	aga Arg	gcc Ala	gtg Val 810	cgg Arg	atg Met	2632
ctc Leu	cac His	cac His	tgc Cys	cga Arg	agc Ser	cac His	agc Ser	acc Thr	gcg Ala	cct Pro	cta Leu	tca Ser	cca Pro	ctc Leu	aga Arg	2680

- 24 -

815	820	825	
agc cgg gtt tcc cac atc cac gag gac agc cag gca tca aga atc tcc			2728
Ser Arg Val Ser His Ile His Glu Asp Ser Gln Ala Ser Arg Ile Ser			
830	835	840	
aca tgt tcc gag cag tcc ctg agc acc cgg agt cca gcc agc acc tgg			2776
Thr Cys Ser Glu Gln Ser Leu Ser Thr Arg Ser Pro Ala Ser Thr Trp			
845	850	855	860
gct tat gtc cag cag ctg aag gtc att gac aac cag cgg gaa ctg tcc			2824
Ala Tyr Val Gln Gln Leu Lys Val Ile Asp Asn Gln Arg Glu Leu Ser			
865	870	875	
cgc ctc tcc cgg gaa ctg gaa cca tgaggaagga ctggctggag caggcacttc			2878
Arg Leu Ser Arg Glu Leu Glu Pro			
880			
tctcagagaa agccagagcc tgtgcaacca agagggtccag aggccagcca cagctgggca			2938
gggctctcca cagagcggac tcaaggccct ggagtgggca gtgtcgaggc agctgtcctc			2998
tgtgatgact gtcagctgtg aagatctttg atgttcacgg ccaaggaaaa ggggccattg			3058
aggccccaga ggggtaggag agctgggagg tgcaggactc tggttcagta gagagccctc			3118
ccaccgggct ttctgcatgt ctgtatgtct gtacatgcag ctgtgtgtcc tggatgccag			3178
gccctgtgct tgtattcaca ggagccagcg agctcacatc tgcattggtgt gtgtgtgtgt			3238
gtgtgtgtgt gtgtgtgtgt gtgtgtgtga gcaactgggtg gtgccttgcc tgggagaggg			3298
tggggagttc tgctattctc accacacatc tgagataaac agctgggtgt gggcaaaaaa			3358
aaaaaaaaa aaaaa			3373

<210> 10
 <211> 884
 <212> PRT
 <213> Rattus norvegicus

<400> 10
 Met Val Leu Lys Arg Met His Arg Pro Arg Cys Cys Ser Tyr Gln Leu
 1 5 10 15
 Val Phe Glu His Arg Arg Pro Ser Cys Ile Gln Gly Leu Arg Trp Thr
 20 25 30
 Pro Leu Thr Asn Ser Glu Gly Ser Leu Asp Phe Arg Val Ser Leu Glu
 35 40 45
 Gln Ala Thr Thr Glu His Val His Lys Ala Gly Lys Leu Leu Tyr Arg
 50 55 60
 His Leu Leu Ala Thr Tyr Pro Thr Leu Ile Arg Asp Arg Lys Tyr His
 65 70 75 80
 Leu Arg Leu His Arg Gln Cys Cys Ser Gly Arg Glu Leu Val Asp Gly
 85 90 95
 Ile Leu Ala Leu Gly Leu Gly Val His Ser Arg Ser Gln Ala Val Gly
 100 105 110
 Ile Cys Gln Val Leu Leu Asp Glu Gly Ala Leu Cys His Val Lys His
 115 120 125
 Asp Trp Thr Phe Gln Asp Arg Asp Ala Gln Phe Tyr Arg Phe Pro Gly
 130 135 140
 Pro Glu Pro Gln Pro Ala Gly Thr His Asp Val Glu Glu Glu Leu Val
 145 150 155 160
 Glu Ala Met Ala Leu Leu Ser Gln Arg Gly Pro Asp Ala Leu Leu Thr
 165 170 175

- 25 -

Val Ala Leu Arg Lys Ser Pro Gly Gln Arg Thr Asp Glu Glu Leu Asp
 180 185 190
 Leu Ile Phe Glu Glu Leu Val His Ile Lys Ala Val Ala His Leu Ser
 195 200 205
 Asn Ser Val Lys Arg Glu Leu Ala Ala Val Leu Leu Phe Glu Pro His
 210 215 220
 Ser Lys Ala Gly Thr Val Leu Phe Ser Gln Gly Asp Lys Gly Thr Ser
 225 230 235 240
 Trp Tyr Ile Ile Trp Lys Gly Ser Val Asn Val Val Thr Arg Gly Lys
 245 250 255
 Gly Leu Val Thr Thr Leu His Glu Gly Asp Asp Phe Gly Gln Leu Ala
 260 265 270
 Leu Val Asn Asp Ala Pro Arg Ala Thr Ile Ile Leu Arg Glu Asn
 275 280 285
 Asn Cys His Phe Leu Arg Val Asp Lys Gln Asp Phe Asn Arg Ile Ile
 290 295 300
 Lys Asp Val Glu Ala Lys Thr Met Arg Leu Glu Glu His Gly Lys Val
 305 310 315 320
 Val Leu Val Leu Glu Arg Thr Ser Gln Gly Ala Gly Pro Ser Arg Pro
 325 330 335
 Pro Thr Pro Gly Arg Asn Arg Tyr Thr Val Met Ser Gly Thr Pro Glu
 340 345 350
 Lys Ile Leu Glu Leu Leu Leu Glu Ala Met Arg Pro Asp Ser Ser Ala
 355 360 365
 His Asp Pro Thr Glu Thr Phe Leu Ser Asp Phe Leu Leu Thr His Ser
 370 375 380
 Val Phe Met Pro Cys Thr Gln Leu Phe Ala Ala Leu Leu His His Phe
 385 390 395 400
 His Val Glu Pro Ser Glu Pro Ala Gly Gly Ser Glu Gln Glu Arg Ser
 405 410 415
 Thr Tyr Ile Cys Asn Lys Arg Gln Gln Ile Leu Arg Leu Val Ser Arg
 420 425 430
 Trp Val Ala Leu Tyr Ser Pro Met Leu Arg Ser Asp Pro Val Ala Thr
 435 440 445
 Ser Phe Leu Gln Lys Leu Ser Asp Leu Val Ser Arg Asp Thr Arg Leu
 450 455 460
 Ser Asn Leu Leu Arg Glu Gln Tyr Pro Glu Arg Arg Arg His His Arg
 465 470 475 480
 Leu Glu Asn Gly Cys Gly Asn Val Ser Pro Gln Thr Lys Ala Arg Asn
 485 490 495
 Ala Pro Val Trp Phe Pro Asn His Glu Glu Pro Leu Pro Ser Ser Ala
 500 505 510
 Gly Ala Ile Arg Val Gly Asp Lys Val Pro Tyr Asp Ile Cys Arg Pro
 515 520 525
 Asp His Ser Val Leu Thr Leu His Leu Pro Val Thr Ala Ser Val Arg
 530 535 540
 Glu Val Met Ala Ala Leu Ala His Glu Asp His Trp Thr Lys Gly Gln
 545 550 555 560
 Val Leu Val Lys Val Asn Ser Ala Gly Asp Val Val Gly Leu Gln Pro
 565 570 575

- 26 -

Asp Ala Arg Gly Val Ala Thr Ser Leu Gly Leu Asn Glu Arg Ile Phe
 580 585 590
 Val Val Asp Pro Gln Glu Val His Glu Leu Thr Pro His Pro Glu Gln
 595 600 605
 Leu Gly Pro Thr Leu Gly Ser Ser Glu Met Leu Asp Leu Val Ser Ala
 610 615 620
 Lys Asp Leu Ala Gly Gln Leu Thr Glu His Asp Trp Asn Leu Phe Asn
 625 630 635 640
 Arg Ile His Gln Val Glu Leu Ile His Tyr Val Leu Gly Pro Gln His
 645 650 655
 Leu Arg Asp Val Thr Thr Ala Asn Leu Glu Arg Phe Met Arg Arg Phe
 660 665 670
 Asn Glu Leu Gln Tyr Trp Val Ala Thr Glu Leu Cys Leu Cys Pro Val
 675 680 685
 Pro Gly Pro Arg Ala Gln Leu Leu Arg Lys Phe Ile Lys Leu Ala Ala
 690 695 700
 His Leu Lys Glu Gln Lys Asn Leu Asn Ser Phe Phe Ala Val Met Phe
 705 710 715 720
 Gly Leu Ser Asn Ser Ala Ile Ser Arg Leu Ala His Thr Trp Glu Arg
 725 730 735
 Leu Pro His Lys Val Arg Lys Leu Tyr Ser Ala Leu Glu Arg Leu Leu
 740 745 750
 Asp Pro Ser Trp Asn His Arg Val Tyr Arg Leu Ala Leu Thr Lys Leu
 755 760 765
 Ser Pro Pro Val Ile Pro Phe Met Pro Leu Leu Leu Lys Asp Met Thr
 770 775 780
 Phe Ile His Glu Gly Asn His Thr Leu Val Glu Asn Leu Ile Asn Phe
 785 790 795 800
 Glu Lys Met Arg Met Met Ala Arg Ala Val Arg Met Leu His His Cys
 805 810 815
 Arg Ser His Ser Thr Ala Pro Leu Ser Pro Leu Arg Ser Arg Val Ser
 820 825 830
 His Ile His Glu Asp Ser Gln Ala Ser Arg Ile Ser Thr Cys Ser Glu
 835 840 845
 Gln Ser Leu Ser Thr Arg Ser Pro Ala Ser Thr Trp Ala Tyr Val Gln
 850 855 860
 Gln Leu Lys Val Ile Asp Asn Gln Arg Glu Leu Ser Arg Leu Ser Arg
 865 870 875 880
 Glu Leu Glu Pro

<210> 11
 <211> 3394
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (216)..(2858)
 <223> cAMP-GEFI

<400> 11
 ggatcccctt atcaaagctg atgggggtcg ctggggaccc cccagccttt tgctagagcc 60

tgcacggctg	tgggagcttg	aaaagaaaca	tgaaggtggg	ctggccaggt	gagagctgct	120										
ggcaggtggg	cctggctgtg	gaggatagcc	cagctctggg	agcaccgcgg	gtgggagccc	180										
tccctgacgt	ggtgccggag	gggacactac	tcaac	atg Met 1	gtg Val Leu Arg agg Arg atg Met 5	233										
cac His	cgg Arg	ccc Pro	cga Arg 10	agc Ser	tgc Cys	tcc Ser	tac Tyr	cag Gln 15	ctg Leu	ctg Leu	ctg Leu	gag Glu	cac His 20	cag Gln	cat His	281
cgg Pro	agc Ser	tgc Cys 25	atc Ile	cag Gln	ggg Gly	ctg Leu	cgc Arg 30	tgg Trp	aca Thr	cca Pro	ctc Leu	acc Thr 35	aac Asn	agc Ser	gag Glu	329
gag Glu	tcc Ser 40	ctg Leu	gat Asp	ttc Phe	agc Ser	gag Glu 45	agc Ser	ctg Leu	gag Glu	cag Gln	gcc Ala 50	tcc Ser	aca Thr	gag Glu	cgg Arg	377
gtg Val 55	ctc Leu	agg Arg	gct Ala	ggg Gly	agg Arg 60	cag Gln	ctg Leu	cat His	cag Gln	cat His 65	cta Leu	ctg Leu	gcc Ala	acc Thr	tgc Cys 70	425
cca Pro	aac Asn	ctc Leu	atc Ile	cga Arg 75	gac Asp	cgg Arg	aag Lys	tac Tyr	cac His 80	ctt Leu	agg Arg	ctc Leu	tat Tyr	cgg Arg 85	cag Gln	473
tgc Cys	tgc Cys	tct Ser	ggc Gly 90	cgg Arg	gag Glu	ctg Leu	gtg Val	gat Asp 95	ggg Gly	atc Ile	ttg Leu	gcc Ala 100	ctg Leu	gga Gly	ctt Leu	521
ggg Gly	gtc Val	cat His 105	tcc Ser	cgg Arg	agc Ser	caa Gln	gtt Val 110	gtg Val	gga Gly	atc Ile	tgc Cys	cag Gln 115	gtg Val	ctg Leu	ctg Leu	569
gat Asp	gaa Glu 120	ggt Gly	gcc Ala	ctc Leu	tgc Cys	cat His 125	gtg Val	aaa Lys	cac His	gac Asp	tgg Trp 130	gcc Ala	ttc Phe	cag Gln	gac Asp	617
cga Arg 135	gat Asp	gcc Ala	caa Gln	ttc Phe	tac Tyr 140	cgg Arg	ttc Phe	ccc Pro	ggg Gly	ccc Pro 145	gag Glu	ccc Pro	gag Glu	ccc Pro	gtg Val 150	665
gga Gly	act Thr	cat His	gag Glu	atg Met 155	gag Glu	gag Glu	gag Glu	ttg Leu	gcc Ala 160	gaa Glu	gct Ala	gtg Val	gcc Ala	ctg Leu 165	ctc Leu	713
tcc Ser	cag Gln	cgg Arg	ggg Gly 170	cct Pro	gac Asp	gcc Ala	ctg Leu	ctc Leu 175	act Thr	gtg Val	gca Ala	ctt Leu	cga Arg 180	aag Lys	ccc Pro	761
cca Pro	ggt Gly	cag Gln	cgc Arg	acg Thr	gat Asp	gaa Glu	gag Glu 190	ctg Leu	gac Asp	ctc Leu	atc Ile	ttt Phe 195	gag Glu	gag Glu	ctg Leu	809
ctg Leu	cac His 200	atc Ile	aag Lys	gct Ala	gtg Val	gcc Ala 205	cac His	ctc Leu	tcc Ser	aac Asn	tcg Ser 210	gtg Val	aag Lys	cga Arg	gaa Glu	857
tta Leu 215	gcg Ala	gct Ala	gtt Val	ctg Leu	ctc Leu 220	ttt Phe	gaa Glu	cca Pro	cac His	agc Ser 225	aag Lys	gca Ala	ggg Gly	acc Thr	gtg Val 230	905
ttg Leu	ttc Phe	agc Ser	cag Gln	ggg Gly 235	gac Asp	aag Lys	ggc Gly	act Thr	tcg Ser 240	tgg Trp	tac Tyr	att Ile	atc Ile	tgg Trp 245	aag Lys	953
gga Gly	tct Ser	gtc Val	aac Asn 250	gtg Val	gtg Val	acc Thr	cat His	ggc Gly 255	aag Lys	ggg Gly	ctg Leu	gtg Val	acc Thr 260	acc Thr	ctg Leu	1001
cat His	gag Glu	gga Gly 265	gat Asp	gat Asp	ttt Phe	gga Gly	cag Gln 270	ctg Leu	gct Ala	ctg Leu	gtg Val	aat Asn 275	gat Asp	gca Ala	ccc Pro	1049

- 28 -

cgg gca gcc acc atc atc ctg cga gaa tac aac tgt cat ttc ctg cgt	1097
Arg Ala Ala Thr Ile Ile Leu Arg Glu Tyr Asn Cys His Phe Leu Arg	
280 285 290	
gtg gac aag cag gac ttc aac cgt atc atc aag gat gtg gag gca aag	1145
Val Asp Lys Gln Asp Phe Asn Arg Ile Ile Lys Asp Val Glu Ala Lys	
295 300 305 310	
acc atg cgg ctg gaa gaa cat ggc aaa gtg gtg ctg gtg ctg gag aga	1193
Thr Met Arg Leu Glu Glu His Gly Lys Val Val Leu Val Leu Glu Arg	
315 320 325	
gcc tct cag ggc gcc ggc cct tcc cga ccc cca acc cca ggc agg aac	1241
Ala Ser Gln Gly Ala Gly Pro Ser Arg Pro Pro Thr Pro Gly Arg Asn	
330 335 340	
cgg tat aca gtg atg tct ggc act cca gat aag atc cta gag ctt ctg	1289
Arg Tyr Thr Val Met Ser Gly Thr Pro Asp Lys Ile Leu Glu Leu Leu	
345 350 355	
ttg gag gcc atg gga cta gat tcc agt gct cat gac cca aaa gaa aca	1337
Leu Glu Ala Met Gly Leu Asp Ser Ser Ala His Asp Pro Lys Glu Thr	
360 365 370	
ttc ctc agc gac ttc ctc ctg acc cac agg gtc ttc atg ccc agc gcc	1385
Phe Leu Ser Asp Phe Leu Leu Thr His Arg Val Phe Met Pro Ser Ala	
375 380 385 390	
caa ctc tgc gct gcc ctt ctg cac cac ttc cat gtg gag cct gcg ggt	1433
Gln Leu Cys Ala Ala Leu Leu His His Phe His Val Glu Pro Ala Gly	
395 400 405	
ggc agc gag cag gag cgc agc acc tac gtc tgc aac aag agg cag cag	1481
Gly Ser Glu Gln Glu Arg Ser Thr Tyr Val Cys Asn Lys Arg Gln Gln	
410 415 420	
atc ttg cgg ctg gtc agc cag tgg gtg gcc ctg tat ggc tcc atg ctc	1529
Ile Leu Arg Leu Val Ser Gln Trp Val Ala Leu Tyr Gly Ser Met Leu	
425 430 435	
cac act gac cct gtg gcc acc agc ttc ctc cac aaa ctc tca gac ctg	1577
His Thr Asp Pro Val Ala Thr Ser Phe Leu His Lys Leu Ser Asp Leu	
440 445 450	
gtg ggc agg gac acc cga ctc agc aac ctg ctg agg gag cag tgg cca	1625
Val Gly Arg Asp Thr Arg Leu Ser Asn Leu Leu Arg Glu Gln Trp Pro	
455 460 465 470	
gag agg cgg cga tgc cac agg ttg gag aat ggc tgt ggg aat gca tct	1673
Glu Arg Arg Arg Cys His Arg Leu Glu Asn Gly Cys Gly Asn Ala Ser	
475 480 485	
cct cag atg aag gcc cgg aac ttg cct gtt tgg ctc ccc aac cag gac	1721
Pro Gln Met Lys Ala Arg Asn Leu Pro Val Trp Leu Pro Asn Gln Asp	
490 495 500	
gag ccc ctt cct ggc agc agc tgt gcc atc caa gtt ggg gat aaa gtc	1769
Glu Pro Leu Pro Gly Ser Ser Cys Ala Ile Gln Val Gly Asp Lys Val	
505 510 515	
ccc tat gac atc tgc cgg cca gac cac tca gtg ttg acc ctg cag ctg	1817
Pro Tyr Asp Ile Cys Arg Pro Asp His Ser Val Leu Thr Leu Gln Leu	
520 525 530	
cct gtg aca gcc tcc gtg aga gag gtg atg gca gcg ttg gcc cag gag	1865
Pro Val Thr Ala Ser Val Arg Glu Val Met Ala Ala Leu Ala Gln Glu	
535 540 545 550	
gat ggc tgg acc aag ggg cag gtg ctg gtg aag gtc aat tct gca ggt	1913
Asp Gly Trp Thr Lys Gly Gln Val Leu Val Lys Val Asn Ser Ala Gly	
555 560 565	
gat gcc att ggc ctg cag cca gat gcc cgt ggt gtg gcc aca tct ctg	1961
Asp Ala Ile Gly Leu Gln Pro Asp Ala Arg Gly Val Ala Thr Ser Leu	

- 29 -

570						575						580						
ggg Gly	ctc Leu	aat Asn 585	gag Glu	cgt Arg	ctc Leu	ttt Phe	gtt Val 590	gtc Val	aac Asn	cca Pro	cag Gln	gaa Glu 595	gtg Val	cat His	gag Glu	2009		
ctg Leu	atc Ile 600	cca Pro	cac His	cct Pro	gac Asp	cag Gln 605	ctg Leu	ggg Gly	ccc Pro	act Thr	gtg Val 610	ggc Gly	tct Ser	gct Ala	gag Glu	2057		
ggg Gly 615	ctg Leu	gac Asp	ctg Leu	gtg Val	agt Ser 620	gcc Ala	aag Lys	gac Asp	ctg Leu	gca Ala 625	ggc Gly	cag Gln	ctg Leu	acg Thr	gac Asp 630	2105		
cac His	gac Asp	tgg Trp	agc Ser	ctc Leu 635	ttc Phe	aac Asn	agt Ser	atc Ile	cac His 640	cag Gln	gtg Val	gag Glu	ctg Leu	atc Ile 645	cac His	2153		
tat Tyr	gtg Val	ctg Leu	ggc Gly 650	ccc Pro	cag Gln	cat His	ctg Leu	cgg Arg 655	gat Asp	gtc Val	acc Thr	acc Thr	gcc Ala 660	aac Asn	ctg Leu	2201		
gag Glu	cgc Arg	ttc Phe 665	atg Met	cgc Arg	cgc Arg	ttc Phe	aat Asn 670	gag Glu	ctg Leu	cag Gln	tac Tyr	tgg Trp 675	gtg Val	gcc Ala	acc Thr	2249		
gag Glu	ctg Leu 680	tgt Cys	ctc Leu	tgc Cys	ccc Pro	gtg Val 685	ccc Pro	ggc Gly	ccc Pro	cgg Arg	gcc Ala 690	cag Gln	ctg Leu	ctc Leu	aaa Lys	2297		
aag Lys 695	ttc Phe	att Ile	aag Lys	ctg Leu	gcg Ala 700	gcc Ala	cac His	ctc Leu	aag Lys	gag Glu 705	cag Gln	aag Lys	aat Asn	gtc Val	aat Asn 710	2345		
tcc Ser	ttc Phe	ttt Phe	gcc Ala	gtc Val 715	atg Met	ttt Phe	ggc Gly	ctc Leu	agc Ser 720	aac Asn	tcg Ser	ccc Pro	atc Ile	agc Ser 725	cgc Arg	2393		
cta Leu	gcc Ala	cac His	acc Thr 730	tgg Trp	gag Glu	cgg Arg	ctg Leu	cct Pro 735	cac His	aaa Lys	gtc Val	cgg Arg	aag Lys 740	ctg Leu	tac Tyr	2441		
tcc Ser	gcc Ala	ctc Leu 745	gag Glu	agg Arg	ctg Leu	ctg Leu	gat Asp 750	ccc Pro	tca Ser	tgg Trp	aac Asn	cac His 755	cgg Arg	gta Val	tac Tyr	2489		
cga Arg	ctg Leu 760	gcc Ala	ctc Leu	gcc Ala	aag Lys	ctc Leu 765	tcc Ser	cct Pro	cct Pro	gtc Val	atc Ile 770	ccc Pro	ttc Phe	atg Met	ccc Pro	2537		
ctt Leu 775	ctt Leu	ctc Leu	aaa Lys	gac Asp	atg Met 780	acc Thr	ttc Phe	att Ile	cat His	gag Glu 785	gga Gly	aac Asn	cac His	aca Thr	cta Leu 790	2585		
gtg Val	gag Glu	aat Asn	ctc Leu	atc Ile 795	aac Asn	ttt Phe	gag Glu	aag Lys	atg Met 800	aga Arg	atg Met	atg Met	gcc Ala 805	aga Arg	gcc Ala	2633		
gcg Ala	cgg Arg	atg Met	ctg Leu 810	cac His	cac His	tgc Cys	cga Arg	agc Ser 815	cac His	aac Asn	cct Pro	gtg Val	cct Pro 820	ctc Leu	tca Ser	2681		
cca Pro	ctc Leu	aga Arg 825	agc Ser	cga Arg	gtt Val	tcc Ser	cac His 830	ctc Leu	cac His	gag Glu	gac Asp	agc Ser 835	cag Gln	gtg Val	gcg Ala	2729		
agg Arg	att Ile 840	tcc Ser	aca Thr	tgc Cys	tcg Ser	gag Glu 845	cag Gln	tcc Ser	ctg Leu	agc Ser	acc Thr 850	cgg Arg	agt Ser	cca Pro	gcc Ala	2777		
agc Ser 855	acc Thr	tgg Trp	gct Ala	tat Tyr	gtc Val 860	cag Gln	cag Gln	ctg Leu	aag Lys	gtc Val 865	att Ile	gac Asp	aac Asn	cag Gln	cgg Arg 870	2825		
gaa	ctc	tcc	cgc	ctg	tcc	cga	gag	ctg	gag	cca	tgaggagg	ggggg	ctggggactgg			2878		

- 30 -

Glu Leu Ser Arg Leu Ser Arg Glu Leu Glu Pro
875 880

agctggagca ggcacttgca gccgggaaag ccagggtgtg ccgggccaag atactcacag 2938
gctggccaca gctgggcaag gctctccgtg gactggactc gactccctgg agcaggcagt 2998
gtggaggcag ccatccccctg tgatgactgg cagctaagga ggacctcgga gtggaccaa 3058
gccaggaata acgaatgacc aaggggccaag gaaggaggga cagagaggcc ccaggagtgg 3118
gtggagagtg gactgcgctg ggacgttgtg tgcaatagag aggtctccac accagatgtc 3178
ttccagattc tgtgcctctg gctttgttgt ccagccaggc ctgcagtta ttttcacagt 3238
ggacagagag agagagagag gctgcatgtg tgtaccgtgt gtggcaaggg cagggccttg 3298
gcctggggca ggggcccttg ctttctttcc acagctttct tccaacagca ggcagtgggg 3358
ctgcgggcct gaaaaaaaaa aaaaaaaaaa aaaaaa 3394

<210> 12
<211> 881
<212> PRT
<213> Homo sapiens

<400> 12
Met Val Leu Arg Arg Met His Arg Pro Arg Ser Cys Ser Tyr Gln Leu
1 5 10 15
Leu Leu Glu His Gln His Pro Ser Cys Ile Gln Gly Leu Arg Trp Thr
20 25 30
Pro Leu Thr Asn Ser Glu Glu Ser Leu Asp Phe Ser Glu Ser Leu Glu
35 40 45
Gln Ala Ser Thr Glu Arg Val Leu Arg Ala Gly Arg Gln Leu His Gln
50 55 60
His Leu Leu Ala Thr Cys Pro Asn Leu Ile Arg Asp Arg Lys Tyr His
65 70 75 80
Leu Arg Leu Tyr Arg Gln Cys Cys Ser Gly Arg Glu Leu Val Asp Gly
85 90 95
Ile Leu Ala Leu Gly Leu Gly Val His Ser Arg Ser Gln Val Val Gly
100 105 110
Ile Cys Gln Val Leu Leu Asp Glu Gly Ala Leu Cys His Val Lys His
115 120 125
Asp Trp Ala Phe Gln Asp Arg Asp Ala Gln Phe Tyr Arg Phe Pro Gly
130 135 140
Pro Glu Pro Glu Pro Val Gly Thr His Glu Met Glu Glu Glu Leu Ala
145 150 155 160
Glu Ala Val Ala Leu Leu Ser Gln Arg Gly Pro Asp Ala Leu Leu Thr
165 170 175
Val Ala Leu Arg Lys Pro Pro Gly Gln Arg Thr Asp Glu Glu Leu Asp
180 185 190
Leu Ile Phe Glu Glu Leu Leu His Ile Lys Ala Val Ala His Leu Ser
195 200 205
Asn Ser Val Lys Arg Glu Leu Ala Ala Val Leu Leu Phe Glu Pro His
210 215 220
Ser Lys Ala Gly Thr Val Leu Phe Ser Gln Gly Asp Lys Gly Thr Ser
225 230 235 240
Trp Tyr Ile Ile Trp Lys Gly Ser Val Asn Val Val Thr His Gly Lys
245 250 255

Gly	Leu	Val	Thr	Thr	Leu	His	Glu	Gly	Asp	Asp	Phe	Gly	Gln	Leu	Ala
			260					265					270		
Leu	Val	Asn	Asp	Ala	Pro	Arg	Ala	Ala	Thr	Ile	Ile	Leu	Arg	Glu	Tyr
		275					280					285			
Asn	Cys	His	Phe	Leu	Arg	Val	Asp	Lys	Gln	Asp	Phe	Asn	Arg	Ile	Ile
	290					295					300				
Lys	Asp	Val	Glu	Ala	Lys	Thr	Met	Arg	Leu	Glu	Glu	His	Gly	Lys	Val
305					310					315					320
Val	Leu	Val	Leu	Glu	Arg	Ala	Ser	Gln	Gly	Ala	Gly	Pro	Ser	Arg	Pro
				325					330					335	
Pro	Thr	Pro	Gly	Arg	Asn	Arg	Tyr	Thr	Val	Met	Ser	Gly	Thr	Pro	Asp
			340					345					350		
Lys	Ile	Leu	Glu	Leu	Leu	Leu	Glu	Ala	Met	Gly	Leu	Asp	Ser	Ser	Ala
		355					360					365			
His	Asp	Pro	Lys	Glu	Thr	Phe	Leu	Ser	Asp	Phe	Leu	Leu	Thr	His	Arg
	370					375					380				
Val	Phe	Met	Pro	Ser	Ala	Gln	Leu	Cys	Ala	Ala	Leu	Leu	His	His	Phe
385					390					395					400
His	Val	Glu	Pro	Ala	Gly	Gly	Ser	Glu	Gln	Glu	Arg	Ser	Thr	Tyr	Val
				405					410					415	
Cys	Asn	Lys	Arg	Gln	Gln	Ile	Leu	Arg	Leu	Val	Ser	Gln	Trp	Val	Ala
			420					425					430		
Leu	Tyr	Gly	Ser	Met	Leu	His	Thr	Asp	Pro	Val	Ala	Thr	Ser	Phe	Leu
		435					440					445			
His	Lys	Leu	Ser	Asp	Leu	Val	Gly	Arg	Asp	Thr	Arg	Leu	Ser	Asn	Leu
	450					455					460				
Leu	Arg	Glu	Gln	Trp	Pro	Glu	Arg	Arg	Arg	Cys	His	Arg	Leu	Glu	Asn
465					470					475					480
Gly	Cys	Gly	Asn	Ala	Ser	Pro	Gln	Met	Lys	Ala	Arg	Asn	Leu	Pro	Val
				485					490					495	
Trp	Leu	Pro	Asn	Gln	Asp	Glu	Pro	Leu	Pro	Gly	Ser	Ser	Cys	Ala	Ile
			500					505					510		
Gln	Val	Gly	Asp	Lys	Val	Pro	Tyr	Asp	Ile	Cys	Arg	Pro	Asp	His	Ser
		515					520					525			
Val	Leu	Thr	Leu	Gln	Leu	Pro	Val	Thr	Ala	Ser	Val	Arg	Glu	Val	Met
						535					540				
Ala	Ala	Leu	Ala	Gln	Glu	Asp	Gly	Trp	Thr	Lys	Gly	Gln	Val	Leu	Val
545					550					555					560
Lys	Val	Asn	Ser	Ala	Gly	Asp	Ala	Ile	Gly	Leu	Gln	Pro	Asp	Ala	Arg
				565					570					575	
Gly	Val	Ala	Thr	Ser	Leu	Gly	Leu	Asn	Glu	Arg	Leu	Phe	Val	Val	Asn
			580					585					590		
Pro	Gln	Glu	Val	His	Glu	Leu	Ile	Pro	His	Pro	Asp	Gln	Leu	Gly	Pro
		595					600					605			
Thr	Val														

- 32 -

Val Thr Thr Ala Asn Leu Glu Arg Phe Met Arg Arg Phe Asn Glu Leu
660 665 670

Gln Tyr Trp Val Ala Thr Glu Leu Cys Leu Cys Pro Val Pro Gly Pro
675 680 685

Arg Ala Gln Leu Leu Lys Lys Phe Ile Lys Leu Ala Ala His Leu Lys
690 695 700

Glu Gln Lys Asn Val Asn Ser Phe Phe Ala Val Met Phe Gly Leu Ser
705 710 715 720

Asn Ser Pro Ile Ser Arg Leu Ala His Thr Trp Glu Arg Leu Pro His
725 730 735

Lys Val Arg Lys Leu Tyr Ser Ala Leu Glu Arg Leu Leu Asp Pro Ser
740 745 750

Trp Asn His Arg Val Tyr Arg Leu Ala Leu Ala Lys Leu Ser Pro Pro
755 760 765

Val Ile Pro Phe Met Pro Leu Leu Leu Lys Asp Met Thr Phe Ile His
770 775 780

Glu Gly Asn His Thr Leu Val Glu Asn Leu Ile Asn Phe Glu Lys Met
785 790 795 800

Arg Met Met Ala Arg Ala Ala Arg Met Leu His His Cys Arg Ser His
805 810 815

Asn Pro Val Pro Leu Ser Pro Leu Arg Ser Arg Val Ser His Leu His
820 825 830

Glu Asp Ser Gln Val Ala Arg Ile Ser Thr Cys Ser Glu Gln Ser Leu
835 840 845

Ser Thr Arg Ser Pro Ala Ser Thr Trp Ala Tyr Val Gln Gln Leu Lys
850 855 860

Val Ile Asp Asn Gln Arg Glu Leu Ser Arg Leu Ser Arg Glu Leu Glu
865 870 875 880

Pro

<210> 13
<211> 4109
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (216)..(1883)
<223> Alternate splicing of cAMP--GEFI

<400> 13
ggatccccctt atcaaagctg atgggggtcg ctggggaccc cccagccttt tgctagagcc 60
tgcacggctg tgggagcttg aaaagaaaca tgaaggtggg ctggccaggt gagagctgct 120
ggcaggtggg cctggctgtg gaggatagcc cagctctggg agcaccgcgg gtgggagccc 180
tccctgacgt ggtgccggag gggacactac tcaac atg gtg ttg aga agg atg 233
Met Val Leu Arg Arg Met
1 5
cac cgg ccc cga agc tgc tcc tac cag ctg ctg ctg gag cac cag cat 281
His Arg Pro Arg Ser Cys Ser Tyr Gln Leu Leu Leu Glu His Gln His
10 15 20
ccg agc tgc atc cag ggg ctg cgc tgg aca cca ctc acc aac agc gag 329
Pro Ser Cys Ile Gln Gly Leu Arg Trp Thr Pro Leu Thr Asn Ser Glu
25 30 35

- 33 -

gag	tcc	ctg	gat	ttc	agc	gag	agc	ctg	gag	cag	gcc	tcc	aca	gag	cgg	377
Glu	Ser	Leu	Asp	Phe	Ser	Glu	Ser	Leu	Glu	Gln	Ala	Ser	Thr	Glu	Arg	
	40					45					50					
gtg	ctc	agg	gct	ggg	agg	cag	ctg	cat	cag	cat	cta	ctg	gcc	acc	tgc	425
Val	Leu	Arg	Ala	Gly	Arg	Gln	Leu	His	Gln	His	Leu	Leu	Ala	Thr	Cys	
	55				60				65						70	
cca	aac	ctc	atc	cga	gac	cgg	aag	tac	cac	ctt	agg	ctc	tat	cgg	cag	473
Pro	Asn	Leu	Ile	Arg	Asp	Arg	Lys	Tyr	His	Leu	Arg	Leu	Tyr	Arg	Gln	
				75					80					85		
tgc	tgc	tct	ggc	cgg	gag	ctg	gtg	gat	ggg	atc	ttg	gcc	ctg	gga	ctt	521
Cys	Cys	Ser	Gly	Arg	Glu	Leu	Val	Asp	Gly	Ile	Leu	Ala	Leu	Gly	Leu	
			90					95				100				
ggg	gtc	cat	tcc	cgg	agc	caa	gtt	gtg	gga	atc	tgc	cag	gtg	ctg	ctg	569
Gly	Val	His	Ser	Arg	Ser	Gln	Val	Val	Gly	Ile	Cys	Gln	Val	Leu	Leu	
		105					110					115				
gat	gaa	ggt	gcc	ctc	tgc	cat	gtg	aaa	cac	gac	tgg	gcc	ttc	cag	gac	617
Asp	Glu	Gly	Ala	Leu	Cys	His	Val	Lys	His	Asp	Trp	Ala	Phe	Gln	Asp	
	120					125					130					
cga	gat	gcc	caa	ttc	tac	cgg	ttc	ccc	ggg	ccc	gag	ccc	gag	ccc	gtg	665
Arg	Asp	Ala	Gln	Phe	Tyr	Arg	Phe	Pro	Gly	Pro	Glu	Pro	Glu	Pro	Val	
					140				145						150	
gga	act	cat	gag	atg	gag	gag	gag	ttg	gcc	gaa	gct	gtg	gcc	ctg	ctc	713
Gly	Thr	His	Glu	Met	Glu	Glu	Glu	Leu	Ala	Glu	Ala	Val	Ala	Leu	Leu	
				155					160					165		
tcc	cag	cgg	ggg	cct	gac	gcc	ctg	ctc	act	gtg	gca	ctt	cga	aag	ccc	761
Ser	Gln	Arg	Gly	Pro	Asp	Ala	Leu	Leu	Thr	Val	Ala	Leu	Arg	Lys	Pro	
			170					175					180			
cca	ggt	cag	cgc	acg	gat	gaa	gag	ctg	gac	ctc	atc	ttt	gag	gag	ctg	809
Pro	Gly	Gln	Arg	Thr	Asp	Glu	Glu	Leu	Asp	Leu	Ile	Phe	Glu	Glu	Leu	
		185					190					195				
ctg	cac	atc	aag	gct	gtg	gcc	cac	ctc	tcc	aac	tcg	gtg	aag	cga	gaa	857
Leu	His	Ile	Lys	Ala	Val	Ala	His	Leu	Ser	Asn	Ser	Val	Lys	Arg	Glu	
	200					205					210					
tta	gcg	gct	gtt	ctg	ctc	ttt	gaa	cca	cac	agc	aag	gca	ggg	acc	gtg	905
Leu	Ala	Ala	Val	Leu	Leu	Phe	Glu	Pro	His	Ser	Lys	Ala	Gly	Thr	Val	
	215				220					225					230	
ttg	ttc	agc	cag	ggg	gac	aag	ggc	act	tcg	tgg	tac	att	atc	tgg	aag	953
Leu	Phe	Ser	Gln	Gly	Asp	Lys	Gly	Thr	Ser	Trp	Tyr	Ile	Ile	Trp	Lys	
				235					240					245		
gga	tct	gtc	aac	gtg	gtg	acc	cat	ggc	aag	ggg	ctg	gtg	acc	acc	ctg	1001
Gly	Ser	Val	Asn	Val	Val	Thr	His	Gly	Lys	Gly	Leu	Val	Thr	Thr	Leu	
			250					255					260			
cat	gag	gga	gat	gat	ttt	gga	cag	ctg	gct	ctg	gtg	aat	gat	gca	ccc	1049
His	Glu	Gly	Asp	Asp	Phe	Gly	Gln	Leu	Ala	Leu	Val	Asn	Asp	Ala	Pro	
		265				270						275				
cgg	gca	gcc	acc	atc	atc	ctg	cga	gaa	tac	aac	tgt	cat	ttc	ctg	cgt	1097
Arg	Ala	Ala	Thr	Ile	Ile	Leu	Arg	Glu	Tyr	Asn	Cys	His	Phe	Leu	Arg	
		280				285					290					
gtg	gac	aag	cag	gac	ttc	aac	cgt	atc	atc	aag	gat	gtg	gag	gca	aag	1145
Val	Asp	Lys	Gln	Asp	Phe	Asn	Arg	Ile	Ile	Lys	Asp	Val	Glu	Ala	Lys	
	295				300					305					310	
acc	atg	cgg	ctg	gaa	gaa	cat	ggc	aaa	gtg	gtg	ctg	gtg	ctg	gag	aga	1193
Thr	Met	Arg	Leu	Glu	Glu	His	Gly	Lys	Val	Val	Leu	Val	Leu	Glu	Arg	
				315					320					325		
gcc	tct	cag	ggc	gcc	ggc	cct	tcc	cga	ccc	cca	acc	cca	ggc	agg	aac	1241
Ala	Ser	Gln	Gly	Ala	Gly	Pro	Ser	Arg	Pro	Pro	Thr	Pro	Gly	Arg	Asn	

- 34 -

330							335					340					
cgg	tat	aca	gtg	atg	tct	ggc	act	cca	gat	aag	atc	cta	gag	ctt	ctg	1289	
Arg	Tyr	Thr	Val	Met	Ser	Gly	Thr	Pro	Asp	Lys	Ile	Leu	Glu	Leu	Leu		
		345					350					355					
ttg	gag	gcc	atg	gga	cta	gat	tcc	agt	gct	cat	gac	cca	aaa	gaa	aca	1337	
Leu	Glu	Ala	Met	Gly	Leu	Asp	Ser	Ser	Ala	His	Asp	Pro	Lys	Glu	Thr		
		360				365					370						
ttc	ctc	agc	gac	ttc	ctc	ctg	acc	cac	agg	gtc	ttc	atg	ccc	agc	gcc	1385	
Phe	Leu	Ser	Asp	Phe	Leu	Leu	Thr	His	Arg	Val	Phe	Met	Pro	Ser	Ala		
		375			380				385						390		
caa	ctc	tgc	gct	gcc	ctt	ctg	cac	cac	ttc	cat	gtg	gag	cct	gcg	ggt	1433	
Gln	Leu	Cys	Ala	Ala	Leu	Leu	His	His	Phe	His	Val	Glu	Pro	Ala	Gly		
				395					400					405			
ggc	agc	gag	cag	gag	cgc	agc	acc	tac	gtc	tgc	aac	aag	agg	cag	cag	1481	
Gly	Ser	Glu	Gln	Glu	Arg	Ser	Thr	Tyr	Val	Cys	Asn	Lys	Arg	Gln	Gln		
			410					415					420				
atc	ttg	cgg	ctg	gtc	agc	cag	tgg	gtg	gcc	ctg	tat	ggc	tcc	atg	ctc	1529	
Ile	Leu	Arg	Leu	Val	Ser	Gln	Trp	Val	Ala	Leu	Tyr	Gly	Ser	Met	Leu		
		425					430					435					
cac	act	gac	cct	gtg	gcc	acc	agc	ttc	ctc	cag	aaa	ctc	tca	gac	ctg	1577	
His	Thr	Asp	Pro	Val	Ala	Thr	Ser	Phe	Leu	Gln	Lys	Leu	Ser	Asp	Leu		
		440				445					450						
gtg	ggc	agg	gac	acc	cga	ctc	agc	aac	ctg	ctg	agg	gag	cag	tgg	cca	1625	
Val	Gly	Arg	Asp	Thr	Arg	Leu	Ser	Asn	Leu	Leu	Arg	Glu	Gln	Trp	Pro		
		455			460				465						470		
gag	agg	cgg	cga	tgc	cac	agg	ttg	gag	aat	ggc	tgt	ggg	aat	gca	tct	1673	
Glu	Arg	Arg	Arg	Cys	His	Arg	Leu	Glu	Asn	Gly	Cys	Gly	Asn	Ala	Ser		
			475						480					485			
cct	cag	atg	aag	gtg	tct	gcc	tgg	ccc	cag	ttt	ctt	tcc	tct	gct	cct	1721	
Pro	Gln	Met	Lys	Val	Ser	Ala	Trp	Pro	Gln	Phe	Leu	Ser	Ser	Ala	Pro		
			490				495						500				
cct	gga	ctg	cag	gca	cct	cct	tgc	ccc	cct	gac	cct	gag	ggg	ctc	tgt	1769	
Pro	Gly	Leu	Gln	Ala	Pro	Pro	Ser	Pro	Pro	Asp	Pro	Glu	Gly	Leu	Cys		
		505					510					515					
ggg	cgt	ggg	aag	ctc	tcc	tcc	cac	aga	cac	acc	ctt	ggg	tct	ctg	ata	1817	
Gly	Arg	Gly	Lys	Leu	Ser	Ser	His	Arg	His	Thr	Leu	Gly	Ser	Leu	Ile		
		520				525					530						
ggt	gtt	cac	ggg	gcc	ctt	gct	gca	tgt	ggt	gcc	ctg	ggc	cag	gcc	gtg	1865	
Gly	Val	His	Gly	Ala	Leu	Ala	Ala	Cys	Gly	Ala	Leu	Gly	Gln	Ala	Val		
		535			540				545					550			
cca	gga	ggc	gca	gag	gcc	taaggtggcc	tcctctctcg	cccactccct								1913	
Pro	Gly	Gly	Ala	Glu	Ala												
			555														
gactcaatgg gccttttatt ccttttggga ggtaattcat gcccacaggt agagcctggg																1973	
agatgaggaa tgggtggctgg agttggcccc tgaggccac ggggtcctg gtggccagt																2033	
ctgtgggagc tcagaggaag gcgaggcccc tccttggaag gtcagagggg gccccaggcc																2093	
attctcagct ggggcttaaa gggaagcaaa gaggggatga gaagatgtga ctgcagccag																2153	
gatttggttg aggaatggtg ggagaaagaa ctggaaaggt agattaggtt ggtggtgggg																2213	
agggctgcac tgggaataaa atccaggggc ctcaccatcc agcaggtcc ccatgggtccc																2273	
accctactgt gtgtcccagc ccctgcctgc tggagactct tactggcttc ttctcctccg																2333	
caggcgaagc ccgttctccc ctcagggcct ttgcacttat cccttagcct ggaagggctc																2393	
ttctctggct ctgcctggca ggatccttct cgttctcctc tcagccaaat gctgggttcc																2453	

- 35 -

cagacaggcc ccctcccggt tccctatccg gagcacccctc ccctttctcc caccacgctc 2513
 tgccttggtg tccctctgtga tttttttcaa agcactctcg ccatgtggag ttgttttctt 2573
 tgcctacttg ctttctgtcc tttggtatct ctcccatccc actggagagt tgacttccct 2633
 cctgcggggcc cccacctccg cttctccttg ctcacatgct gcctggctct tggtgacgc 2693
 tcagaaactg atgtgggctc accctcgcag gctgggcact gcgctagggt ctgatgctgc 2753
 acctcattca accctggcct gtggtggctg cagtcaggca aggggcagag cagttcaaca 2813
 acccgtgatg tgcagtgaac cgggacactt tccctgaatg tgcactggag tcggctcttc 2873
 caactgtagg tccgctgcct taaaccagga aggggaagag ccaactccag tgcagattca 2933
 gggaaagtgt cccgtgtaag cgactactgg agttgagagc tgcagggggc aagggtggag 2993
 gaagaagagg attcctggtg ggcaaaccga ggaggaaagg gaaccagga ggaggatccc 3053
 tggaggagcg agagtaagag taggacccca gagcaggcag gaggtgggca gggccccctg 3113
 ggcaaggaca ggggtctgat ctttgtccta agagcagtgc aaaccattaa aggggtttga 3173
 gccaaggttg gcaaagtctg atttgtgttt tgaataggct agctaaagag cctgggcttt 3233
 ctccagcaga caatggacac cactgaagtc gagtgcggga gcttcacagg gctctggtca 3293
 ggcagattgg aggaggagg ctggaggcac ctgggaggga ggaggaggag catagttggg 3353
 ccattggagt agtaaggagt gaggcctcgt gggcagggtg aactggagtt agcctgggca 3413
 ggggaggagg gggcacagaa gaccacttc aaagaagaat cttcaaagca agatgacaag 3473
 ctacggaagt gtggaggagc ctggagctgg ggagaatggc tggggaacag agtggctctg 3533
 gaggcaggat gcaaggatcc gatgggtata tggagtgtga ggtaatggtt cattcatgtg 3593
 gaaggatgca ggggtttttt gagaccaggg tttggaagag agttcagcac tgctggtagt 3653
 tttgggaatc acccatgtgc aggcgacaca tgaggcagta aggaactctg cagggttccc 3713
 tgagatttgg aaatgtaggg aagagcaatg gattgaggtc cgaacctgga ggatctgcta 3773
 tacgcagagc tgggaggagg gacagagtca gtaccagagt cggaaaaaag cagggtggga 3833
 aggggaacct gagtcaggag acttgctctg caggcgctgc cctgccagca gaggcctgac 3893
 agtggtttcc atgaactgca tccctgctgt gggctgggac agggccactg acacagtatc 3953
 ggagcacaga aggggaaagg agcaggaggg attccaactc tgccagttag cagctgtgtg 4013
 gctttgggca tgttacttaa cctctctgag cctcatttat ttcattcata aaatggaaat 4073
 aaaaataata cttttgtcaa aaaaaaaaaa aaaaaa 4109

<210> 14
 <211> 556
 <212> PRT
 <213> Homo sapiens

<400> 14
 Met Val Leu Arg Arg Met His Arg Pro Arg Ser Cys Ser Tyr Gln Leu
 1 5 10 15
 Leu Leu Glu His Gln His Pro Ser Cys Ile Gln Gly Leu Arg Trp Thr
 20 25 30
 Pro Leu Thr Asn Ser Glu Glu Ser Leu Asp Phe Ser Glu Ser Leu Glu
 35 40 45
 Gln Ala Ser Thr Glu Arg Val Leu Arg Ala Gly Arg Gln Leu His Gln
 50 55 60

- 36 -

His Leu Leu Ala Thr Cys Pro Asn Leu Ile Arg Asp Arg Lys Tyr His
 65 70 75 80
 Leu Arg Leu Tyr Arg Gln Cys Cys Ser Gly Arg Glu Leu Val Asp Gly
 85 90 95
 Ile Leu Ala Leu Gly Leu Gly Val His Ser Arg Ser Gln Val Val Gly
 100 105 110
 Ile Cys Gln Val Leu Leu Asp Glu Gly Ala Leu Cys His Val Lys His
 115 120 125
 Asp Trp Ala Phe Gln Asp Arg Asp Ala Gln Phe Tyr Arg Phe Pro Gly
 130 135 140
 Pro Glu Pro Glu Pro Val Gly Thr His Glu Met Glu Glu Glu Leu Ala
 145 150 155 160
 Glu Ala Val Ala Leu Leu Ser Gln Arg Gly Pro Asp Ala Leu Leu Thr
 165 170 175
 Val Ala Leu Arg Lys Pro Pro Gly Gln Arg Thr Asp Glu Glu Leu Asp
 180 185 190
 Leu Ile Phe Glu Glu Leu Leu His Ile Lys Ala Val Ala His Leu Ser
 195 200 205
 Asn Ser Val Lys Arg Glu Leu Ala Ala Val Leu Leu Phe Glu Pro His
 210 215 220
 Ser Lys Ala Gly Thr Val Leu Phe Ser Gln Gly Asp Lys Gly Thr Ser
 225 230 235 240
 Trp Tyr Ile Ile Trp Lys Gly Ser Val Asn Val Val Thr His Gly Lys
 245 250 255
 Gly Leu Val Thr Thr Leu His Glu Gly Asp Asp Phe Gly Gln Leu Ala
 260 265 270
 Leu Val Asn Asp Ala Pro Arg Ala Ala Thr Ile Ile Leu Arg Glu Tyr
 275 280 285
 Asn Cys His Phe Leu Arg Val Asp Lys Gln Asp Phe Asn Arg Ile Ile
 290 295 300
 Lys Asp Val Glu Ala Lys Thr Met Arg Leu Glu Glu His Gly Lys Val
 305 310 315 320
 Val Leu Val Leu Glu Arg Ala Ser Gln Gly Ala Gly Pro Ser Arg Pro
 325 330 335
 Pro Thr Pro Gly Arg Asn Arg Tyr Thr Val Met Ser Gly Thr Pro Asp
 340 345 350
 Lys Ile Leu Glu Leu Leu Leu Glu Ala Met Gly Leu Asp Ser Ser Ala
 355 360 365
 His Asp Pro Lys Glu Thr Phe Leu Ser Asp Phe Leu Leu Thr His Arg
 370 375 380
 Val Phe Met Pro Ser Ala Gln Leu Cys Ala Ala Leu Leu His His Phe
 385 390 395 400
 His Val Glu Pro Ala Gly Gly Ser Glu Gln Glu Arg Ser Thr Tyr Val
 405 410 415
 Cys Asn Lys Arg Gln Gln Ile Leu Arg Leu Val Ser Gln Trp Val Ala
 420 425 430
 Leu Tyr Gly Ser Met Leu His Thr Asp Pro Val Ala Thr Ser Phe Leu
 435 440 445
 Gln Lys Leu Ser Asp Leu Val Gly Arg Asp Thr Arg Leu Ser Asn Leu
 450 455 460

- 37 -

Leu Arg Glu Gln Trp Pro Glu Arg Arg Arg Cys His Arg Leu Glu Asn
 465 470 475 480
 Gly Cys Gly Asn Ala Ser Pro Gln Met Lys Val Ser Ala Trp Pro Gln
 485 490 495
 Phe Leu Ser Ser Ala Pro Pro Gly Leu Gln Ala Pro Pro Ser Pro Pro
 500 505 510
 Asp Pro Glu Gly Leu Cys Gly Arg Gly Lys Leu Ser Ser His Arg His
 515 520 525
 Thr Leu Gly Ser Leu Ile Gly Val His Gly Ala Leu Ala Ala Cys Gly
 530 535 540
 Ala Leu Gly Gln Ala Val Pro Gly Gly Ala Glu Ala
 545 550 555

<210> 15
 <211> 1966
 <212> DNA
 <213> Rattus norvegicus

<220>
 <221> CDS
 <222> (3).. (875)
 <223> cAMP-GEFII

<400> 15
 aa ggt gtg ctc aaa cct aat gat gtt tca gta ttt acg acg ctc acc 47
 Gly Val Leu Lys Pro Asn Asp Val Ser Val Phe Thr Thr Leu Thr 15
 1 5 10
 att aat gga cgc ctg ttt gcc tgc ccg cga gag caa ttc gac tca ctg 95
 Ile Asn Gly Arg Leu Phe Ala Cys Pro Arg Glu Gln Phe Asp Ser Leu 20 25 30
 act ccc ttg cca gaa cag gag ggc ccg acc act ggg aca gtg ggg acg 143
 Thr Pro Leu Pro Glu Gln Glu Gly Pro Thr Thr Gly Thr Val Gly Thr 35 40 45
 ttt gaa ctg atg agc tcg aaa gac ttg gcg tac cag atg aca acg tat 191
 Phe Glu Leu Met Ser Ser Lys Asp Leu Ala Tyr Gln Met Thr Thr Tyr 50 55 60
 gac tgg gaa ctc ttc aac tgt gtg ctc gag ctg gag cta atc tac cac 239
 Asp Trp Glu Leu Phe Asn Cys Val Leu Glu Leu Glu Leu Ile Tyr His 65 70 75
 aca ttt gga agg cat aat ttt aaa aag acc aca gca aac ttg gat ttg 287
 Thr Phe Gly Arg His Asn Phe Lys Lys Thr Thr Ala Asn Leu Asp Leu 80 85 90 95
 ttc ctg agg aga ttt aat gaa att cag ttt tgg gtt gtc act gag atc 335
 Phe Leu Arg Arg Phe Asn Glu Ile Gln Phe Trp Val Val Thr Glu Ile 100 105 110
 tgc ctt tgt tcc cag ctc agc aag cgt gtt cag ctt ttg aaa aaa tgt 383
 Cys Leu Cys Ser Gln Leu Ser Lys Arg Val Gln Leu Leu Lys Lys Cys 115 120 125
 atc aag ata gcg gct cac tgc aag gag tac aaa aac ttg aat tcc ttc 431
 Ile Lys Ile Ala Ala His Cys Lys Glu Tyr Lys Asn Leu Asn Ser Phe 130 135 140
 ttc gcc atc gtc atg ggg ctc agt aac gtg gct gag agc cgc ctg gca 479
 Phe Gly Ile Val Met Gly Leu Ser Asn Val Ala Glu Ser Arg Leu Ala 145 150 155
 tta aca tgg gag aaa ctg ccg agc aag ttt aag aag ttc tat gcg gag 527
 Leu Thr Trp Glu Lys Leu Pro Ser Lys Phe Lys Lys Phe Tyr Ala Glu 160 165 170 175

- 38 -

ttt gag agc tta atg gat cct tcc aga aat cac aag gcg tac agg ctg 575
 Phe Glu Ser Leu Met Asp Pro Ser Arg Asn His Lys Ala Tyr Arg Leu
 180 185 190

aca gca gct aaa ctg gag ccc ccc ctc atc cct ttc atg ccc ttg ctt 623
 Thr Ala Ala Lys Leu Glu Pro Pro Leu Ile Pro Phe Met Pro Leu Leu
 195 200 205

att aaa gat atg aca ttt act cat gag ggg aac aag aca ttc att gac 671
 Ile Lys Asp Met Thr Phe Thr His Glu Gly Asn Lys Thr Phe Ile Asp
 210 215 220

aat cta gta aac ttt gaa aaa atg cgc atg att gca aat act gcc aga 719
 Asn Leu Val Asn Phe Glu Lys Met Arg Met Ile Ala Asn Thr Ala Arg
 225 230 235

acg gtg cgc tac tac agg agc cag cca ttc aat ccg gat gct gct caa 767
 Thr Val Arg Tyr Tyr Arg Ser Gln Pro Phe Asn Pro Asp Ala Ala Gln
 240 245 250 255

gct aat aag aac cat cag gat gtc cgg agt tat gta cgg caa tta aat 815
 Ala Asn Lys Asn His Gln Asp Val Arg Ser Tyr Val Arg Gln Leu Asn
 260 265 270

gtg att gac aac cag aga act tta tca cag atg tca cac aga tta gag 863
 Val Ile Asp Asn Gln Arg Thr Leu Ser Gln Met Ser His Arg Leu Glu
 275 280 285

cct cgc agg cca tagacatctg cagtgccag agtgatgctc cgtctccagt 915
 Pro Arg Arg Pro

290

ccacaatctt tcaaaagatg ctgtgtatgc tactactgac tgtgttgcta ctagagaatt 975
 cccagaatg agcaagagac acctcctgag agccccctcgg ggccacatcc tgctttccga 1035
 ccacacagga gaaggatctg tcttgtctaa cgcggacatg ccgtagctta ggaaccatca 1095
 gctgtagtca tcttcttcac gggtggcaca ccaccgcagg ctcacgtgaa ggcataacct 1155
 ggcgaggcta caccaggccc ctgacatccc ttcccaggct gttgcagcat gagactgtcc 1215
 cgtggatagg tttgacttgg aatcgctgca atgatataat tgaatgattt gtttacttag 1275
 caccttattt ggggtctggg ttctggggag ggtgttgacc ataaaagtcc aaattatcca 1335
 tcatgttcct ccacgtcat aatcttacct ctgaaggaat ggaacctcat cacaacacta 1395
 tgaaacatta tgactgttca gtctgtaatt tcggaatgat ctatagaata atatgtttac 1455
 attgtaactt ttaaaaaactt acaaatcagg attacacaca tgagaattcc actaagaaac 1515
 accaaggttc ttaatatcgc cagcgttaag atagaaagta acatttcaga agagcacaat 1575
 atacacaaaa cattttttca aattgaaata ttttcctggg cattaaaaaa cctttccact 1635
 acaaatttat tgttactgat gaaaaaaaaa gcatattttc tggacttaaa tgttattaca 1695
 aaaatcttaa ttttcagcaa ttgttttgca ctttcagata gattgtaaat aggttatgca 1755
 gtcaatggta tagaattatt tatttgctac ataatagaca ttgtgccaaa taattccttt 1815
 ttatttattt tattcagtat gaaattttgg agtacatttt ttctgttttc ttaattagac 1875
 tacatttaat gtataggaat tgtatgtaca tatctcttct gtaaataaca gccagtatct 1935
 tcattaaata tacttgacaa gaaaaaaaaa a 1966

<210> 16
 <211> 291
 <212> PRT
 <213> Rattus norvegicus
 <400> 16

- 39 -

Gly Val Leu Lys Pro Asn Asp Val Ser Val Phe Thr Thr Leu Thr Ile
 1 5 10 15
 Asn Gly Arg Leu Phe Ala Cys Pro Arg Glu Gln Phe Asp Ser Leu Thr
 20 25 30
 Pro Leu Pro Glu Gln Glu Gly Pro Thr Thr Gly Thr Val Gly Thr Phe
 35 40 45
 Glu Leu Met Ser Ser Lys Asp Leu Ala Tyr Gln Met Thr Thr Tyr Asp
 50 55 60
 Trp Glu Leu Phe Asn Cys Val Leu Glu Leu Glu Leu Ile Tyr His Thr
 65 70 75 80
 Phe Gly Arg His Asn Phe Lys Lys Thr Thr Ala Asn Leu Asp Leu Phe
 85 90 95
 Leu Arg Arg Phe Asn Glu Ile Gln Phe Trp Val Val Thr Glu Ile Cys
 100 105 110
 Leu Cys Ser Gln Leu Ser Lys Arg Val Gln Leu Leu Lys Lys Cys Ile
 115 120 125
 Lys Ile Ala Ala His Cys Lys Glu Tyr Lys Asn Leu Asn Ser Phe Phe
 130 135 140
 Gly Ile Val Met Gly Leu Ser Asn Val Ala Glu Ser Arg Leu Ala Leu
 145 150 155 160
 Thr Trp Glu Lys Leu Pro Ser Lys Phe Lys Lys Phe Tyr Ala Glu Phe
 165 170 175
 Glu Ser Leu Met Asp Pro Ser Arg Asn His Lys Ala Tyr Arg Leu Thr
 180 185 190
 Ala Ala Lys Leu Glu Pro Pro Leu Ile Pro Phe Met Pro Leu Leu Ile
 195 200 205
 Lys Asp Met Thr Phe Thr His Glu Gly Asn Lys Thr Phe Ile Asp Asn
 210 215 220
 Leu Val Asn Phe Glu Lys Met Arg Met Ile Ala Asn Thr Ala Arg Thr
 225 230 235 240
 Val Arg Tyr Tyr Arg Ser Gln Pro Phe Asn Pro Asp Ala Ala Gln Ala
 245 250 255
 Asn Lys Asn His Gln Asp Val Arg Ser Tyr Val Arg Gln Leu Asn Val
 260 265 270
 Ile Asp Asn Gln Arg Thr Leu Ser Gln Met Ser His Arg Leu Glu Pro
 275 280 285
 Arg Arg Pro
 290

<210> 17
 <211> 3013
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (407)..(2953)
 <223> CAMP-GEFII

<400> 17
 gatccagcga agatgtggat ataattcttca ctgcactgaa agaagttaaa gcttttgaga 60
 aatttcaccc aaatctcctt catcagattt gcttatgtgg ttattatgag aatctggaaa 120
 aggaataac attatttcgc cagggtgata tggaacaaac tggatgctg cctggcaggg 180

tcttggatg	ttaaagtatc	tgagaccagc	agtcaccagg	atgctgtgac	catctgtacc	240
ctgggaattg	ggacggcctt	tggagagtcc	attctggaca	acacaccccg	ccatgcaacc	300
atcgttacca	gggagagcag	tgaactgctc	cgcacgcagc	agaaggactt	caaggcacta	360
tgggagaaat	atcgacagta	tatggcagga	cttctggctc	ctcctt	atg gta tta Met Val Leu 1	415
tgg aaa cgg gct cta aca atg aca gga ttc ctg aca agg aga aca cac	Trp Lys 5 Arg Ala Leu Thr Met 10 Thr Gly Phe Leu Thr 15 Arg Arg Thr His	463				
ctc att gaa cct cac gtt cct ctt cgt cct gct aac acc att acc aag	Leu Ile Glu Pro His Val 25 Pro Leu Arg Pro Ala 30 Asn Thr Ile Thr Lys 35	511				
gtc cct tca gag aag atc ctc aga gct gga aaa att tta cga aat gcc	Val Pro Ser Glu Lys 40 Ile Leu Arg Ala Gly 45 Lys Ile Leu Arg Asn 50 Ala	559				
att ctc tct cga gca cct cac atg ata aga gat aga aaa tac cac cta	Ile Leu Ser Arg 55 Ala Pro His Met Ile Arg Asp Arg Lys Tyr 65 His Leu	607				
aag aca tac aga caa tgc tgt gtg gga act gaa ctg gtg gac tgg atg	Lys Thr Tyr 70 Arg Gln Cys Cys Val 75 Gly Thr Glu Leu Val 80 Asp Trp Met	655				
atc gac gag aca cca tgt gtt cac tcc cgg act caa gct gtt gcc atg	Ile Asp 85 Glu Thr Pro Cys Val 90 His Ser Arg Thr Gln Ala Val Gly Met	703				
tgg caa gtc ctg tta gaa gat ggt gtt ctc aac cac gtg gac cag gag	Trp Gln Val Leu Leu 105 Glu Asp Gly Val Leu 110 Asn His Val Asp Gln Glu 115	751				
cac cat ttc caa gac ttt tat tta ttc tat cga ttt ctg gat gat gag	His His Phe Gln Asp 120 Phe Tyr Leu Phe Tyr 125 Arg Phe Leu Asp Asp Glu 130	799				
cac gag gat gcc cct ttg cct act gag gag gag aag aag gag tgt gat	His Glu Asp Ala 135 Pro Leu Pro Thr Glu Glu Glu Lys Lys 145 Glu Cys Asp	847				
gag gag ctc cag gac acc atg ctg ctg ctg tca cag atg ggc ccc gac	Glu Glu Leu 150 Gln Asp Thr Met Leu 155 Leu Leu Ser Gln Met 160 Gly Pro Asp	895				
gcc cac atg agg atg atc ctt cgc aaa cca cct ggc cag agg act gtg	Ala His Met Arg Met Ile Leu 170 Arg Lys Pro Pro Gly 175 Gln Arg Thr Val	943				
gat gac cta gag att atc tat gag gag ctt ctt cat att aaa gcc tta	Asp Asp Leu Glu Ile 185 Ile Tyr Glu Glu Leu Leu 190 His Ile Lys Ala Leu 195	991				
tcc cat ctt tct acc aca gtg aaa cga gag tta gca ggt gtt ctc att	Ser His Leu Ser Thr 200 Thr Val Lys Arg Glu Leu Ala Gly Val 210 Leu Ile	1039				
ttt gag tct cac gcc aaa gga ggg act gtg ttg ttt aac cag ggg gaa	Phe Glu Ser His 215 Ala Lys Gly Gly Thr 220 Val Leu Phe Asn Gln Gly Glu	1087				
gaa ggt acc tcc tgg tac att att cta aaa gga tca gtg aat gta gtc	Glu Gly Thr 230 Ser Trp Tyr Ile 235 Leu Lys Gly Ser 240 Val Asn Val Val	1135				
att tac ggc aag ggt gtg gtc tgc acc ctg cat gaa gga gat gac ttc	Ile Tyr 245 Gly Lys Gly Val 250 Val Cys Thr Leu His Glu Gly Asp Asp Phe	1183				
ggc aag tta gca cta gtg aat gat gcc cca cga gct gcc tct atc gtc		1231				

- 41 -

Gly 260	Lys	Leu	Ala	Leu	Val 265	Asn	Asp	Ala	Pro	Arg 270	Ala	Ala	Ser	Ile	Val 275	
tta	cga	gaa	gat	aac	tgc	cat	ttc	tta	aga	gta	gac	aag	gag	gat	ttc	1279
Leu	Arg	Glu	Asp	Asn 280	Cys	His	Phe	Leu	Arg 285	Val	Asp	Lys	Glu	Asp 290	Phe	
aac	cgg	atc	cta	agg	gac	gtg	gag	gag	aat	aca	gtc	aga	ctt	aaa	gaa	1327
Asn	Arg	Ile	Leu 295	Arg	Asp	Val	Glu	Ala 300	Asn	Thr	Val	Arg	Leu 305	Lys	Glu	
cat	gac	caa	gat	gtc	ttg	gtg	ctg	gag	aag	gtc	cca	gca	ggg	aac	aga	1375
His	Asp	Gln 310	Asp	Val	Leu	Val	Leu 315	Glu	Lys	Val	Pro	Ala 320	Gly	Asn	Arg	
gct	tct	aat	caa	gga	aac	tca	cag	cct	cag	caa	aag	tat	act	gtg	atg	1423
Ala	Ser	Asn	Gln	Gly	Asn 330	Ser	Gln	Pro	Gln	Gln	Lys 335	Tyr	Thr	Val	Met	
tca	gga	aca	cct	gaa	aaa	att	tta	gag	cat	ttt	cta	gaa	aca	ata	cgc	1471
Ser	Gly	Thr	Pro	Glu	Lys 345	Ile	Leu	Glu	His	Phe 350	Leu	Glu	Thr	Ile	Arg 355	
ctt	gag	gca	act	tta	aat	gaa	gca	aca	gat	tct	gtt	tta	aat	gac	ttt	1519
Leu	Glu	Ala	Thr	Leu 360	Asn	Glu	Ala	Thr	Asp 365	Ser	Val	Leu	Asn	Asp 370	Phe	
att	atg	atg	cac	tgt	gtt	ttt	atg	cca	aat	acc	cag	ctt	tgc	ccg	gca	1567
Ile	Met	Met	His 375	Cys	Val	Phe	Met	Pro 380	Asn	Thr	Gln	Leu	Cys 385	Pro	Ala	
ctg	gtg	gcc	cac	tac	cac	gca	cag	cct	tca	caa	ggt	aca	gaa	cag	gag	1615
Leu	Val	Ala 390	His	Tyr	His	Ala	Gln 395	Pro	Ser	Gln	Gly	Thr 400	Glu	Gln	Glu	
aaa	atg	gat	tat	gcc	ctc	aac	aat	aag	agg	cga	gtc	atc	cgc	ctg	gtt	1663
Lys	Met 405	Asp	Tyr	Ala	Leu 410	Asn	Asn	Lys	Arg	Arg	Val 415	Ile	Arg	Leu	Val	
cta	cag	tgg	gct	gcc	atg	tat	gga	gac	ctc	ctg	caa	gag	gat	gac	gta	1711
Leu	Gln	Trp	Ala	Ala	Met 425	Tyr	Gly	Asp	Leu	Leu 430	Gln	Glu	Asp	Asp	Val 435	
tct	atg	gcc	ttc	ctg	gag	gag	ttt	tat	gta	tct	gta	tca	gat	gat	gcc	1759
Ser	Met	Ala	Phe	Leu 440	Glu	Glu	Phe	Tyr	Val 445	Ser	Val	Ser	Asp	Asp 450	Ala	
cgg	atg	att	gct	gcc	ctc	aag	gag	caa	ctg	cca	gag	ttg	gag	aag	att	1807
Arg	Met	Ile	Ala 455	Ala	Leu	Lys	Glu	Gln 460	Leu	Pro	Glu	Leu	Glu	Lys	Ile	
gtc	aag	caa	atc	tca	gaa	gat	gca	aag	gca	cca	caa	aag	aag	cac	aag	1855
Val	Lys 470	Gln	Ile	Ser	Glu	Asp	Ala 475	Lys	Ala	Pro	Gln	Lys 480	Lys	His	Lys	
gtt	ctt	ttg	caa	cag	ttc	aat	acg	ggc	gat	gag	aga	gcc	cag	aag	cgc	1903
Val	Leu 485	Leu	Gln	Gln	Phe	Asn 490	Thr	Gly	Asp	Glu	Arg 495	Ala	Gln	Lys	Arg	
cag	cct	atc	cgc	ggc	tct	gat	gaa	gtt	ctg	ttt	aag	gtc	tat	tgc	atg	1951
Gln	Pro	Ile	Arg	Gly 505	Ser	Asp	Glu	Val	Leu	Phe 510	Lys	Val	Tyr	Cys	Met 515	
gac	cac	acc	tac	aca	acc	att	cgg	gtg	cca	gtg	gcc	act	tcg	gtg	aag	1999
Asp	His	Thr	Tyr	Thr 520	Thr	Ile	Arg	Val	Pro 525	Val	Ala	Thr	Ser	Val 530	Lys	
gaa	gtc	atc	agt	gca	gtt	gcc	gac	aag	ctg	ggc	tcc	ggg	gag	ggc	ctg	2047
Glu	Val	Ile	Ser 535	Ala	Val	Ala	Asp	Lys 540	Leu	Gly	Ser	Gly	Glu	Gly	Leu	
atc	ata	gtc	aag	atg	agt	tcc	gga	gga	gaa	aag	gtg	gtg	ctc	aaa	cct	2095
Ile	Ile	Val 550	Lys	Met	Ser	Ser	Gly 555	Gly	Glu	Lys	Val	Val 560	Leu	Lys	Pro	

- 42 -

aat gat gtt tca gta ttt acg acg ctc acc att aat gga cgc ctg ttt	2143
Asn Asp Val Ser Val Phe Thr Leu Thr Ile Asn Gly Arg Leu Phe	
565 570 575	
gct tgc ccg cga gag caa ttc gat tca ctg act tta cca gaa cag	2191
Ala Cys Pro Arg Glu Gln Phe Asp Ser Leu Thr Pro Leu Pro Glu Gln	
580 585 590 595	
gaa ggc cca act gtt gga aca gtg gga act ttt gaa ctg atg agc tcc	2239
Glu Gly Pro Thr Val Gly Thr Val Gly Thr Phe Glu Leu Met Ser Ser	
600 605 610	
aaa gat tta gca tac cag atg aca att tat gat tgg gaa ctc ttc aac	2287
Lys Asp Leu Ala Tyr Gln Met Thr Ile Tyr Asp Trp Glu Leu Phe Asn	
615 620 625	
tgc gtg cat gag ctg gag cta atc tat cac aca ttt gga agg cat aat	2335
Cys Val His Glu Leu Glu Leu Ile Tyr His Thr Phe Gly Arg His Asn	
630 635 640	
ttt aaa aag acc aca gca aac ttg gat ttg ttc ctg agg aga ttt aat	2383
Phe Lys Lys Thr Thr Ala Asn Leu Asp Leu Phe Leu Arg Arg Phe Asn	
645 650 655	
gaa att cag ttt tgg gtc gtc act gag atc tgc ctt tgt tct cag ctc	2431
Glu Ile Gln Phe Trp Val Val Thr Glu Ile Cys Leu Cys Ser Gln Leu	
660 665 670 675	
agc aag cgt gtt cag cta tta aaa aaa ttt att aag ata gca gcc cac	2479
Ser Lys Arg Val Gln Leu Leu Lys Lys Phe Ile Lys Ile Ala Ala His	
680 685 690	
tgt aag gag tat aaa aat ctg aat tcc ttt ttt gcc atc gtc atg gga	2527
Cys Lys Glu Tyr Lys Asn Leu Asn Ser Phe Phe Ala Ile Val Met Gly	
695 700 705	
cta agt aac att gct gtg agc cgc ttg gca cta acg tgg gag aaa ctg	2575
Leu Ser Asn Ile Ala Val Ser Arg Leu Ala Leu Thr Trp Glu Lys Leu	
710 715 720	
cca agc aag ttc aag aag ttc tat gcg gag ttt gaa agt tta atg gac	2623
Pro Ser Lys Phe Lys Lys Phe Tyr Ala Glu Phe Glu Ser Leu Met Asp	
725 730 735	
cct tca agg aac cac agg gcc tac agg ctg aca gta gct aag ctg gaa	2671
Pro Ser Arg Asn His Arg Ala Tyr Arg Leu Thr Val Ala Lys Leu Glu	
740 745 750 755	
cct cct ctc atc ccc ttc atg cct ttg ctc att aaa gat atg aca ttt	2719
Pro Pro Leu Ile Phe Met Pro Leu Ile Lys Asp Met Thr Phe	
760 765 770	
act cat gag ggg aac aag acg ttc att gac aat cta gta aac ttt gaa	2767
Thr His Glu Gly Asn Lys Thr Phe Ile Asp Asn Leu Val Asn Phe Glu	
775 780 785	
aaa atg cgc atg att gca aat acg gcc aga aca gtg aga tac tac agg	2815
Lys Met Arg Met Ile Ala Asn Thr Ala Arg Thr Val Arg Tyr Tyr Arg	
790 795 800	
agc caa ccc ttc aat cct gat gca gct caa gct aat aag aac cat cag	2863
Ser Gln Pro Phe Asn Pro Asp Ala Ala Gln Ala Asn Lys Asn His Gln	
805 810 815	
gat gtc cgg agt tat gta cgg caa tta aat gtg att gac aac cag aga	2911
Asp Val Arg Ser Tyr Val Arg Gln Leu Asn Val Ile Asp Asn Gln Arg	
820 825 830 835	
act tta tca cag atg tca cac aga tta gag cct cgt cga cca	2953
Thr Leu Ser Gln Met Ser His Arg Leu Glu Pro Arg Arg Pro	
840 845	
tagacatttc aaatgcccaa agcaacagtt tgtctccagt ccacaatttt caaaaatgcc	3013

- 43 -

<210> 18
 <211> 849
 <212> PRT
 <213> Homo sapiens

<400> 18
 Met Val Leu Trp Lys Arg Ala Leu Thr Met Thr Gly Phe Leu Thr Arg
 1 5 10 15
 Arg Thr His Leu Ile Glu Pro His Val Pro Leu Arg Pro Ala Asn Thr
 20 25 30
 Ile Thr Lys Val Pro Ser Glu Lys Ile Leu Arg Ala Gly Lys Ile Leu
 35 40 45
 Arg Asn Ala Ile Leu Ser Arg Ala Pro His Met Ile Arg Asp Arg Lys
 50 55 60
 Tyr His Leu Lys Thr Tyr Arg Gln Cys Cys Val Gly Thr Glu Leu Val
 65 70 75 80
 Asp Trp Met Ile Asp Glu Thr Pro Cys Val His Ser Arg Thr Gln Ala
 85 90 95
 Val Gly Met Trp Gln Val Leu Leu Glu Asp Gly Val Leu Asn His Val
 100 105 110
 Asp Gln Glu His His Phe Gln Asp Phe Tyr Leu Phe Tyr Arg Phe Leu
 115 120 125
 Asp Asp Glu His Glu Asp Ala Pro Leu Pro Thr Glu Glu Lys Lys
 130 135 140
 Glu Cys Asp Glu Glu Leu Gln Asp Thr Met Leu Leu Ser Gln Met
 145 150 155 160
 Gly Pro Asp Ala His Met Arg Met Ile Leu Arg Lys Pro Pro Gly Gln
 165 170 175
 Arg Thr Val Asp Asp Leu Glu Ile Ile Tyr Glu Glu Leu Leu His Ile
 180 185 190
 Lys Ala Leu Ser His Leu Ser Thr Thr Val Lys Arg Glu Leu Ala Gly
 195 200 205
 Val Leu Ile Phe Glu Ser His Ala Lys Gly Gly Thr Val Leu Phe Asn
 210 215 220
 Gln Gly Glu Glu Gly Thr Ser Trp Tyr Ile Ile Leu Lys Gly Ser Val
 225 230 235 240
 Asn Val Val Ile Tyr Gly Lys Gly Val Val Cys Thr Leu His Glu Gly
 245 250 255
 Asp Asp Phe Gly Lys Leu Ala Leu Val Asn Asp Ala Pro Arg Ala Ala
 260 265 270
 Ser Ile Val Leu Arg Glu Asp Asn Cys His Phe Leu Arg Val Asp Lys
 275 280 285
 Glu Asp Phe Asn Arg Ile Leu Arg Asp Val Glu Ala Asn Thr Val Arg
 290 295 300
 Leu Lys Glu His Asp Gln Asp Val Leu Val Leu Glu Lys Val Pro Ala
 305 310 315 320
 Gly Asn Arg Ala Ser Asn Gln Gly Asn Ser Gln Pro Gln Gln Lys Tyr
 325 330 335
 Thr Val Met Ser Gly Thr Pro Glu Lys Ile Leu Glu His Phe Leu Glu
 340 345 350
 Thr Ile Arg Leu Glu Ala Thr Leu Asn Glu Ala Thr Asp Ser Val Leu
 355 360 365

- 44 -

Asn Asp Phe Ile Met Met His Cys Val Phe Met Pro Asn Thr Gln Leu
 370 375 380
 Cys Pro Ala Leu Val Ala His Tyr His Ala Gln Pro Ser Gln Gly Thr
 385 390 395 400
 Glu Gln Glu Lys Met Asp Tyr Ala Leu Asn Asn Lys Arg Arg Val Ile
 405 410 415
 Arg Leu Val Leu Gln Trp Ala Ala Met Tyr Gly Asp Leu Leu Gln Glu
 420 425 430
 Asp Asp Val Ser Met Ala Phe Leu Glu Glu Phe Tyr Val Ser Val Ser
 435 440 445
 Asp Asp Ala Arg Met Ile Ala Ala Leu Lys Glu Gln Leu Pro Glu Leu
 450 455 460
 Glu Lys Ile Val Lys Gln Ile Ser Glu Asp Ala Lys Ala Pro Gln Lys
 465 470 475 480
 Lys His Lys Val Leu Leu Gln Gln Phe Asn Thr Gly Asp Glu Arg Ala
 485 490 495
 Gln Lys Arg Gln Pro Ile Arg Gly Ser Asp Glu Val Leu Phe Lys Val
 500 505 510
 Tyr Cys Met Asp His Thr Tyr Thr Thr Ile Arg Val Pro Val Ala Thr
 515 520 525
 Ser Val Lys Glu Val Ile Ser Ala Val Ala Asp Lys Leu Gly Ser Gly
 530 535 540
 Glu Gly Leu Ile Ile Val Lys Met Ser Ser Gly Gly Glu Lys Val Val
 545 550 555 560
 Leu Lys Pro Asn Asp Val Ser Val Phe Thr Thr Leu Thr Ile Asn Gly
 565 570 575
 Arg Leu Phe Ala Cys Pro Arg Glu Gln Phe Asp Ser Leu Thr Pro Leu
 580 585 590
 Pro Glu Gln Glu Gly Pro Thr Val Gly Thr Val Gly Thr Phe Glu Leu
 595 600 605
 Met Ser Ser Lys Asp Leu Ala Tyr Gln Met Thr Ile Tyr Asp Trp Glu
 610 615 620
 Leu Phe Asn Cys Val His Glu Leu Glu Leu Ile Tyr His Thr Phe Gly
 625 630 635 640
 Arg His Asn Phe Lys Lys Thr Thr Ala Asn Leu Asp Leu Phe Leu Arg
 645 650 655
 Arg Phe Asn Glu Ile Gln Phe Trp Val Val Thr Glu Ile Cys Leu Cys
 660 665 670
 Ser Gln Leu Ser Lys Arg Val Gln Leu Leu Lys Lys Phe Ile Lys Ile
 675 680 685
 Ala Ala His Cys Lys Glu Tyr Lys Asn Leu Asn Ser Phe Phe Ala Ile
 690 695 700
 Val Met Gly Leu Ser Asn Ile Ala Val Ser Arg Leu Ala Leu Thr Trp
 705 710 715 720
 Glu Lys Leu Pro Ser Lys Phe Lys Lys Phe Tyr Ala Glu Phe Glu Ser
 725 730 735
 Leu Met Asp Pro Ser Arg Asn His Arg Ala Tyr Arg Leu Thr Val Ala
 740 745 750
 Lys Leu Glu Pro Pro Leu Ile Pro Phe Met Pro Leu Leu Ile Lys Asp
 755 760 765

- 45 -

Met Thr Phe Thr His Glu Gly Asn Lys Thr Phe Ile Asp Asn Leu Val
 770 775 780
 Asn Phe Glu Lys Met Arg Met Ile Ala Asn Thr Ala Arg Thr Val Arg
 785 790 800
 Tyr Tyr Arg Ser Gln Pro Phe Asn Pro Asp Ala Ala Gln Ala Asn Lys
 805 810 815
 Asn His Gln Asp Val Arg Ser Tyr Val Arg Gln Leu Asn Val Ile Asp
 820 825 830
 Asn Gln Arg Thr Leu Ser Gln Met Ser His Arg Leu Glu Pro Arg Arg
 835 840 845
 Pro

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/82, 16/32, 14/47, C12Q 1/68, C12N 5/10, A01K 67/027, G01N 33/53, 33/574	A3	(11) International Publication Number: WO 00/24768 (43) International Publication Date: 4 May 2000 (04.05.00)
(21) International Application Number: PCT/US99/24826 (22) International Filing Date: 22 October 1999 (22.10.99) (30) Priority Data: 60/105,507 23 October 1998 (23.10.98) US 60/108,685 16 November 1998 (16.11.98) US (71) Applicant (for all designated States except US): MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02138 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KAWASAKI, Hiroaki [JP/JP]; 3-20-2, Aoba, Higashi-ku, Fukuoka 813-0025 (JP). GRAYBIEL, Ann [US/US]; Boyce Farm Road, Lincoln, MA 01773 (US). HOUSMAN, David [US/US]; 64 Homer Street, Newton, MA 02158 (US). (74) Agent: CAMACHO, Jennifer, A.; Testa, Hurwitz & Thibault, LLP, High Street Tower, 125 High Street, Boston, MA 02110 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 9 November 2000 (09.11.00)
(54) Title: GENES INTEGRATING SIGNAL TRANSDUCTION PATHWAYS (57) Abstract The present invention describes the identification, isolation, sequencing and characterization of two human CalDAG-GEF, and two human cAMP-GEF genes, which are associated with the Ras pathway. Also identified are CalDAG-GEF gene homologues in mice and cAMP-GEF gene homologues in rats. Nucleic acids and proteins comprising or derived from the CalDAG-GEFs and/or cAMP-GEFs are useful in screening and diagnosing certain Ras-associated cancers, in identifying and developing therapeutics for treatment of certain Ras-associated cancers, and in producing cell lines and transgenic animals useful as models of Ras-associated cancers.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 99/24826

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/82 C07K16/32 C07K14/47 C12Q1/68
C12N5/10 A01K67/027 G01N33/53 G01N33/574

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A01K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EBINU, J.O. ET AL.: "RasGRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs." SCIENCE, (1998 MAY 15) 280 (5366) 1082-6, XP000882708 the whole document	1
A	GOTOH, T. ET AL.: "Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G." MOLECULAR AND CELLULAR BIOLOGY, (1995) 15 (12) 6746-53, XP000881340 the whole document	1
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

5 April 2000

Date of mailing of the international search report

3 July 2000 (03.07.00)

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Nichogiannopoulou, A

INTERNATIONAL SEARCH REPORT

Internat' Application No
PCT/US 99/24826

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KAIBUCHI, K. ET AL.: "Molecular cloning of the cDNA for stimulatory GDP/GTP exchange protein fo smg p21s (ras p21-like small GTP-binding proteins) and characterization o stimulatory GDP/GTP exchange protein." MOLECULAR AND CELLULAR BIOLOGY, (1991) 11 (5) 2873-80, XP000881341 the whole document	1
X	KEDRA D ET AL: "THE GERMINAL CENTER KINASE GENE AND A NOVEL CDC25-LIKE GENE ARE LOCATED IN THE VICINITY OF THE PYGM GENE ON 11Q13" HUM. GENET., vol. 100, 1 October 1997 (1997-10-01), pages 611-619, XP002069545 page 613, last paragraph -page 615, paragraph FIRST; figure 2 & DATABASE EMBL [Online] AC Y12336, 19 June 1997 (1997-06-19) KEDRA D ET AL: "H. sapiens mRNA for F25B3.3 kinase like protein from C. elegans" Protein with 96.9% identity to SEQ ID No:2 and 100% identity to SEQ ID No:4 the whole document	1,3,5-8, 10, 38-54, 63-69
P,X	WO 98 53061 A (QUEENSLAND INST MED RES; HANCOCK JOHN (AU); SILINS GINTERS (AU)) 26 November 1998 (1998-11-26) MCG7, a hu protein with 100% identity in 609 aa overlap with SEQ ID No:4 claim 5; figure 13B	1,3,5-8, 10, 38-54, 63-69
P,X	KAWASAKI H ET AL: "A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia" PROC. NATL. ACAD. SCI. USA, vol. 95, October 1998 (1998-10), pages 13278-13283, XP000882748 the whole document	1,3,5-8, 10, 38-54, 63-69

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/24826

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 76-81, 86-109 and 127 -in as far as they concern in vivo methods- are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1, 3-8, 10, 12-19, 28-32, 38-70, 72, 73-75, 76, 78-82, 84, 86, 88-98, 110-112, 116, 118, 119, 121-129 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1, 3-8, 10, 12-19, 28-32, 38-70, 72, 73-75, 76, 78-82, 84, 86, 88-98, 110-112, 116, 118, 119, 121-129 (all partially)

Claims relating to CalDAG-GEFI proteins and nucleic acids encoding them, mutants, variants, species orthologs and homologues, functional domains and antigenic determinants thereof. Methods for identifying variants or homologues of such proteins. Recombinant expression vectors, host cells and animal models for cancer expressing such recombinant modified proteins. Methods for producing said proteins and pure preparations of such. Antibodies selectively binding to such proteins, methods and cell lines for producing them. Methods for identifying compounds that modulate the expression of such proteins, and for identifying compounds that can selectively bind to them. Diagnostic methods for detecting mutations and pharmaceutical preparations comprising pure protein, expression vectors encoding the protein or antisense sequences. Pharmaceutical preparations comprising antibodies or antigenic determinants and methods of treatment.

2. Claims: 1, 3-8, 10, 12-19, 28-32, 38-70, 72, 73-75, 76, 78-82, 84, 86, 88-98, 110-112, 116, 118, 119, 121-129 (all partially)

As in subject 1, the proteins being CalDAG-GEFII proteins.

3. Claims: 2, 4-7, 9, 11, 20-27, 33-69, 71-75, 77-81, 83, 85, 87, 99-109, 113-115, 117, 118, 120-126, 130 (all partially)

As in subject 1, the proteins being cAMP-GEFI proteins.

4. Claims: 2, 4-7, 9, 11, 20-27, 33-69, 71-75, 77-81, 83, 85, 87, 99-109, 113-115, 117, 118, 120-126, 130 (all partially)

As in subject 1, the proteins being cAMP-GEFII proteins.

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 99/24826

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0 9853061 A	26-11-1998	AU 7512998 A	11-12-1998

THIS PAGE BLANK (USP10)